



**Decision Diagnostics Corp.**

**ANNUAL REPORT FOR OTC PINK**  
**Supplemental Disclosures**  
**Annual Report for the Year Ended**  
**December 31, 2019**

**Trading Symbol: DECN**  
**CUSIP Number: 243443 108**

# Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

## Decision Diagnostics Corp.

A Nevada Corporation

2660 Townsgate Road Suite 300  
Westlake Village, CA 92361

---

(805) 446-1973

www.decisiondiagnostics.com

info@desisiocdiagnostics.com

5122, 7371

### **Quarterly Report**

**For the Period Ending: December 31, 2019**  
(the "Reporting Period")

As of December 31, 2019, the number of shares outstanding of our Common Stock was:

159,399,161

As of December 31, 2018, the number of shares outstanding of our Common Stock was:

134,551,840

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes:  No:  (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes:  No:

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name of the issuer and its predecessors (if any)**

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

11/25/2011 Company named changed from Instacare Corp. to Decision Diagnostics Corp.

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada, active

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes:  No:

**2) Security Information**

Trading symbol:	<u>DECN</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<b>243443 108</b>	
Par or stated value:	<u>\$.001</u>	
Total shares authorized:	<u>495,000,000</u>	as of date: <u>November 25, 2011</u>
Total shares outstanding:	<u>159,399,161</u>	as of date: <u>December 31, 2019</u>
Number of shares in the Public Float <sup>2</sup> :	<u>135,664,887</u>	as of date: <u>December 31, 2019</u>
Total number of shareholders of record:	<u>454</u>	as of date: <u>December 31, 2019</u>

*Additional class of securities (if any):* **N/A**

Trading symbol:	_____	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	as of date: _____
Total shares outstanding:	_____	as of date: _____

Transfer Agent

Name: Action Stock Transfer  
Phone: (801) 274-1088  
Email: jb@actionstocktransfer.com

Is the Transfer Agent registered under the Exchange Act?<sup>3</sup> Yes:  No:

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period. See Table below.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
2/2/16	New Issuance	970,980	Common	\$ 0.102	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
2/17/16	New Issuance	1,614,248	Common	\$ 0.102	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
2/25/16	New Issuance	100,000	Preferred "E"	\$ 0.16	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
2/25/16	New Issuance	750,000	Common	\$ 0.16	No	New Issuance-Robert Herskowitz (2)	Debt conversion	Restricted	Section 144
3/21/16	New Issuance	800	Preferred "C"	\$ 0.35	No	New Issuance-Paradigm Capital Holdings (3)	Consulting services	Restricted	Section 144
3/21/16	New Issuance	1,400,000	Common	\$ 0.35	No	New Issuance-Paradigm Capital Holdings (3)	Consulting services	Restricted	Section 144
3/21/16	New Issuance	200,000	Common	\$ 0.35	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
3/29/16	New Issuance	404,630	Common	\$ 0.35	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
3/29/16	New Issuance	500,000	Common	\$ 0.06	No	New Issuance-James J Loures	Cash	Restricted	Section 144
4/13/16	New Issuance	280,000	Common	\$ 0.10	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
4/13/16	New Issuance	280,000	Common	\$ 0.10	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
4/13/16	New Issuance	140,000	Common	\$ 0.10	No	New Issuance-Robert Herskowitz 2011 Irv TR (2)	Financing cost	Restricted	Section 144
4/13/16	New Issuance	148,160	Common	\$ 0.10	No	New Issuance-Chase Financial (2)	Financing cost	Restricted	Section 144
4/13/16	New Issuance	185,195	Common	\$ 0.10	No	New Issuance-Mark Herskowitz	Financing cost	Restricted	Section 144
4/13/16	New Issuance	37,040	Common	\$ 0.10	No	New Issuance-Andrew Schoenzeit	Financing cost	Restricted	Section 144
4/13/16	New Issuance	431,376	Common	\$ 0.10	No	New Issuance-Robert Herskowitz 2011 Irv TR (2)	Financing cost	Restricted	Section 144
4/26/16	New Issuance	1,837,500	Common	\$ 0.10	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
4/26/16	Conversion	(14,300)	Preferred "E"	\$ -	No	Conversion-Mayer & Associates (5)	Share exchange	Restricted	Section 144
4/26/16	Conversion	200,200	Common	\$ 0.10	No	Conversion-Mayer & Associates (5)	Share exchange	Restricted	Section 144
5/2/16	New Issuance	472,106	Common	\$ 0.10	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
5/5/16	New Issuance	998,099	Common	\$ 0.102	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
5/17/16	New Issuance	422,669	Common	\$ 0.10	No	New Issuance-Alpha Capital Anstalt (1)	Financing cost	Restricted	Section 144

5/17/16	Conversion	(125)	Preferred "C"	\$ -	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
5/17/16	Conversion	625,000	Common	\$ 0.10	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
5/18/16	New Issuance	525,000	Common	\$ 0.10	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
5/18/16	New Issuance	220,000	Common	\$ 0.10	No	New Issuance-Mayer & Associates (5)	Consulting services	Restricted	Section 144
6/1/16	New Issuance	814,314	Common	\$ 0.102	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
6/6/16	New Issuance	1,000,000	Common	\$ 0.102	No	New Issuance-Mark Herskowitz (2)	Debt conversion	Restricted	Section 144
6/6/16	New Issuance	1,050,000	Common	\$ 0.102	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Debt conversion	Restricted	Section 144
6/6/16	New Issuance	280,000	Common	\$ 0.10	No	New Issuance-Robert Herskowitz	Financing cost	Restricted	Section 144
6/6/16	New Issuance	70,000	Common	\$ 0.10	No	New Issuance-Robert Herskowitz 2011 Irv TR (2)	Financing cost	Restricted	Section 144
6/6/16	New Issuance	100,000	Preferred "E"	\$ 0.10	No	New Issuance-Mark Herskowitz 401K Trust	Financing cost	Restricted	Section 144
6/6/16	New Issuance	35,000	Preferred "E"	\$ 0.10	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Financing cost	Restricted	Section 144
6/6/16	New Issuance	25,000	Preferred "E"	\$ 0.10	No	New Issuance-Chase Financing (2)	Financing cost	Restricted	Section 144
6/8/16	New Issuance	484,148	Common	\$ 0.10	No	New Issuance-Alpha Capital Anstalt (1)	Financing cost	Restricted	Section 144
6/27/16	Conversion	(125)	Preferred "C"	\$ -	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
6/27/16	Conversion	625,000	Common	\$ 0.14	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
6/30/16	New Issuance	1,725	Preferred "C"	\$ 0.14	No	New Issuance-LICGO Partners (3)	Cash	Restricted	Section 144
7/18/16	New Issuance	100,000	Common	\$ 0.14	No	New Issuance-Cadence Holdings LLC (4)	Consulting services	Restricted	Section 144
7/18/16	New Issuance	150,000	Common	\$ 0.14	No	New Issuance-TPC Holdings Group (4)	Consulting services	Restricted	Section 144
7/21/16	New Issuance	(30,000)	Preferred "E"	\$ -	No	New Issuance-Robert Herskowitz (2)	Share exchange	Restricted	Section 144
7/21/16	New Issuance	420,000	Common	\$ 0.12	No	New Issuance-Robert Herskowitz (2)	Share exchange	Restricted	Section 144
7/21/16	New Issuance	270,000	Common	\$ 0.12	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
7/21/16	New Issuance	70,000	Common	\$ 0.13	No	New Issuance-Robert Herskowitz 2011 Irv TR (2)	Financing cost	Restricted	Section 144
7/21/16	Conversion	(67,500)	Preferred "E"	\$ -	No	Conversion-Chase Financial (2)	Share exchange	Restricted	Section 144
7/21/16	Conversion	945,000	Common	\$ 0.13	No	Conversion-Chase Financial (2)	Share exchange	Restricted	Section 144
8/2/16	Conversion	(125)	Preferred "C"	\$ -	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
8/2/16	Conversion	625,000	Common	\$ 0.14	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
8/29/16	New Issuance	954,925	Common	\$ 0.102	No	New Issuance-Alpha Capital Anstalt (1)	Financing cost	Restricted	Section 144
9/7/16	Conversion	(67,500)	Preferred "E"	\$ -	No	Conversion-Chase Financial (2)	Share exchange	Restricted	Section 144
9/7/16	Conversion	945,000	Common	\$ 0.13	No	Conversion-Chase Financial (2)	Share exchange	Restricted	Section 144
9/19/16	New Issuance	521,784	Common	\$ 0.12	No	New Issuance-Alpha Capital Anstalt (1)	Financing cost	Restricted	Section 144
9/19/16	New Issuance	805,147	Common	\$ 0.102	No	New Issuance-Mark Herskowitz (2)	Debt conversion	Restricted	Section 144
9/19/16	New Issuance	400,000	Common	\$ 0.12	No	New Issuance-Marc Berger	Consulting services	Restricted	Section 144
9/19/16	New Issuance	75,000	Preferred "E"	\$ 0.12	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Financing cost	Restricted	Section 144
12/6/16	New Issuance	1,919,603	Common	\$ 0.11	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
12/12/16	New Issuance	755,300	Common	\$ 0.11	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
1/9/17	New Issuance	971,074	Common	\$ 0.102	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
1/9/17	New Issuance	400,000	Common	\$ 0.102	No	New Issuance-Mark Herskowitz (2)	Debt conversion	Restricted	Section 144
3/1/17	New Issuance	989,425	Common	\$ 0.0678	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
3/3/17	New Issuance	50,000	Preferred "E"	\$ 0.12	No	New Issuance-Chase Financing (2)	Financing cost	Restricted	Section 144
3/3/17	New Issuance	70,000	Preferred "E"	\$ 0.12	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Financing cost	Restricted	Section 144
3/3/17	Conversion	(100,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing (2)	Share exchange	Restricted	Section 144
3/3/17	Conversion	1,400,000	Common	\$ 0.12	No	Conversion-Chase Financing (2)	Share exchange	Restricted	Section 144
3/3/17	New Issuance	560,000	Common	\$ 0.0678	No	New Issuance-Robert Herskowitz (2)	Debt conversion	Restricted	Section 144

3/3/17	New Issuance	140,000	Common	\$ 0.0678	No	New Issuance-R Herskowitz 2011 Irrv. TR (2)	Debt conversion	Restricted	Section 144
3/10/17	New Issuance	400,000	Common	\$ 0.0678	No	Issuance-Mark Herskowitz	Debt conversion	Restricted	Section 144
3/21/17	New Issuance	355,803	Common	\$ 0.0678	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
4/19/17	Conversion	(80)	Preferred "C"	\$ -	No	Conversion-Paradigm Capital Holdings (3)	Share exchange	Restricted	Section 144
4/19/17	Conversion	400,000	Common	\$ 0.08	No	Conversion-Paradigm Capital Holdings (3)	Share exchange	Restricted	Section 144
4/19/11	New Issuance	157	Preferred "C"	\$ 0.08	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
5/10/17	Conversion	(125)	Preferred "C"	\$ -	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
5/10/17	Conversion	625,000	Common	\$ 0.07	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
5/17/17	New Issuance	100,000	Common	\$ 0.07	No	New Issuance-OmniVance Advisors LLC (6)	Consulting services	Restricted	Section 144
5/17/17	New Issuance	100,000	Preferred "E"	\$ 0.07	No	New Issuance-Chase Financing (2)	Financing cost	Restricted	Section 144
6/19/17	New Issuance	1,096,312	Common	\$ 0.0540	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
7/11/17	Conversion	(100,000)	Preferred "E"	\$ -	No	Conversion-Robert Herskowitz	Share exchange	Restricted	Section 144
7/11/17	Conversion	1,400,000	Common	\$ 0.05	No	Conversion-Robert Herskowitz	Share exchange	Restricted	Section 144
7/11/17	Conversion	(100,000)	Preferred "E"	\$ -	No	Conversion-Chase Financial (2)	Share exchange	Restricted	Section 144
7/11/17	Conversion	1,400,000	Common	\$ 0.05	No	Conversion-Chase Financial (2)	Share exchange	Restricted	Section 144
7/24/17	Conversion	(125)	Preferred "C"	\$ -	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
7/24/17	Conversion	625,000	Common	\$ 0.08	No	Conversion-Navesink (3)	Share exchange	Restricted	Section 144
7/24/17	Conversion	(295)	Preferred "C"	\$ -	No	Conversion-Paradigm Capital Holdings (3)	Share exchange	Restricted	Section 144
7/24/17	Conversion	1,475,000	Common	\$ 0.08	No	Conversion-Paradigm Capital Holdings (3)	Share exchange	Restricted	Section 144
7/25/17	New Issuance	196	Preferred "C"	\$ 0.08	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
8/1/17	New Issuance	350,000	Common	\$ 0.10	No	New Issuance-Mark Herskowitz (2)	Debt conversion	Restricted	Section 144
8/7/17	New Issuance	981,067	Common	\$ 0.06	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
8/21/17	New Issuance	971,043	Common	\$ 0.062	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
8/24/17	New Issuance	700,000	Common	\$ 0.062	No	New Issuance-R Herskowitz 2011 Irrv. TR (2)	Debt conversion	Restricted	Section 144
8/24/17	New Issuance	50,000	Preferred "E"	\$ 0.07	No	New Issuance-Chase Financing (2)	Financing cost	Restricted	Section 144
8/24/17	New Issuance	50,000	Preferred "E"	\$ 0.07	No	New Issuance-Chase Financing Inc (2) Profit Sh.	Financing cost	Restricted	Section 144
9/5/17	New Issuance	350,000	Common	\$ 0.062	No	New Issuance-Mark Herskowitz (2)	Debt conversion	Restricted	Section 144
9/20/17	New Issuance	952,043	Common	\$ 0.062	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
9/28/17	New Issuance	300	Preferred "C"	\$ 0.09	No	New Issuance-Gerald Hickson (3)	Financing cost	Restricted	Section 144
10/3/17	New Issuance	987,640	Common	\$ 0.062	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
10/18/17	New Issuance	40	Preferred "D"	\$ 0.18	No	New Issuance-Sovereign Partners (3)	Debt conversion	Restricted	Section 144
10/23/17	New Issuance	991,943	Common	\$ 0.062	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
10/23/17	New Issuance	210	Preferred "C"	\$ 0.14	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
11/6/17	New Issuance	500,000	Common	\$ 0.062	No	New Issuance-Mark Herskowitz (2)	Debt conversion	Restricted	Section 144
11/6/17	New Issuance	2,878,058	Common	\$ 0.062	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
12/4/17	New Issuance	1,502,294	Common	\$ 0.062	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
12/6/17	Conversion	(50,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc (2)	Share exchange	Restricted	Section 144
12/6/17	Conversion	700,000	Common	\$ 0.10	No	Conversion-Chase Financing Inc (2)	Share exchange	Restricted	Section 144
12/12/17	New Issuance	100,000	Preferred "E"	\$ 0.09	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
12/19/17	Conversion	(100,000)	Preferred "E"	\$ -	No	Conversion-Robert Herskowitz (2)	Share exchange	Restricted	Section 144
12/19/17	Conversion	1,400,000	Common	\$ 0.08	No	Conversion-Robert Herskowitz (2)	Share exchange	Restricted	Section 144
1/8/18	New Issuance	1,504,281	Common	\$ 0.057	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
1/18/18	New Issuance	100,000	Preferred "E"	\$ 0.06	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144

2/9/18	New Issuance	1,496,661	Common	\$ 0.057	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
2/23/18	Conversion	(100,000)	Preferred "E"	\$ -	No	Conversion-Robert Herskowitz (2)	Share exchange	Restricted	Section 144
2/23/18	Conversion	1,400,000	Common	\$ 0.05	No	Conversion-Robert Herskowitz (2)	Share exchange	Restricted	Section 144
2/23/18	Conversion	(70,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc Profit Sh.(2)	Share exchange	Restricted	Section 144
2/23/18	Conversion	980,000	Common	\$ 0.05	No	Conversion-Chase Financing Inc Profit Sh. (2)	Share exchange	Restricted	Section 144
3/5/18	New Issuance	1,510,797	Common	\$ 0.057	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
3/31/18	New Issuance	1,521,904	Common	\$ 0.057	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
4/3/18	New Issuance	849,123	Common	\$ 0.10	No	New Issuance-Mark Herskowitz (2)	Financing cost	Restricted	Section 144
4/16/18	New Issuance	1,513,789	Common	\$ 0.057	No	New Issuance-Alpha Capital Anstalt (1)	Share exchange	Restricted	Section 144
4/16/18	New Issuance	100,000	Preferred "E"	\$ 0.06	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Financing cost	Restricted	Section 144
4/23/18	New Issuance	1,039,571	Common	\$ 0.057	No	New Issuance-Alpha Capital Anstalt (1)	Share exchange	Restricted	Section 144
5/11/18	New Issuance	420	Preferred "C"	\$ 0.06	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
5/11/18	New Issuance	100,000	Preferred "E"	\$ 0.06	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Financing cost	Restricted	Section 144
5/29/18	New Issuance	1,985,374	Common	\$ 0.049	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
5/29/18	New Issuance	1,550,000	Common	\$ 0.049	No	New Issuance-Robert Herskowitz (2)	Debt conversion	Restricted	Section 144
6/11/18	Conversion	(75,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc Profit Sh. (2)	Share exchange	Restricted	Section 144
6/11/18	Conversion	1,050,000	Common	\$ 0.05	No	Conversion-Chase Financing Inc Profit Sh. (2)	Share exchange	Restricted	Section 144
6/30/18	New Issuance	14,300	Preferred "E"	\$ 0.04	No	Immaterial reconciling items	N/A	Restricted	Section 144
6/30/18	New Issuance	10,000	Common	\$ 0.04	No	Immaterial reconciling items	N/A	Restricted	Section 144
7/3/18	New Issuance	1,520,646	Common	\$ 0.049	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
7/30/18	Conversion	(125)	Preferred "C"	\$ -	No	Conversion-Navesink Device Initiatives (3)	Share exchange	Restricted	Section 144
7/30/18	Conversion	625,000	Common	\$ 0.04	No	Conversion-Navesink Device Initiatives (3)	Share exchange	Restricted	Section 144
7/30/18	Conversion	(125)	Preferred "C"	\$ -	No	Conversion-Navesink Device Initiatives (3)	Share exchange	Restricted	Section 144
7/30/18	Conversion	625,000	Common	\$ 0.04	No	Conversion-Navesink Device Initiatives (3)	Share exchange	Restricted	Section 144
7/31/18	New Issuance	710	Preferred "C"	\$ 0.04	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
7/31/18	New Issuance	105	Preferred "C"	\$ 0.04	No	New Issuance-Sovereign Partners LLC (3)	Financing cost	Restricted	Section 144
7/31/18	New Issuance	50	Preferred "D"	\$ 0.04	No	New Issuance-Navesink Device Initiatives (3)	Financing cost	Restricted	Section 144
7/31/18	New Issuance	10	Preferred "D"	\$ 0.04	No	New Issuance-Paradigm Capital (3)	Financing cost	Restricted	Section 144
7/31/18	New Issuance	200,000	Preferred "E"	\$ 0.04	No	New Issuance-Chase Financing Inc Profit Sh. (3)	Financing cost	Restricted	Section 144
8/23/18	Conversion	(35,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc Profit Sh. (3)	Share exchange	Restricted	Section 144
8/23/18	Conversion	490,000	Common	\$ 0.04	No	Conversion-Chase Financing Inc Profit Sh.(3)	Share exchange	Restricted	Section 144
8/23/18	Conversion	(50,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing (2)	Share exchange	Restricted	Section 144
8/23/18	Conversion	700,000	Common	\$ 0.04	No	Conversion-Chase Financing (2)	Share exchange	Restricted	Section 144
8/27/18	New Issuance	816,326	Common	\$ 0.049	No	New Issuance-Mark Herskowitz (2)	Financing cost	Restricted	Section 144
10/9/18	New Issuance	1,031,758	Common	\$ 0.034	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
11/26/18	Conversion	(50,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc Profit Sh.(1)	Share exchange	Restricted	Section 144
11/26/18	Conversion	700,000	Common	\$ 0.02	No	Conversion-Chase Financing Inc Profit Sh. (1)	Share exchange	Restricted	Section 144
11/26/18	Conversion	(100,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc Profit Sh. (1)	Share exchange	Restricted	Section 144
11/26/18	Conversion	1,400,000	Common	\$ 0.02	No	Conversion-Chase Financing Inc Profit Sh. (1)	Share exchange	Restricted	Section 144
1/2/19	New Issuance	420	Preferred "C"	\$ 0.03	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
1/2/19	New Issuance	140	Preferred "C"	\$ 0.03	No	New Issuance-Sovereign Partners LLC (3)	Financing cost	Restricted	Section 144
1/2/19	New Issuance	10	Preferred "D"	\$ 0.03	No	New Issuance-Paradigm Capital (3)	Financing cost	Restricted	Section 144
2/5/19	New Issuance	5,004,552	Common	\$ 0.029	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144

2/13/19	New Issuance	600,000	Common	\$ 0.02	No	New Issuance-Mark Herskowitz (2)	Consulting services	Restricted	Section 144
3/12/19	Conversion	(100,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc Profit Sh. (2)	Share exchange	Restricted	Section 144
3/12/19	Conversion	1,400,000	Common	\$ 0.04	No	Conversion-Chase Financing Inc Profit Sh. (2)	Share exchange	Restricted	Section 144
4/1/19	New Issuance	4,139,272	Common	\$ 0.029	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
4/5/19	New Issuance	600,000	Common	\$ 0.05	No	New Issuance-Mark Herskowitz (2)	Financing cost	Restricted	Section 144
5/1/19	New Issuance	413,218	Common	\$ 0.05	No	New Issuance-Chase Financing Inc (2)	Financing cost	Restricted	Section 144
5/1/19	New Issuance	1,091,718	Common	\$ 0.05	No	New Issuance-Robert Herskowitz (2)	Financing cost	Restricted	Section 144
5/1/19	New Issuance	1,395,555	Common	\$ 0.05	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Financing cost	Restricted	Section 144
5/8/19	New Issuance	420	Preferred "C"	\$ 0.04	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
5/8/19	New Issuance	140	Preferred "C"	\$ 0.04	No	New Issuance-Sovereign Partners LLC (3)	Financing cost	Restricted	Section 144
5/8/19	New Issuance	10	Preferred "D"	\$ 0.04	No	New Issuance-Paradigm Capital (3)	Financing cost	Restricted	Section 144
5/8/19	New Issuance	30	Preferred "D"	\$ 0.04	No	New Issuance-Thomas Nelson (7)	Financing cost	Restricted	Section 144
5/8/19	New Issuance	15	Preferred "D"	\$ 0.04	No	New Issuance-JAN Stock Trust (7)	Financing cost	Restricted	Section 144
5/8/19	New Issuance	15	Preferred "D"	\$ 0.04	No	New Issuance-KEN Stock Trust (7)	Financing cost	Restricted	Section 144
5/8/19	New Issuance	175,000	Preferred "E"	\$ 0.04	No	New Issuance-Robert Herskowitz (2)	Consulting services	Restricted	Section 144
5/8/19	New Issuance	150,000	Preferred "E"	\$ 0.04	No	New Issuance-Kenneth Schaefer (7)	Consulting services	Restricted	Section 144
6/11/19	New Issuance	600,000	Common	\$ 0.05	No	New Issuance-Mark Herskowitz (3)	Financing cost	Restricted	Section 144
6/19/19	New Issuance	4,083,006	Common	\$ 0.0195	No	New Issuance-Alpha Capital Anstalt (1)	Debt conversion	Restricted	Section 144
7/11/19	New Issuance	2,800,000	Common	\$ 0.04	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Financing cost	Restricted	Section 144
7/16/19	New Issuance	400	Preferred "B"	\$ 0.04	No	New Issuance-LICGO Partners LLC (3)	Financing cost	Restricted	Section 144
7/16/19	New Issuance	210	Preferred "B"	\$ 0.04	No	New Issuance-Sovereign Partners LLC (3)	Financing cost	Restricted	Section 144
7/16/19	New Issuance	130	Preferred "B"	\$ 0.04	No	New Issuance-Paradigm Capital Holdings (3)	Financing cost	Restricted	Section 144
7/16/19	New Issuance	260	Preferred "B"	\$ 0.04	No	New Issuance-Navesink Device Initiatives LLC (3)	Financing cost	Restricted	Section 144
7/16/19	New Issuance	210	Preferred "C"	\$ 0.04	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
7/16/19	New Issuance	70	Preferred "C"	\$ 0.04	No	New Issuance-Sovereign Partners LLC (3)	Financing cost	Restricted	Section 144
7/16/19	New Issuance	10	Preferred "D"	\$ 0.04	No	New Issuance-Paradigm Capital (3)	Financing cost	Restricted	Section 144
10/9/19	New Issuance	300,000	Preferred "E"	\$ 0.03	No	New Issuance-Chase Financing Inc Profit Sh. (2)	Share exchange	Restricted	Section 144
10/11/19	New Issuance	210	Preferred "C"	\$ 0.02	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
10/11/19	New Issuance	105	Preferred "C"	\$ 0.02	No	New Issuance-Sovereign Partners LLC (3)	Financing cost	Restricted	Section 144
10/11/19	New Issuance	10	Preferred "D"	\$ 0.02	No	New Issuance-Paradigm Capital (3)	Financing cost	Restricted	Section 144
10/29/19	New Issuance	1,400,000	Common	\$ 0.02	No	New Issuance-Chase Financing Inc Profit Sh.(2)	Share exchange	Restricted	Section 144
10/29/19	New Issuance	(100,000)	Preferred "E"	\$ -	No	Conversion-Chase Financing Inc Profit Sh. (2)	Share exchange	Restricted	Section 144
11/15/19	New Issuance	600,000	Common	\$ 0.02	No	New Issuance-Mark Herskowitz (2)	Financing cost	Restricted	Section 144
12/31/19	New Issuance	720,000	Common	\$ 0.02	No	New Issuance - Nelson Group (7)	Financing cost	Restricted	Section 144
12/31/19	New Issuance	210	Preferred "C"	\$ 0.02	No	New Issuance-LICGO Partners (3)	Financing cost	Restricted	Section 144
12/31/19	New Issuance	70	Preferred "C"	\$ 0.02	No	New Issuance-Sovereign Partners LLC (3)	Financing cost	Restricted	Section 144
12/31/19	New Issuance	10	Preferred "D"	\$ 0.02	No	New Issuance-Paradigm Capital (3)	Financing cost	Restricted	Section 144

- (1) Alpha Capital Anstalt is an entity controlled by its Board of Directors. The managing directors are Konrad Ackerman and Nicole Feuerstein.
- (2) Chase Financing Inc. and Chase Financing Inc. Profit Sharing and 401K Plan are entities controlled by Robert Herskowitz and Mark Herskowitz.
- (3) Paradigm Capital Partners LLC, Navasink Device Initiatives LLC, Sovereign Partners LLC and LICGO Partners LLC are entities controlled, in equal parts by Alan Goddard and Michael Lichtenstein.
- (4) Cadence Holdings LLC and TPC Holdings Group LLC are entities controlled in equal parts by Steven Pollan and Daniel Meyers.
- (5) Mayer and Associates LLC is an entity controlled by Benjamin Mayer
- (6) OmniVance Advisors has ceased operations or has not notified the company of any changes. All communications from the company have gone unanswered.
- (7) Thomas Nelson and the KEN and JAN Stock Trusts are all partnerships and/or Trusts controlled by Thomas Nelson and his agents

Use the space below to provide any additional details, including footnotes to the table above:



## COMMON STOCK

Date	Description	Change in Shares	Running Total
2/2/2016	New Issuance-Alpha Capital Anstalt	970,980	59,753,464
2/17/2016	New Issuance-Alpha Capital Anstalt	1,614,248	61,367,712
2/25/2016	New Issuance-Robert Herskowitz	750,000	62,117,712
3/21/2016	New Issuance-Paradigm Capital Holdings	1,400,000	63,517,712
3/21/2016	New Issuance-Robert Herskowitz	200,000	63,717,712
3/29/2016	New Issuance-Alpha Capital Anstalt	404,630	64,122,342
3/29/2016	New Issuance-James J Loures	500,000	64,622,342
4/13/2016	New Issuance-Robert Herskowitz	280,000	64,902,342
4/13/2016	New Issuance-Robert Herskowitz	280,000	65,182,342
4/13/2016	New Issuance-Robert Herskowitz 2011 Irv TR	140,000	65,322,342
4/13/2016	New Issuance-Chase Financial	148,160	65,470,502
4/13/2016	New Issuance-Mark Herskowitz	185,195	65,655,697
4/13/2016	New Issuance-Andrew Schoenzeit	37,040	65,692,737
4/13/2016	New Issuance-Robert Herskowitz 2011 Irv TR	431,376	66,124,113
4/26/2016	New Issuance-LICGO Partners	1,837,500	67,961,613
4/26/2016	Conversion-Mayer & Associates	200,200	68,161,813
5/2/2016	New Issuance-Robert Herskowitz	472,106	68,633,919
5/5/2016	New Issuance-Alpha Capital Anstalt	998,099	69,632,018
5/17/2016	New Issuance-Alpha Capital Anstalt	422,669	70,054,687
5/17/2016	New Issuance-Navesink	625,000	70,679,687
5/18/2016	New Issuance-LICGO Partners	525,000	71,204,687
5/18/2016	Conversion-Mayer & Associates	220,000	71,424,687
6/1/2016	New Issuance-Alpha Capital Anstalt	814,314	72,239,001
6/6/2016	New Issuance-Mark Herskowitz	1,000,000	73,239,001
6/6/2016	New Issuance-Chase Financing Inc Profit Sh.	1,050,000	74,289,001
6/6/2016	New Issuance-Robert Herskowitz	280,000	74,569,001
6/6/2016	New Issuance-Robert Herskowitz 2011 Irv TR	70,000	74,639,001
6/8/2016	New Issuance-Alpha Capital Anstalt	484,148	75,123,149
6/27/2016	New Issuance-Navesink	625,000	75,748,149
7/18/2016	New Issuance-Cadence Holdings LLC	100,000	75,848,149
7/18/2016	New Issuance-TPC Holdings Group	150,000	75,998,149
7/21/2016	New Issuance-Robert Herskowitz	700,000	76,698,149
7/21/2016	New Issuance-Robert Herskowitz 2011 Irv TR	70,000	76,768,149
7/21/2016	New Issuance-Chase Financial	945,000	77,713,149
8/2/2016	New Issuance-Navesink	625,000	78,338,149
8/29/2016	New Issuance-Alpha Capital Anstalt	954,925	79,293,074
9/7/2016	New Issuance-Chase Financial	945,000	80,238,074
9/19/2016	New Issuance-Alpha Capital Anstalt	521,784	80,759,858
9/19/2016	New Issuance-Mark Herskowitz	805,147	81,565,005
9/19/2016	New Issuance-Marc Berger	400,000	81,965,005
11/21/2016	New Issuance-Alpha Capital Anstalt	957,485	82,922,490
12/6/2016	New Issuance-Alpha Capital Anstalt	962,118	83,884,608
12/12/2016	New Issuance-LICGO Partners	755,300	84,639,908
1/9/2017	New Issuance-Alpha Capital Anstalt	971,074	85,610,982
1/9/2017	New Issuance-Mark Herskowitz	400,000	86,010,982
3/1/2017	New Issuance-Alpha Capital Anstalt	989,425	87,000,407
3/3/2017	New Issuance-Chase Financial	1,400,000	88,400,407
3/3/2017	New Issuance-Robert Herskowitz	560,000	88,960,407
3/3/2017	New Issuance-R Herskowitz 2011 Irrv. TR	140,000	89,100,407

3/10/2017	Issuance-Mark Herskowitz	400,000	89,500,407
3/21/2017	New Issuance-Alpha Capital Anstalt	355,803	89,856,210
4/19/2017	New Issuance-Paradigm Capital Holdings	400,000	90,256,210
5/10/2017	New Issuance-Navesink	625,000	90,881,210
5/17/2017	New Issuance-OmniVance Advisors LLC	100,000	90,981,210
6/19/2017	New Issuance-Alpha Capital Anstalt	1,096,312	92,077,522
7/11/2017	New Issuance-Robert Herskowitz	1,400,000	93,477,522
7/11/2017	New Issuance-Chase Financial	1,400,000	94,877,522
7/24/2017	New Issuance-Navesink	625,000	95,502,522
7/24/2017	New Issuance-Paradigm Capital Holdings	1,475,000	96,977,522
8/1/2017	New Issuance-Mark Herskowitz	350,000	97,327,522
8/7/2017	New Issuance-Alpha Capital Anstalt	981,067	98,308,589
8/21/2017	New Issuance-Alpha Capital Anstalt	971,043	99,279,632
8/24/2017	New Issuance-R Herskowitz 2011 Irrv. TR	700,000	99,979,632
9/5/2017	New Issuance-Mark Herskowitz	350,000	100,329,632
9/20/2017	New Issuance-Alpha Capital Anstalt	952,043	101,281,675
10/3/2017	New Issuance-Alpha Capital Anstalt	987,640	102,269,315
10/23/2017	New Issuance-Alpha Capital Anstalt	991,943	103,261,258
11/6/2017	New Issuance-Mark Herskowitz	500,000	103,761,258
11/6/2017	New Issuance-Alpha Capital Anstalt	2,878,058	106,639,316
12/4/2017	New Issuance-Alpha Capital Anstalt	1,502,294	108,141,610
12/6/2017	New Issuance-Chase Financing Inc	700,000	108,841,610
12/12/2017	New Issuance-Scott J Weiner	1,000,000	109,841,610
12/19/2017	New Issuance-Robert Herskowitz	1,400,000	111,241,610
12/31/2017	Cancellation-Scott J Weiner	(1,000,000)	110,241,610
1/8/2018	New Issuance-Alpha Capital Anstalt	1,504,281	111,745,891
2/9/2018	New Issuance-Alpha Capital Anstalt	1,496,661	113,242,552
2/23/2018	New Issuance-Robert Herskowitz	1,400,000	114,642,552
2/23/2018	New Issuance-Chase Financing Inc Profit Sh.	980,000	115,622,552
3/5/2018	New Issuance-Alpha Capital Anstalt	1,510,797	117,133,349
4/2/2018	New Issuance-Alpha Capital Anstalt	1,521,904	118,655,253
4/3/2018	New Issuance-Mark Herskowitz	849,123	119,504,376
4/16/2018	New Issuance-Alpha Capital Anstalt	1,513,789	121,018,165
4/23/2018	New Issuance-Alpha Capital Anstalt	1,039,571	122,057,736
5/29/2018	New Issuance-Alpha Capital Anstalt	1,985,374	124,043,110
5/29/2018	New Issuance-Robert Herskowitz	1,550,000	125,593,110
6/11/2018	New Issuance-Chase Financing Inc Profit Sh.	1,050,000	126,643,110
7/3/2018	New Issuance-Alpha Capital Anstalt	1,520,646	128,163,756
7/30/2018	New Issuance-WilCo	625,000	128,788,756
7/30/2018	New Issuance-WilCo	625,000	129,413,756
8/23/2018	New Issuance-Chase Financing Inc Profit Sh.	490,000	129,903,756
8/23/2018	New Issuance-Chase Financing	700,000	130,603,756
8/27/2018	New Issuance-Mark Herskowitz	816,326	131,420,082
10/9/2018	New Issuance-Alpha Capital Anstalt	1,031,758	132,451,840
11/26/2018	New Issuance-Chase Financing Inc Profit Sh.	700,000	133,151,840
11/26/2018	New Issuance-Chase Financing Inc Profit Sh.	1,400,000	134,551,840
2/5/2019	New Issuance-Alpha Capital Anstalt	5,004,552	139,556,392
2/13/2019	New Issuance-Mark Herskowitz	600,000	140,156,392
3/12/2019	New Issuance-Chase Financing Inc Profit Sh.	1,400,000	141,556,392
4/1/19	New Issuance-Alpha Capital Anstalt	4,139,272	145,695,664
4/5/19	New Issuance-Mark Herskowitz	600,000	146,295,664
5/1/19	New Issuance-Chase Financing Inc	413,218	146,708,882

5/1/19	New Issuance-Robert Herskowitz	1,091,718	147,800,600
5/1/19	New Issuance-Chase Financing Inc Profit Sh.	1,395,555	149,196,155
6/11/19	New Issuance-Mark Herskowitz	600,000	149,796,155
6/19/19	New Issuance-Alpha Capital Anstalt	4,083,006	153,879,161
7/11/19	New Issuance-Chase Financing Inc Profit Sh.	2,800,000	156,679,161
10/29/19	New Issuance-Chase Financing Inc Profit Sh.	1,400,000	158,079,161
11/15/19	New Issuance-Mark Herskowitz	600,000	158,679,161
12/31/19	New Issuance- Chase Financing	720,000	159,399,161

PREFERRED B STOCK

Date	Description	Change in Shares	Running Total
3/23/2011*	New Issuance-Centurion Credit Resources	1,000	1,000
7/16/19	New Issuance-LICGO Partners LLC	400	1,400
7/16/19	New Issuance-Sovereign Partners LLC	210	1,610
7/16/19	New Issuance-Paradigm Capital Holdings	130	1,740
7/16/19	New Issuance-Navesink Device Initiatives LLC	260	2,000

(\*) These shares were placed on Stop Transfer in 2016 due to criminal action against the parent company of the holder. In 2017 the Company's Board of Directors canceled these shares.

PREFERRED C STOCK

Date	Description	Change in Shares	Running Total
3/21/2016	New Issuance-Paradigm Capital	800	4,885
4/26/2016	New Issuance-LICGO Partners	1,050	5,935
4/26/2016	New Issuance-Paradigm Capital	325	6,260
5/17/2016	Conversion-Navesink Device	(125)	6,135
5/18/2016	New Issuance-LICGO Partners	300	6,435
5/18/2016	New Issuance-Paradigm Capital	50	6,485
6/27/2016	Conversion-Navesink Device	(125)	6,360
8/2/2016	Conversion-Navesink Device	(125)	6,235
4/19/2017	Conversion-Paradigm Capital	(80)	6,155
4/19/2017	New Issuance-LICGO Partners	157	6,312
5/10/2017	Conversion-Navesink Device	(125)	6,187
7/24/2017	Conversion-Navesink Device	(125)	6,062
7/24/2017	Conversion-Paradigm Capital	(295)	5,767
7/25/2017	New Issuance-LICGO Partners	196	5,963
9/28/2017	New Issuance-Gerald Hickson	300	6,263
10/23/2017	New Issuance-LICGO Partners	210	6,473
1/18/2018	New Issuance-LICGO Partners	210	6,683
5/11/2018	New Issuance-LICGO Partners	210	6,893
7/30/2018	Conversion-Navesink Device	(125)	6,768
7/30/2018	Conversion-Navesink Device	(125)	6,643
7/31/2018	New Issuance-LICGO Partners	500	7,143
7/31/2018	New Issuance-LICGO Partners	210	7,353
7/31/2018	New Issuance-Sovereign Partners LLC	105	7,458
1/2/2019	New Issuance-LICGO Partners	420	7,878
1/2/2019	New Issuance-Sovereign Partners LLC	140	8,018
5/8/19	New Issuance-LICGO Partners	420	8,438
5/8/19	New Issuance-Sovereign Partners LLC	140	8,578
7/16/19	New Issuance-LICGO Partners	210	8,788
7/16/19	New Issuance-Sovereign Partners LLC	70	8,858
10/11/19	New Issuance-LICGO Partners	210	9,068
10/11/19	New Issuance-Sovereign Partners LLC	105	9,173
12/31/19	New Issuance-LICGO Partners	210	9,383

12/31/19	New Issuance-Sovereign Partners LLC	70	9,453
----------	-------------------------------------	----	-------

PREFERRED D STOCK

<u>Date</u>	<u>Description</u>	<u>Change in Shares</u>	<u>Running Total</u>
12/31/2017	New Issuance-Sovereign Partners	40	40
7/31/2018	New Issuance-Navesink Device Initiatives	50	90
7/31/2018	New Issuance-Paradigm Capital	10	100
1/2/2019	New Issuance-Paradigm Capital	10	110
5/8/19	New Issuance-Paradigm Capital	10	120
5/8/19	New Issuance-Thomas Nelson	30	150
5/8/19	New Issuance-JAN Stock Trust	15	165
5/8/19	New Issuance-KEN Stock Trust	15	180
7/16/19	New Issuance-Paradigm Capital	10	190
10/11/19	New Issuance-Paradigm Capital	10	200
12/31/19	New Issuance-Paradigm Capital	10	210

PREFERRED E STOCK

<u>Date</u>	<u>Description</u>	<u>Change in Shares</u>	<u>Running Total</u>
2/25/2016	New Issuance-Robert Herskowitz	100,000	787,540
3/21/2016	New Issuance-Mayer & Associates	14,300	801,840
4/26/2016	Conversion-Mayer & Associates	(14,300)	787,540
4/26/2016	New Issuance-Mayer & Associates	14,300	801,840
5/18/2016	Conversion-Mayer & Associates	(14,300)	787,540
6/6/2016	New Issuance-Mark Herskowitz 401K Trust	100,000	887,540
6/6/2016	New Issuance-Chase Financing Inc Profit Sh.	35,000	922,540
6/6/2016	New Issuance-Chase Financing	100,000	1,022,540
6/6/2016	Conversion-Chase Financing Inc Profit Sh.	(75,000)	947,540
7/21/2016	Conversion-Chase Financing Inc	(67,500)	880,040
7/21/2016	Conversion-Robert Herskowitz	(30,000)	850,040
9/7/2016	Conversion-Chase Financing Inc	(67,500)	782,540
9/19/2016	New Issuance-Chase Financing Inc Profit Sh.	75,000	857,540
1/9/2017	New Issuance-Chase Financing Inc Profit Sh.	105,000	962,540
3/3/2017	Cancellation	(105,000)	857,540
3/3/2017	New Issuance-Chase Financing	50,000	907,540
3/3/2017	New Issuance-Chase Financing Inc Profit Sh.	70,000	977,540
3/3/2017	Conversion-Chase Financing	(100,000)	877,540
5/17/2017	New Issuance-Chase Financing	100,000	977,540
7/11/2017	Conversion-Robert Herskowitz	(100,000)	877,540
7/11/2017	Conversion-Chase Financing	(100,000)	777,540
8/24/2017	New Issuance-Chase Financing	50,000	827,540
8/24/2017	New Issuance-Chase Financing Inc Profit Sh.	50,000	877,540
12/6/2017	New Issuance-Chase Financing	(50,000)	827,540
12/12/2017	New Issuance-Robert Herskowitz	100,000	927,540
12/19/2017	Conversion-Robert Herskowitz	(100,000)	827,540
1/18/2018	New Issuance-Robert Herskowitz	100,000	927,540
2/23/2018	Conversion-Robert Herskowitz	(100,000)	827,540
2/23/2018	Conversion-Chase Financing Inc Profit Sh.	(70,000)	757,540
4/16/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	857,540
5/11/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	957,540
6/11/2018	Conversion-Chase Financing Inc Profit Sh.	(75,000)	882,540
7/31/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	982,540
7/31/2018	New Issuance-Chase Financing Inc Profit Sh.	100,000	1,082,540
8/23/2018	Conversion-Chase Financing Inc Profit Sh.	(35,000)	1,047,540
8/23/2018	Conversion-Chase Financing	(50,000)	997,540
11/26/2018	Conversion-Chase Financing Inc Profit Sh.	(50,000)	947,540
11/26/2018	Conversion-Chase Financing Inc Profit Sh.	(100,000)	847,540
3/12/2019	Conversion-Chase Financing Inc Profit Sh.	(100,000)	747,540
5/8/19	New Issuance-Robert Herskowitz	175,000	922,540
5/8/19	New Issuance-Kenneth Schaefer	150,000	1,072,540
7/1/19	Conversion-Chase Financing Inc Profit Sh.	(200,000)	872,540
10/9/19	New Issuance-Chase Financing Inc Profit Sh.	300,000	1,172,540
10/29/19	Conversion-Chase Financing Inc Profit Sh.	(100,000)	1,072,540

## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures in the past two completed fiscal years and any subsequent interim period. See Table below.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)
03/29/2016	-	316,250.00	-	3/28/17	Convertible into common shares at \$.0678/share on due date	Alpha Capital Anstalt (1)	Loan Services
04/21/2016	-	460,005.75	-	4/20/17	Convertible into common shares at \$.0678/share on due date	Alpha Capital Anstalt (1)	Loan Services
05/13/2016	153,527.88	307,055.75	-	5/12/17	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
09/16/2016	402,505.75	402,505.75	-	9/15/17	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
12/31/2016	345,005.75	345,005.75	-	12/30/17	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
08/16/2017	345,005.75	345,005.75	-	8/15/18	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
11/06/2017	362,382.25	362,382.25	-	11/5/18	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
12/31/2017	402,505.75	402,505.75	-	12/30/18	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
05/22/2018	431,382.25	431,382.25	-	5/21/19	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
10/05/2018	230,005.75	230,005.75	-	10/4/19	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
03/22/2019	287,505.75	287,505.75	-	3/21/20	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
6/18/2019	250,010.00	250,010.00	-	6/17/2020	Convertible into common shares at \$.0195/share on due date	Alpha Capital Anstalt (1)	Loan Services
04/08/2016	-	345.00	-	4/7/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
04/14/2016	-	115.00	-	4/13/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
04/22/2016	-	57,523.00	-	4/21/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
05/26/2016	-	126.50	-	5/25/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
06/01/2016	-	172,615.00	-	5/31/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
06/02/2016	-	57,615.00	-	6/1/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
09/30/2016	-	28,750.00	-	9/29/17	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
09/30/2017	86,001.15	86,001.15	-	9/29/18	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
11/03/2017	27,600.00	27,600.00	-	11/2/18	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
01/18/2018	-	138.00	-	1/17/19	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
05/16/2018	28,750.00	28,750.00	-	5/15/19	Convertible into common shares at \$.0195/share on due date	Robert Herskowitz (2)	Loan Services
03/31/2019	108,000.00	108,000.00	-	3/30/20	Inventory revolving line of credit	American Express	Loan Services
12/16/2019	227,304.00	250,000.00	-	12/16/20	Inventory revolving line of credit	Reliant Funding	Loan Services

Use the space below to provide any additional details, including footnotes to the table above:

- (1) Alpha Capital Anstalt is an entity controlled by its Board of Directors. The managing directors are Konrad Ackerman and Nicole Feuerstein.
- (2) Chase Financing Inc. and Chase Financing Inc. Profit Sharing and 401K Plan are entities controlled by Robert Herskowitz.
- (3) Paradigm Capital Partners LLC, Navasink Device Initiatives LLC, Sovereign Partners LLC and LICGO Partners LLC are entities controlled, in equal parts by Alan Goddard and Michael Lietenstein.

<u>Notes payable - Convertible</u>	<u>Date</u>	<u>Account</u>	<u>Amount</u>	<u>OID @ 15%</u>	<u>Total Investment</u>
Note Payable - Alpha Capital Anstalt	04/21/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 400,005.00	\$ 60,000.75	\$ 460,005.75
Note Payable - Alpha Capital Anstalt	05/13/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 267,005.00	\$ 40,050.75	\$ 307,055.75
Note Payable - Alpha Capital Anstalt	09/16/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 350,005.00	\$ 52,500.75	\$ 402,505.75
Note Payable - Alpha Capital Anstalt	12/23/2016	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 300,005.00	\$ 45,000.75	\$ 345,005.75
Note Payable - Alpha Capital Anstalt	08/16/2017	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 300,005.00	\$ 45,000.75	\$ 345,005.75
Note Payable - Alpha Capital Anstalt	11/06/2017	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 315,115.00	\$ 47,267.25	\$ 362,382.25
Note Payable - Alpha Capital Anstalt	05/22/2018	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 375,115.00	\$ 56,267.25	\$ 431,382.25
Note Payable - Alpha Capital Anstalt	10/05/2018	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 200,005.00	\$ 30,000.75	\$ 230,005.75
Note Payable - Alpha Capital Anstalt	10/05/2018	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 200,005.00	\$ 30,000.75	\$ 230,005.75
Note Payable - Alpha Capital Anstalt	6/18/2019	Notes payable - Convertible:Note Payable - Alpha Capital Anstalt (1)	\$ 250,010.00	\$ 37,500.00	\$ 287,510.00

#### 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP  
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: Keith M. Berman  
Title: CEO & CFO  
Relationship to Issuer: Officer & Director

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;  
D. Statement of income;  
E. Statement of cash flows;  
F. Financial notes; and  
G. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

See documents attached hereto.

## 5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

### Overview

Decision Diagnostics Corp. is a necessary services worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose, the PetSure! glucose test strip for the glucose testing of dogs and cats, a test strip designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter, the GenUltimate! 4Pets Glucose system a proprietary glucose measuring system inclusive of the company's GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats and horses. The company also has its GenUltimate! Sure and GenUltimate! Precis test strips, products for off-shore sales. The company has begun Definitive Agreement writing with a large Eastern European distributor for their distribution in the Russian Federation and aligned countries. Both of these products will primarily be sold as an international private label market entry. Export Certificates for GenUltimate! Sure and GenUltimate! Precis have been allowed, and manufacturing and sales were scheduled to begin in February 2020, until the advent of the Coronavirus shut down of our Korean contract manufacturer. There is no domestic or North American markets for these products.

In addition, the company's GenChoice! glucose test strip has completed its clinical trials and filed a 510K application with the U.S. FDA for its clearance. The company has had eleven formal communications with the FDA, inclusive of a face-to-face meeting with FDA management and the review staff. We expect clearance of this product, although we have moved the completion and shipment of our Covid-19 products, due to emergency, ahead of our GenChoice. The explanation below is a done in a manner that all readers will understand.

In mid-February 2020 we were first advised of the large outbreak of Coronavirus in Korea, and in particular in the city of Daegu, Korea. Daegu is the Korean city where since 2016 the company's manufacturing facility and patient trials hospital are located. At first it was difficult to receive information as to the severity of the virus and how it was affecting the company's facility in Daegu, Korea. Subsequently we learned for the first time the use of words "lock down" and lock up." Our contract manufacturer The Bio Co., Ltd. ("The Bio") was eventually described to us as locked down and locked up and was unable to manufacture or ship to us our diabetic testing products from February 22 through March 27, 2020. It was explained that even though The Bio had reopened for business in early March 2020, some of their suppliers, both locally, and in other parts of Korea, and outside of Korea, were still locked down.

As this Coronavirus spread, and with time on their hands during the lock down, we asked The Bio several days after their mid-February 2020 lock down, to look into whether some of our diabetic detection and management technologies could be put to use to develop a coronavirus test.

We had decided that if such a test methodology were possible it was worthwhile from a humanitarian standpoint to use our limited resources at least to try to develop such a test. A few days later we received three cites from The Bio regarding technical papers written in the last five years where the researchers and scientists discussed in those white papers the ability to use a method called impedance to identify and classify certain (now familiar) classes of virus. All three papers described their methodologies in detail and included sample data sets.

In all three cases the researchers designed and built a bench level chemistry methodology and their version of an identification device, and then performed tests on live patients. In all cases the number of patients (subjects) tested was statistically significant. The importance of these publications indicated that a testing device and chemistry method, using impedance (better described as an energy

pulse with traits somewhat similar to an electric current and a radio wave pulse), could be created in short order to measure the presence or absence of such a virus (of interest) such as influenza and H1N1 influenza, and of course SARS and Covid-19. The company's GenUltimate TBG product makes use of impedance technology to measure the number of red blood cells in a patient blood sample, information relevant to a glucose measurement in that same patient. Mr. Berman, the company's CEO, became convinced that a similarly configured device could be built for the determination of Covid-19.

As quickly as it could the company engaged Matthew Musho, PhD (holder or collaborator in 32 patents published in parallel fields) and his wife Leslie to assist in the design of a testing method and device for the measurement of Covid-19.


<https://patents.justia.com/inventor/matthew-k-musho>

The company also engaged FDA practice counsel to prepare the company and its new product for submission for emergency use authorization (EUA) by the FDA. Counsel, already familiar with the company's products and technologies, understood almost immediately what the company was trying to achieve and during the last week in February counsel contacted the FDA. This contact was made a day or two prior to the FDA's eased guidance for EUA, published on February 27, 2020. A subsequent further easing of FDA past policy appeared in a March 16, 2020 guidance policy.

The specifications guidelines set down by Mr. Berman, for creating this Covid-19 testing device and its important chemistry, were that the test must be measured on the company's existing Precise or Advantage glucometers, because they were completed products, having been tested to great length, and now to be adapted for detection of Covid-19 instead of whole blood glucose. In addition, the resulting chemistry would necessarily run using a patients (small sample of) whole blood taken from a finger prick, and later defined as 1-2 microliters (a small drop on a finger tip), and perform the test and provide a result in one minute or less (later redefined as 15 seconds or less), with at least a 95% accuracy. Mr. Berman believed this device was capable of 97-98% accuracy. Three alternative designs were provided and given to the company on March 2. Two of the designs were diagrammed by Mathew Musho, PhD, the third design by a chemist and engineer from The Bio in Korea. The chosen of the three alternative product designs would bear the trade name GenViro! Swift.

The company then set to work, along with Matthew Musho, PhD ("Musho"), to evaluate the designs, keeping in mind the desired specifications of the DECEN CEO and product Program Director, which included availability of components without wait time, time to market (assuming FDA EUA), whether the chosen method was applicable to use in point of care and at-home environments, time of assay from commencement of test and until result, size of the blood sample, and finally cost to produce. Given the company's experience in working with biosensors and with electrode technology, the design review process took less time than originally expected. The entire process took 13 days. The last of these days used to determine which of the two Musho specifications was to be chosen. The design provided by The Bio was discarded because it could not be read on the existing company meter technology, and therefore would require additional development. At the end of this process, the company chose to produce the product shown in the illustrations, the second of the two Musho alternative versions, but shortly thereafter to begin work on the other Musho specification, to be used as a confirmation tool.

**Product Design 1 (chosen)**




The design above is in many regards similar to the direct antibody antigen approaches favored by some of the competitive companies in the Covid-19 testing field. But the major difference (magic) is that the approach used by the company in its GenViro! product allows for swift (15 seconds or less) results using a minimum of blood from a finger prick. As of this writing, work has commenced on the product specification above with components such as the platinum electrodes, platinum carbon paste, industrial films (several types) to make the biosensor, and perhaps a new impedance chip for the meter. The company is operating on an 8-week development schedule and is some 10 days into this schedule. The current development cycle is considered advanced development. For FDA EUA filing and the granting of a Pre-EUA by the FDA, the company is preparing its final working concept filing, to be completed within days of this writing.



On April 1, 2020 the company plans to begin development work on its second product design, a confirmation test for Covid-19. This test, a hybrid but direct antibody/antigen (IGG) method, again making use of the company's expertise in biosensors, will be designed to be used on those the tested Positive Covid-19, and those that tested Negative but are suspected to be false Negatives. This product design is not yet in the advanced development cycle.

**Product Design 2 (confirmation)**



As stated, the company anticipates filing its latest and complete EUA documents with the FDA during the week beginning March 30, 2020, for the registration of its Covid-19 test for Point of Care and At-Home usage. The company is unsure if the At-Home use application can be cleared for Pre-UEA at this point, owing to the historical use of EUA being limited to Point of Care uses. However, the company is in the process of completing packaging and package inserts for three versions of its GenViro! Product, GenViro! Point of Care, GenViro! At-Home use, and GenViro! International in English, Spanish, French, German and Russian languages. The most immediate request made to the FDA will be for Pre-UEA, the new accepted standard for emergency diagnostic products.

Regarding additional product development, the company has completed advanced development work and third party testing of its GenUltimate! TBG test strip and TGB Precise meter and are ready to begin patient testing (clinical trials) in Korea. A clinical site at a prestigious Korean research hospital has been identified and appropriate documentation filed with the Korean FDA. This application was delayed for 30 days beginning in August 2019 when DECN CEO Berman requested the development engineers for the TGB product to change the active enzyme in the chemistry to a variant of Glucose Dehydrogenase (GDH), which provided the TGB product an added precision in use. Earlier in 2019, and in association with the company's advanced development engineers, company CEO Keith Berman asked for a change to the engineering foundation of the GenUltimate! TBG system to work in an identical manner with the company's GenUltimate test strip, same chemistry, same family of meters, thereby allowing the company to offer three essentially identical products, each serving its own somewhat unique purposes, all running on the same test strip foundation, an FDA cleared device. The TGB enhanced version of GenUltimate! is named GenUltimate! Premier and will go on sale commercially just as soon as the company's FDA registered contract manufacturer recovers from the Korean experience with the Covid-19 virus that began in Korea in late January 2020 and reached critical proportions in February 2020. The main needs now to begin manufacturing of this new version (Version 3) test strip is certain tooling needed to be added at the company's manufacturing facility. Gen Premier! owing to its near analyzer level precision (in a handheld device) will carry a substantially higher MSRP, Big Box, and wholesale pricing. The company will continue to sell its GenUltimate! product in existing markets.



As off-shore products GenUltimate! Sure and GenUltimate! Precise are test strips that run on four existing Platinum/Lifescan legacy meters, and will only be sold in select international markets, primarily in the Russian Federation. There are no USA markets for either test strip. The International roll-out decisions were to choose those markets where the products will not encounter certain

performance criteria issues created by the legacy metering platforms that the GenUltimate! Sure and GenUltimate! Precis test strips run on. The GenUltimate! Sure product in particular, although sharing many similarities with the company's GenUltimate! product, does not have the capability for future improvement or upgrade and as a result is viewed in the market and by DECN as a small niche product. Thus, most of the company's attention for International markets will be focused on GenUltimate! Precis. However, manufacturing of the GenUltimate! Sure product will allow the company to continue manufacturing the existing GenUltimate! test strip which uses the same manufacturing line. The GenUltimate! Precis product has more potential in that it is capable of having portions of the company's TGB technology added-on at a later date. Thus, the conclusion was that having two finished products is better than having no product at all, so the company will continue to perform compatibility testing with the family of legacy meters as we grow our relationship with the large Eastern European distributor.

Resources permitting, as 2019 transitions into 2020, we intend to register the company's GenChoice! and GenUltimate! TBG products in the EU, because these products **do** meet ISO guidelines without further development. The GenUltimate! TBG meter, which will undergo 510K prosecution for its metering system, is next up of our diabetes related products for FDA clearance. The test strip, a close relative of the company's GenUltimate! test strip which is already FDA cleared. The company has contracted with the same expert organization that wrote the 510K document and a credentialed IRB who completed the GenChoice! clinical trial data and who will follow the same clearance path for the GenUltimate! TBG system.

### Our Current Business Foundation

Our subsidiaries, Pharma Tech Solutions, Inc., PDA Services, Inc. and PharmaTech Sensor Development Corp. operate in several healthcare products channels. In addition our subsidiary Decision IT Corp. engages in the acquisition and holding of Intellectual Property including Patents and Trademarks and specialty manufacturing equipment acquired for our Korean contract manufacturer of our GenUltimate! as well as our GenSure! and GenChoice! products. Our newest subsidiary Pharmatech Sensor Development Corp. manages our investment in specialty manufacturing machinery and testing laboratories, as well as an inventory credit line to finance inventory purchases of our GenUltimate! and PetSure! products. The company will endeavor to expand the credit line for the management of our GenChoice! and GenUltimate! TBG products in 2019. The company has discontinued its earlier GenStrip 50 product and ended the selling of the last of the inventory in November 2016. All of the GenStrip 50 test strips have subsequently reached expiration dates.

In March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a new product which the company calls GenUltimate! TBG. This product represents a major improvement in diabetic glucose monitoring. The GenUltimate! TBG system will be the first of its kind +/- 7% system. Current ISO (2015) and FDA (2014) guidelines call for glucose monitoring systems to meet a +/- 15% standard, whereby the meter and strip must be within +/- 15% of a reference method in repeated testings 95% of the time. GenUltimate! and GenChoice! are +/- 15% test strips, with GenChoice! perhaps a little bit better, but in each case 97+% of the time in repeated samplings. GenUltimate! TBG is designed to meet the written standards of the ISO and FDA at +/- 7%, 97% of the time – effectively setting a new standard. The company has been funding the development of this system product since 2017, as well as a test strip only derivative version for use with a legacy meter sold overseas. In October 2018 the company implemented a strategic change to its development and manufacturing processes whereby we will standardize around two technology foundations, our GenUltimate! technology and our GenChoice! technology. PetSure! was the first marketable product to make use of the GenChoice! technology foundation, and is currently selling in pet testing channels in the USA, Canada and the EU. GenUltimate! TBG will be the first enhancement of our GenUltimate! technology foundation. The company believes that these changes in our product development processes will lead to quicker to market products and streamlined and less costly manufacturing processes. .



As of this writing, GenUltimate! Precis and GenChoice! products are not yet available for sale in the U.S. or Puerto Rico.

## Historical Construct

Shasta Technologies LLC, the original specifications provider of GenStrip, had an extremely difficult relationship with the US FDA and was the subject of a detailed and damning FDA (Enforcement) Warning Letter on April 8, 2014, and when they refused to respond to this Warning Letter in an expected fashion, the FDA then broadcast a worldwide Safety Notice on April 29, 2014, the FDA version of the Death Penalty. This second letter effectively ended Shasta's ability to be a product design specifier and manufacturer, due to a total lack of regulatory adherence in the highly regulated medical device industry. It is confusing to consider what Shasta could have possibly been thinking. The company's acquisition of Genstrip (now GenUltimate!) was fortuitous in its timing given the finality and outcome of Shasta Technologies' fatal troubles with the FDA. Shasta contested our acquisition and took other legal steps against their FDA lawyer and in retaliation against the company. During the efficacy of these litigations we had success in the courts. In December 2018 we received a grant of a judgment against Shasta for \$3.6 million. We perfected this judgment in California, Pennsylvania, Oregon (Shasta's domicile) and Minnesota. As we began levy against Shasta we accepted their offer of Settlement. As a result of this Settlement we were able to value our acquisition of GenStrip under our 2014 Agreement. A substantial gain occurred and is fully described in our financial report.

The worldwide market for at-home blood glucose testing is an estimated \$17.6 billion as of 2018, inclusive of the 2013 and 2016 changes to the Federal Medicare programs which gutted almost one-third of the U.S. market. The current GenUltimate! competes directly with one of the largest worldwide platform manufacturers the venerable Platinum (formerly Johnson & Johnson) Lifescan Inc. Ultra legacy product. J&J, which had owned Lifescan for more than 25 years, sold its Lifescan division and its venerable products to Platinum, a private equity firm. GenUltimate! (and the earlier GenStrip 50) were developed for use with the Lifescan OneTouch Ultra legacy system for at-home blood glucose testing, a system currently used daily by over 3 million diabetes afflicted Americans and 5.8 million diabetics world-wide. GenUltimate! competes in the overall at-home testing market by offering an economical solution to former users of the legacy platform provider's product. The company's GenUltimate! product is a much improved version. Our business model is unique to this market channel as our major business focus is directed toward diabetics who have attempted a change of their glucose monitoring platforms (systems) or those currently using the Lifescan legacy products but are dealing with escalating prices and lower (if any) insurance reimbursements. At the time of the introduction of GenStrip in March 2013, Lifescan controlled just under 40% of this market and 100% of its own Lifescan, Inc. OneTouch Ultra market. Their overall market share has since dropped below 30%. In October 2018 Lifescan, Inc. was sold to a large California based private equity firm in an asset sale arrangement. This event gave impetus to the changes we have made to our GenUltimate! TBG system, the first and only evolutionary enhancement to be offered to the Lifescan Ultra family of products still in use by over 4 million diabetics worldwide (see Litigation section).

We began our transition into these medical products channels on November 1, 2011 when we completed the acquisition of Diagnostic Newco LLC from its owner Kimberly Binder. Diagnostic Newco LLC was a design company that specialized in product packaging design, medical products advertising design and graphic art. Ms. Binder subsequently joined the staff of the company's Pharma Tech Solutions, Inc. subsidiary specifically for these purposes, and has worked closely with the contract manufacturers for GenUltimate!, making subtle changes to packaging design and more recently integrating the new FDA UDI product identification data system, among other responsibilities. She is also responsible for the package design for new diagnostic products the company is currently working on, including the GenSure! and the upcoming GenChoice! and GenUltimate! TBG products. Ms. Binder is also owner of Genstrip Direct LLC and Full Circle Diabetes LLC, her own distribution companies, which she operates separately from her (Decision Diagnostics Corp. and Pharma Tech Solutions, Inc.) company related responsibilities.

The original Shasta product was acquired by our Pharma Tech subsidiary on March 20, 2014, and fits into a diagnostic product niche, fitting nicely into the world-wide self-test (home test) market that has been growing at a 15% annual rate. Since GenUltimate! is a rather unique product offering, employing a brand name razor blade only model (diagnostic test strip) into a razor (diagnostic meter) -- razor blade (diagnostic test strip) market, the Genstrip 510(k) application made for unusual challenges for the FDA and an educational challenge and opportunity for the company. In fact, the company only concluded its dealings with the FDA in March 2016, but has had subsequent issues pre and post market review staff, an on-going process that was begun on a very sour note by Shasta in October 2009 and ended even more sourly in early 2014. The company believes that upcoming product offerings such as the GenChoice! and GenUltimate! TBG products, which will also be regulated by the FDA but we hope will go through the rigorous comment process, particularly since receipt of a directed landmark ruling by the U.S. FDA, covering our third party developed diagnostics (developed, in development and to be developed). The FDA, however, is accountable to no third party and while we did win major victories and we did deal with certain biases and retaliation during the GenStrip 510K prosecution, we have seen this same type of treatment for our GenChoice! product. However, we remain ever vigilant and continue to retain litigation counsel.

Until our receipt of the March 2016 ruling from the FDA, two years (and growing) was a standard development to market timeline for in-vitro diagnostic products similar to Genstrip / GenUltimate! In fact the long review periods and stifling performance standards established have contributed to a large decline in new products offerings in the USA and the industry since 2014.

In 2019 we again improved GenUltimate!. GenUltimate! has become the only version of the original Genstrip line that will be packaged to conform with the FDA UDI standards, and was released as UDI compliant as of September 24, 2016. Manufacturing of Genstrip 50 ended and on-going sales continued under the GenUltimate! brand, and includes the FDA UDI packaging.

On the business side, in June 2010 the company was approached by the largest retailer in the world for the distribution and sale of the Genstrip product, then about to enter the 510k regulatory review process, at over 5,000 retail stores worldwide. A contract with this retailer was negotiated in September 2010 and subsequently renegotiated and renewed in April 2011 and then for a third time Beginning in November 2016, and as soon as the retail contract was agreed to and as a means to conduct market research, the company began seeking pre-conditioned letters of intent (pre-orders) for Genstrip, while continuing the prosecution of the 510(k) application on behalf of Shasta Technologies before the FDA.

Lifescan Inc., until October 2018, then the diabetes testing division of Johnson & Johnson, sued the company in three separate suits, all in Federal court, beginning in September 2011. These suits proved costly in that their intended purpose was to keep the Genstrip product off of retail market shelves. Until these suits were settled in May 2016, the company's marketing abilities were severely limited. In fact, even as of this writing, the company faces market obstacles brought about by the original litigation with Lifescan, Inc. However, it should be noted that Johnson & Johnson announced in January 2018 that their entire diabetic business (three divisions, multiple products) had been put up for sale, and offers for some or all of their businesses had been received. The sale closed in October 2018 with the completion of an asset sale to a large California based private equity firm, Platinum Private Equity.

The settlements we did achieve with J&J provided a hard-fought victory for the company, particularly since in 2015 Shasta had admitted to patent infringements of all three J&J diabetic medical device patents that were being adjudicated. We settled these lawsuits in a novel manner, where Johnson & Johnson paid the company a settlement amount in cash, in those lawsuits where the company was a defendant, a rarity in matters where the Plaintiff (J&J) had initiated the strike suit in the first place. J&J, as a part of the settlement, also granted the company licenses to three J&J patents (including one patent that J&J subsequently lost as a result of 3<sup>rd</sup> party prosecution by the company, through final action by the US Supreme Court), the larger value gained from this 5-year legal battle. In March 2016, prior to its settlement, the company's Pharma Tech Solutions, Inc. and Decision IT Corp. subsidiaries brought suit against Johnson & Johnson and Lifescan, Inc. in Nevada Federal court for patent infringement, the company alleging that Lifescan, Inc.'s OneTouch Ultra product was and had been infringing both of the company's patents. In March 2017, after a protracted battle with J&J where they tried to invalidate the company's lawsuit, the court in a major ruling agreed that the company will be allowed to move forward (a major victory so early in the suit) and will also be allowed to allege the Doctrine of Equivalents, a legal doctrine that would preclude J&J from twisting words through its pleadings and expert reports to escape justice. In April 2016 the company amended its original suit to include allegations under the Doctrine of Equivalents.

*"The doctrine of equivalents is a legal rule in many (but not all) of the world's patent systems that allows a court to hold a party liable for patent infringement even though the infringing device or process does not fall within the literal scope of a patent claim, but nevertheless is equivalent to the claimed invention(s)."*

Further, in January 2016 the US Supreme Court ruled that the Doctrine of Laches, a defense used by many Defendants in patent infringement suits could no longer be used. This ruling further deprived J&J of one of its most important defenses against the company's current patent infringement claims. All of this action did not dissuade the Nevada District Court trial judge from granting J&J a Motion for Summary Judgment in October 2018. As a result of this ruling, the company filed an appeal to the U.S. Court of Appeals for the Federal Circuit ("Federal Circuit court") in Washington, DC (the patent court). The company's appeal was ruled against by the Federal Circuit court in 4Q 2019. The company, with many other irons in the fire, decided not to avail ourselves of further appeal, thus ending this litigation.

## The Current Business

In the next 120 days the company expects to enter the Covid-19 test kit market with unique, cost effective, accurate and wholly proprietary products. Almost all available resources are being directed to the Covid-19 products (see Business Introduction). It is unknown how big this market will eventually grow to encompass, but given the severity of the Covid-19 pandemic, the fact that the company is developing screening tests, we expect to make a big market entry as we finish our product, manufacture it, and achieve FDA initial and then complete clearance.

The current foundation business is focused on the diabetes testing market, a market dominated by four large pharmaceutical manufacturers who provide very similar and equally focused products, selling at essentially equal prices. Our Genstrip's original introduction, even with the fits and starts, employed a business model different than those models employed by the major market players. Recent successes in the on-line marketplace has allowed the company to alter the market dynamics, lowering average price (which has

occurred) or allowing for increased testing by diabetics for a lesser price, thereby affecting all market segments. The company's major current market focus is to pharmacy chains, grocery chains with in-store pharmacies, large all-purpose retailers with in-store pharmacies, and group buying and chain pharmacy organizations, and for its pet testing products, on-line sales and chain pet supply stores and retail pet outlets. Although this has been part of the company's plans in the recent past, the difficult litigation with Johnson & Johnson as well as the advent of the July 2013 and July 2016 changes to Medicare reimbursement (and followed by private insurers) and the October 2016 reimbursement engineering, pharmacy business models are now blurred. Thus the company successfully added on-line sales to its business model.

The company has also implemented a successful "direct to diabetic" business model and has (independently or along with our distributors) executed on-line agreements with several of the largest retail chains, diabetic supply co-operatives, group purchasing organizations, as well as on-line mass merchandisers such as Amazon.com, EBay, Walmart, Sears, Jet.com and approximately 1050 other on-line cooperatives and product aggregators. The company considers this rapid adoption to be a success gained in a very short period of time.

In June 2017 we were notified by Amazon.com, the largest retail portal for our products where we now currently sell approximately 35,000 boxes of GenUltimate per month, that the listings for our products had been "hacked" by ghost sellers -- individuals and people who listed our products, accepted orders and cash money from diabetics, but were unknown to the company. Oftentimes product was never delivered to the diabetic even after receipt of payment. This practice called freeloading (by Amazon) is not rare, but once started it is difficult to eradicate. The company had to replace almost 6,500 units of GenUltimate as a result of the freeloading. In March 2018 another 3,000 boxes were replaced, leading to lower sales margins in the periods where the replacements too place. The company is in on-going friendly negotiations with its distributors to provide compensation for the effect of the freeloaders. While freeloaders had a cost basis of zero, legitimate sellers and distributors were forced to compete with these zero cost sellers. Prices for GenUltimate plummeted and by October 2017 the product in its largest portal showed a price decline on average of 35%.

With the assistance of Amazon, who themselves became a distributor of GenUltimate!, the company was able to overcome some of these issues. With the assistance of Amazon we reordered our selling practice, implementing base (floor) pricing and implementing real-time policing of listings. As a result, we were able to overcome this freeloading practice. Prices have recovered about one half of the Fall 2017 decline. We are currently in the process of raising prices again. Also, as a result of the "Amazon debacle," the company also eliminated many small distributors of GenUltimate! from the Amazon portal. In 1Q 2019 we further eliminated a group of our wholesalers who may still sell our products, but not on Amazon. While these actions had the effect of lowering sales throughout 2018 and into 2019, our margins and our sales levels are recovering, as our sales increase. The effect of barring wholesalers from selling on Amazon cost the company \$90,000 to \$120,000 in sales for 1Q 2019, mostly through lower inventory levels by our wholesalers. Subsequently, the advent of Covid-19 closed down our Korean contract manufacturer from mid-February through March 27. Our Korean contract manufacturer was the only finished goods producer of our GenUltimate! and PetSure! products. This bottleneck was alleviated as of March 27, but sales were greatly impaired during 1Q 2020.

In March 2017 the company was contacted by the retail giant Walmart, who along with their acquired on-line retailer Jet.com, are attempting to duplicate and surpass the Amazon portal. Our GenUltimate! products have been sold on Walmart's (and Jet.com's) portals since November 2016. In the 2018 discussions Walmart offered us preferential listings on portals and Walmart Depot stocking at their regional transit facilities. We also began discussions, now in process, for the manufacturer of a Walmart house brand version of our GenUltimate! As a result of our agreements with Walmart, GenUltimate! is now sold and fulfilled directly by Walmart. In addition, Walmart has implemented a large on-line store pickup, allowing GenUltimate! users to pick their GenUltimate! product up at Walmart stores. We accepted Walmart's offer (who wouldn't) and changed our distribution agreement with Walmart (and Jet) so that Walmart would sell and fulfill our products directly. We accomplished this while still selling our products directly through Walmart. This business model is called cannibalization with the goal of overall sales maximization. Walmart customers who previously received standing orders for their legacy J&J Lifescan test strips are a part of this new program. The company believes this to be a market enhancing deal since Walmart will become both a "push" and a "pull" retailer. No special pricing of our GenUltimate! products was required to implement this plan, owing, no doubt, to the footprint we have established on the other large on-line portals. Walmart purchase orders for Walmart sales of our products have increased dramatically. We continue to evaluate our prospects with Walmart and we believe we will move toward a global agreement with Walmart for our GenUltimate!, PetSure! and GenChoice! (when cleared) and GenUltimate! TBG products. Meetings were scheduled in the month of May 2019 at both Walmart and CVS pharmacies, primarily for our GenUltimate TBG products. Subsequently we are gearing up our Covid-19 kit business quickly, albeit because of the times, using remote capabilities to reach out to Walmart, CVS, many, many others in the USA, Canada, and internationally.

In March 2016 we also retained a product source company called Retail Monster, to represent our products to large drug chains ("big box pharmacy"), large retailers, chain grocers and the like. Unfortunately the arrangement with Retail Monster did not succeed, primarily because a group of company shareholders and persons claiming to be shareholders poisoned our relationship with Retail Monster early in our contract term, by advocating during repeated calls, a "palace coup." After these incursions by shareholders and

persons claiming to be shareholders, our relationship with Retail Monster remained cordial but was, unfortunately, destined to fail. The two companies decided to end the engagement on December 31, 2016.

The efforts being expended in the “big-box” arena are greatly aided by the company’s recent success with the explosively growing on-line Marketplaces, many sponsored by the large retail pharmacies and retail stores. We expect the same type of response, perhaps even greater for our upcoming Covid-19 test kits. These Marketplaces are fast growing sister organizations to these retailers, and typically not a part of legacy manufacturers marketing plans. The company’s recent successes in the on-line Marketplaces has given the company a beachhead in this market as the uncertainty brought on by the J&J lawsuits has (finally) waned. In mid-March 2016 the largest US retailer agreed to raise the company’s standing to the highest retail “rung” by offering a new supplier contract and in mid-March 2018 this retailer and its recently acquired wholesale products partner contacted the company and implemented a direct relationship. This decision led to inquiries by other big box sellers.

In March 2019 we entered into a long term relationship with PARAGON Sales and Marketing Inc. to support the national growth of both our branded and private label retail products sold under our "Gen" brand, and our private label brands of Alltara!, ConsumerValue!, Infatig!, and Medicius!. We have expanded this relationship to include our Covid-19 sales and distribution efforts.

Initial accounts were assigned to PARAGON for big box and private brand big box agreements include Walmart, CVS, Walgreens, Costco, Kroger and Cardinal Health. PARAGON will also work closely with us in evaluating other potential new retail product categories and products that we may launch in both branded and private label offerings in the future. Sadly, shareholders and non-shareholders have already attempted to contact PARAGON, one such incursion occurring during the writing of our 3Q 2019 Quarterly Report. The company has promised PARAGON that we will take legal action against these people should this activity continue. Instead we were notified that PARAGON contacted their own commerce lawyer and in addition verified the person (name, address, etc.) behind the incursion.



Alltara choice, and GenUltimate TBG is not yet available for sale or distribution in the United States or Puerto Rico.

Since March 2015 when we first we acquired special intellectual property and specialty manufacturing equipment which will shall serve our business interests now and into the future. We have increasingly turned to Alpha Capital Anstalt (“Alpha”), Navesink Device Initiatives, Sovereign Partners and Licgo Partners, whereby these organizations either purchased an 18-month 15% OID derivative instruments or Preferred C stock units, to facilitate the acquisition of intellectual property or manufacturing equipment, or to finance our growth. In 1Q, 2Q and 4Q 2016 and 2Q, 3Q and 4Q 2017, 2Q and 3Q 2018, and 1Q and 2Q 2019 we completed additional financing transactions with both Alpha and/or, Sovereign, and Licgo. Our most recent transactions with Alpha also financed an inventory credit line for the company so that we can meet many of the requirements of the largest retailers and maintain at least \$300,000 in stock on hand at any time. From time to time we drop below this \$300,000 threshold, primarily at the end of fiscal quarters. Alpha also financed our acquisition of new specialty manufacturing equipment to facilitate our contract manufacturer in Korea as they develop our new GenChoice! product.

In June 2018 the company came to terms with an international distributor who would sell the company’s products in Mexico, Puerto Rico and in select South American countries. Initially the sales by the distributor would have been our GenUltimate! test strips and meters, and our GenUltimate! Sure test strips and meters. Governmental approval was needed for these products. This distributor did not distinguish themselves and the association was ended.

However, in late July 2019 the company was contacted by a large Eastern European distributor of J&J/Lifescan, now (Platinum Equity) products. To begin, this distributor wishes to distribute the company’s GenUltimate! Precis product, a product that has no USA market, does not require FDA clearance to be sold overseas but appears to be a natural for Eastern European markets, particularly in

CIS states and the Ukraine. The company must complete an “accuracy” test for the GenPrecis! product, complete the packaging in several Eastern European languages, and then schedule a manufacturing line.

### Additional Background and Foundation

In May 2010, we entered into agreement with Shasta Technologies, Inc. and Broadtree, Inc. This agreement granted our Pharma Tech Solutions, Inc. subsidiary the exclusive marketing rights to a new diagnostic product not yet on the market named Shasta Genstrip (“Genstrip”). The Genstrip product was developed to compete against the market leader in the then \$6.5 billion at home testing market. Shasta was in default of this 2010 Agreement within 90 days of its initiation. Penalties under that agreement and monies owed totaled in excess of \$2 million in “delay” penalties, which they were unable to pay. In April 2011, the company renegotiated its agreement changing its many roles and adding responsibility for regulatory approval, manufacturing and forecasting, international sales and additional sales markets in the U.S. Shasta defaulted under this agreement as well. On March 20, 2014 we acquired the GenStrip intellectual property, its marks and the cleared 510(k). Shasta defaulted on this agreement as well. In addition Shasta breached or defaulted on two insurance settlement agreements, owing to the aforementioned J&J litigation. Shasta also confessed to patent infringement of J&J’s three patents and for one reason or another thought it was in their best interest to sue their previous FDA lawyer, who supposedly did not stop Shasta from commercially damaging themselves.

On April 30, 2014 we first implemented our FDA mandated Quality Plan and are now operating as the manufacturer (operator) of the GenUltimate! test strip. We have implemented subsequent Quality Plans with our Korean contract manufacturer for our GenUltimate! product. Similar Quality Plans and FDA registrations will be in place for the company’s GenChoice! and GenUltimate! TBG products in the near term, and for our GenAccord and GenCambre products later in the coming months. Our overall Quality Plan, a living document, is in its fifth re-write.

The company brought suit against Shasta and the former contract manufacturer in Pennsylvania in November 2018. On December 31, 2018 the Pennsylvania court awarded the company with a \$3.6 million judgment against Shasta. We were pursuing collection of this judgment in Minnesota, California, Oregon and Pennsylvania. To that end we filed for a Writ of Attachment against Shasta for the \$3,600,000. This Writ will allow the company to bring an end to the litigation against Shasta in California and Minnesota (in an action stat that includes our FDA lawyer). On June 29, 2019 Settlement documents were executed by Shasta and the company to bring an end to the litigation in the four states. Shasta agreed to drop all claims against the company, and we agreed not to further pursue Shasta (but not Conductive Technologies, Inc. and not the former DECN shareholders). After five years, the company can now value its acquisition of the GenStrip technology and Marks, and any knowhow. We have done so as of the period ended September 30, 2019 (see financials) and have realized a gain in the period.

We continue to litigate in Pennsylvania against the former contract manufacturer and anticipate a handsome settlement in the coming months, who apparently while working for us, was also working against us and for Johnson & Johnson. The company is also pursuing those persons who owned stock in the company who may have traded stock in the market based on information and documents provided by Shasta, or who were given confidential documents by Shasta, gained through the litigation discovery and provided to these shareholders, who then posted the information on public message boards.

We currently employ nine professionals at or locally managed through our executive business office located at 2660 Townsgate Road, Suite 300, Westlake Village, California 91361. In addition, we maintain two full-time and seven part-time positions located throughout the United States. We also maintain a Quality Assurance office through our exclusive agent in Seoul, Korea as a means to fulfill our quality commitments to the FDA. Our telephone number is (805) 446-1973 and our website addresses are and [www.pharmatechsolutionsinc.com](http://www.pharmatechsolutionsinc.com) and [www.genultimate.com](http://www.genultimate.com). and [www.decisiondiagnostics.com](http://www.decisiondiagnostics.com). Additional web sites will be added for our GenChoice! product (site now in FDA 510K prosecution), our GenUltimate! TBG product and our GenViro! Covid-19 testing products.

As a part of the company’s strategic plans, we have applied (to register) for fourteen Trademarks with the USPTO. The company’s Genstrip product is a registered Trademark of Shasta Technologies LLC. Now that we own this Mark, we do not intend to renew it. Our applications were filed with the USPTO in 1Q and 2Q 2015 and throughout 2016, 2017, 2018 and 2019. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and the establishment of a family of Marks associated with our company and its place in our industry.

As of March 30, 2020, the company has received registration confirmation from the USPTO for the following Marks:

“Alltara!”  
“GenUltimate!”  
“GenSure!”  
“GenChoice!”  
“GenAccord!”  
“GenCambre!”  
“GenUltimate! TBG”  
“Firefly!”  
“ConsumerValue!”  
“Infatig”  
“Medicius!”

Our marks for Alltara!, ConsumerValue!, Infatig!, and Medicius! will be used for product families as an integral part of our relationships with the “big-box” entities. We have several Marks that were filed to further enhance our GenUltimate! TBG product and technology. These Marks were first filed in 2Q 2019. Subsequently we have filed for trademarks for GenUltimate! TBG and Genviro!.

As a result of a product embargo by Shasta and Conductive Technologies, Inc. the company ran into an inventory shortage, and in fact ran out of product on several occasions. However, the inventory problem began to clear up in late May 2016, and with the advent of adding the GenUltimate! product from Korea, shortages were alleviated. The company’s capacity for GenUltimate! production is now 750,000 packages per month (50 count and 100 count packages), for the new GenSure! product 100,000 packages per month (25 count and 50 count packages) and the new GenChoice! product (initial) 150,000 packages per month (50 count and 100 count packages). A mega-retailer has requested minimum inventories of finished product of 150,000 units/boxes. We expect other retailers to make similar requests. The manufacture of GenUltimate! and GenSure! are very similar and this capacity can be viewed as interchangeable. Similarly the manufacture of GenChoice! and GenUltimate! TBG will be similar to the manufacture of GenAccord! and GenCambre! Manufacture of GenPrecis will require additional investment in plant and machinery. The company is also in discussions with Korean contract manufacturers to augment our GenViro! Products, a product line we expect to require capacity to manufacture millions of these kits.

The company is also in discussions with prospective partners for our GenUltimate! TBG and GenViro! Products. While we are much further along with our GenUltimate! TBG product, a competitive mainline, legacy products company. The interest expressed in our GenViro! product has been unprecedented, at least for us, both from large USA based manufacturers and distributors, as well as those overseas. We have thus far decided to take on our Russian Federation partner to distribute our GenViro! test kits in the Russian Federation and elsewhere in Eastern Europe.

The company’s stock currently trades on the OTCMarkets OTC Pink Current tier of the market. The company’s shares are DTC and DWAC eligible.

In mid-2018 the company chose to file a Regulation A offering in an effort to improve its disclosure to the SEC. The company had planned to use this filing, reviewed by the SEC without comment on August 23, 2018, to move toward uplist on the OTCMarkets exchange in 2019. In February 2019 the company, after completing all of the ancillary tasks required of a Reg. A filer, amended its registration with the SEC, a necessary requirement. Subsequently, the company’s stock price improved so that the registration offering price was much lower than the stock trading price. In early March, during the stock price rise, the company was informed that a certain party, who at that point claimed to own approximately 4% of the company’s outstanding shares, wished to buy the entire Reg. A offering on the date said offering became qualified. That would allow this certain party to gain control of the company for approximately \$5.3 million, a value much lower than the trading price of the company’s common stock. This was/is a common predatory M&A strategy often used by private equity funds. On March 18, 2019, acting on a resolution by the company’s Board of Directors, the Reg. A registration was withdrawn.

In February 2019 the company was approved for Deposit/Withdrawal at Custodian (DWAC) a method of electronically transferring new shares or paper [share certificates](#) to and from the [Depository Trust Company \(DTC\)](#) using a Fast Automated Securities Transfer (FAST) service transfer agent as the distribution point. DWAC transfer is a method employed by most funds and large investors.



Business activities throughout the next twelve months:

The company's business on a day-to-day basis includes the distribution of our GenUltimate! products, (50 count and 100 count versions), International distribution of our GenUltimate! Sure and GenUltimate! Precis products (25 count and 50 count versions), and our PetSure! products (30 count and 60 count versions), and throughout 2020 our GenChoice! (25 count, 50 count and 100 count versions), at least in international markets, and the GenUltimate! TBG (25 count, 50 count, 100 count versions and a meter), also in 2020. The company's GenUltimate! TBG product will be sold worldwide and will, require a strategic partner, unless a settlement of our litigation with Johnson & Johnson allows us to sell GenUltimate! TGB independently. The company has chosen one prospective partner looking to pay for the license rights to the GenUltimate! TBG product, a long term royalty for their continuing sales, and the settlement of other matters. The company has just completed a redesign of its GenUltimate! TBG test strip, building a technology foundation around its GenUltimate! technology.

In 1Q and 2Q 2020 we began the development of our GenViro! test kits, two different proprietary and unique technologies. During the month of March 2020 virtually all available company resources have been directed to GenViro!.

In March 2019 the company announced the hiring of PARAGON Marketing and Sales, Inc., a nationwide retail accounts sales and management firm. The company has assigned several high worth "big box" retail accounts to PARAGON, including Walmart Stores, CVS Pharmacies, Walgreens Pharmacies, Cardinal Health (Wholesale). McKesson (private label brands), Kroger and others.

Companies in the manufacturing and marketing channels in the industry all employ packaging processes, including Korean, Chinese and Taiwanese manufacturers. In truth, the manufacturer operations collectively decided **not** to pay an extra \$10,000 for each of the packaging machines, or the \$0.10 for a slightly larger test strip vial (holder). The company believes this "me-tooism" to be a form of mental blinders. In implementing the company's new private label strategy, Decision Diagnostics decided not to bow to the packaging machine or "me-too" limitations. Instead the new packaging to be employed by the company will take into account diabetic testing patterns and the average number of testing days in a month. Private label versions of the company's products will be packaged in sizes of 30 count, 60 count and 120 count packages. This concept has been readily accepted by the company's private label target list in a detailed survey, and it is believed that this new packaging concept will be a marketing coup. Diabetics test every day of the month, not just 1.67 times a day. So a vial of 30 of the company's test strips (and 60 and 120) will accommodate the testing needs of the user, not the limitations of a particular type of packaging machine. Sales to the private label industry will be through private label product groups where every private label partner will own a private label group, each group containing all of the company's products in selective private label packaging.

The company currently has three major private label targets, the largest drug store chain, another top-5 drug store chain, and the second largest grocery store chain. In addition, the private label packaging is being offered to the largest drug store chains in Mexico and Canada. The Mexican chain, who also has numerous stores in Chile and Argentina has moved quickly. However, in all cases the sales process is in the closing stages. Closes of this nature, do however, take time. The company has Trademarked four product label groups for exclusive sales of products to the private label concerns: Alltara!, Advant!, Infatig!, and Medicius!.

Our 12-month business objectives include:

1. The practice of specializing in the distribution of GenUltimate! and PetSure! and GenUltimate! 4Pets products, and the completion of the GenViro!, GenChoice!, and GenUltimate! TBG products. We also intend to add several brand-name medical diagnostic and medical disposable products, lancets through our Firefly! product, as well as several lines of insulin syringes and pen needles, all associated with the on-going care of diabetes-inflicted patients, and the world-wide distribution of our proprietary diagnostic products.
2. Combining our wholesale and retail diagnostics distribution with the major successes we have had in the on-line retail markets, and adding legacy retail organizations (already some legacy retailers of note). See discussion above concerning private label opportunities and our private label lines.
3. Continue to implement the plans provided by our agent MWK LLC, and PARAGON Sales and Marketing in efforts to secure big-box pharmacy chains, chain grocers and nationwide retailers in addition to the private label groups previously discussed.

### Recent Business Milestones:

In 1Q 2019, 2Q 2019, 3Q and 4Q 2019 and 1Q 2020 the company has accomplished the following milestones.

1. In March 2020 we completed design of two Covid-19 test kits for commercial sale as soon as FDA Pre-EUA and EUA approval is gained (see Business Section Introduction).
2. We have prepared for introduction a premier version of our popular GenUltimate! test strip for launch on September 3, 2019. First deliveries for this test strip designed and provided for the benefit of big box stores will be in the 3<sup>rd</sup> week in September.
3. We completed the design and manufacture of PetSure! glucose test strips for the international markets, and completed development of our GenChoice!, GenUltimate! 4Pets and GenUltimate! TBG products.
4. We began FDA 510K prosecution, patient clinical, 3<sup>rd</sup> Party testing and/or clinical trials of two new test strip products, our GenChoice! and GenUltimate! TBG test strips and the GenUltimate! TBG Precise meter. Neither the PetSure! nor GenUltimate! 4Pets products required live patient (pet) clinical testing. We most recently added GenChoice! TBG to our Advanced Development schedule.
5. The company initiated a marketing program to the on-line Marketplaces sponsored by pharmacy chain, department store and grocery store retailers, as well as mass merchandisers, and including the largest retailers. This program has so far been the most successful endeavor since our inception.
6. The company has retained patent counsel to file three patents (in 3Q 2019) for our GenUltimate! TBG and GenPrecis meters and test strips, and for our newest adaptation, our teo GenViro! Covid-19 test kits.

### **Financing Requirements**

At December 31, 2019, we had cash of \$114,334 and negative working capital of \$3,644,036. We anticipate that we will require up to \$250 million in **trade debt financing** to finance our expected sales of our GenViro!, GenUltimate!, GenUltimate! Premier (for big box) GenUltimate! TBG, and GenChoice!. Trade debt financing is traditional debt where the borrower borrows cash, usually from a revolving line of credit used to finance pre-payment for inventory. Money for this type of debt is readily available from wealthy individuals, finance companies or a bank or other financial institution and at the term of the loan pays the lender back in cash. The company has noted substantial disinformation in public forums regarding trade debt financing. The above paragraph is the company's final position regarding its trade debt posture. We will borrow money, finance manufacturing of our product purchases, and then pay the money back to the lender. Fancy derivative and/or toxic equity financing will not be used. We will operate our business like a business. Most financing is hard to get for a small company, nonetheless we will aspire to endure. Without the financing our sales will be curtailed.

In July 2019 CEO Keith Berman approached the company Board of Directors with a plan and offer to, from time to time, lend the company up to \$450,000 through a combination of sources available to him. The Board accepted this offer, which came without precondition. Mr. Berman made it clear that he would rather lend the company money himself or through close friends and family, than instead to sell low priced equity to small institutions. Through this writing, the entirety of this \$450,000 has been rendered.

In March 2020 the company entered into four Notes (loans) with its main investor, Alpha Capital Anstalt for a total of \$1 million. As of this writing, Alpha has rendered \$700,000 in loans, based on Alpha's funding and fulfillment of three of these Notes. The remainder of the \$1 million in loans from Alpha is anticipated during the week beginning March 30, 2020.

In March 2012 we renewed our agreement with Alpha Credit Resources ("ACR") for a third time in order to obtain this debt financing. After the expiration of that agreement, in November 2013 we executed a new line of credit with Alpha Credit Resources, replacing our previous line. This credit line was for \$12.5 million, but with the velocity of our product sales, could yield over \$250 million in annually available credit. We never did draw down any credit financing from ACR, although we many times tried. On December 14, 2015 this credit line expired. Subsequently we learned that ACR and its parent, Platinum Credit became the subject of

several Federal criminal investigations and trials. In September 2016, the major funds controlled by Platinum filed for liquidation. The company immediately froze all of its securities held by Platinum, securities paid from 2007 through 2014, but none subsequently. Platinum had not been granted any requests for any conversion or sale transactions since December 2014. As a part of this liquidation the company is now seeking return of most of the securities granted to the Platinum funds from 2007 through 2014.

We will from time to time continue to seek a combination of equity and long-term debt financing as well as other traditional cash flow and asset backed financing to meet our financing needs and to reduce our overall cost of capital. Additionally, in order to accelerate our growth rate and to finance general corporate activities, we may supplement our existing sources of funds with financing arrangements at the operating system level or through additional short-term borrowings. As a further capital resource, we may sell or lease certain rights or assets from our portfolio as appropriate opportunities become available. However, there can be no assurance that we will be able to obtain any additional financing, on acceptable terms or at all.

### Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our original Genstrip product required initial regulatory approval by the USFDA as well as on-going USFDA approvals during the product life cycle. Further, Genstrip required medical patient trials and competes directly with a major platform manufacturer. We insure against any claims made against the company for our Genstrip product.

Our GenSure product is sold only in international markets. We are protected against claims of patent and/or trademark infringement by virtue of our 2016 settlement agreement with Johnson & Johnson and two J&J divisions.

Our GenChoice! and GenUltimate! TBG products will be sold worldwide. The company will have to protect against claims of infringement for both of these products. Patent and trademark infringement suits are often filed for strategic business reasons, having only a passing relationship to the patents or trademarks claimed to be at issue.

Healthcare, especially those segments where the company competes, is also very litigious. Competing companies often use litigation as a marketing tool, bringing litigation as a means to protect market share and limit market exposure. The medical industry is also intertwined. From time to time, we may become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, litigation that arises over payment disputes or claims of fair value. We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers. It is not uncommon in our industry to find that a litigant has filed claims in multiple jurisdictions involving the same transaction or a single transaction. The company maintains substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. The company has also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, the company accrues contingent legal fees and product liability fees. As of December 31, 2019, our accrual was \$485,069.

From time to time, the company may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered potentially material to us.

In December 2018 the company and Mr. Berman were sued by a former employee who made employment practices claims. This employee had been terminated some 16 months earlier, for insubordination. The company filed a counter-suit against the former employee for misappropriating and hiding company property, secrets, and for violating HIPAA statutes as a result of these actions. The company and Mr. Berman are both insured against these types of lawsuits. In 1Q 2020, with the assistance and resources of its insurer, this lawsuit was settled.

We were in litigation with Lifescan Inc. a subsidiary of Johnson & Johnson beginning in September 2011. Lifescan had maintained throughout that our Genstrip (now known as GenUltimate!) product infringed on three of their patents. One of these patents became the subject of peripheral litigation activities, and two Appeals (one for each side) to the U.S. Appeals Court for the Federal Circuit (the patents appeals court). In January 2016 the Court of Appeals for the Federal Circuit ruled in its Mandate that this one foundational patent and the claims made by the assignee Lifescan, Inc. was struck (killed) due to obviousness (a clever wording meant to obscure a connection between the Lifescan, Inc. invention and earlier generation technologies dating back to the late 1970s). Throughout this Appeal process, and a litigation process waged through the USPTO, the company prevailed. In addition, as a result of certain claims and

allegations made by Lifescan after the close of the USPTO final determination (in favor of the company), the office of the Solicitor General intervened against Lifescan Inc. in the Federal Circuit court and was of great assistance in getting the Lifescan, Inc. patent revoked. Nonetheless the seeming baseless allegations and claims made by Lifescan against the company have taken their toll, limited our ability to sell our GenStrip (now known as GenUltimate) to large entities (“big box stores”) and greatly extended the court processes.

In May 2016 the company became aware of a clause Lifescan had inserted in its Franchise agreements. This clause set a penalty structure whereby should any Franchisee who also bought non-Lifescan products (but more clearly our GenUltimate) they would lose their access to product rebates, and in certain instances their Franchise. Once aware of these illegal tie-ins the company complained to the Federal government, and in January 2017, for the first time since the onset of litigation with J&J, the tie-in clause was globally lifted by J&J. During the pendency of the 2011 and 2012 lawsuits, Lifescan was guilty of a number of unethical practices.

In March 2016 the company filed suit against Johnson & Johnson and two Lifescan divisions through our two IP subsidiaries. DECN filed the lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV, Case 2:16-cv-00564, titled Pharma Tech Solutions, Inc. et al v. Lifescan, Inc. et al naming Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. for alleged infringement in relation to U.S. Patent numbers 6,153,069, an apparatus patent, and 6,413,411, a method patent. The suit sought at least \$400 million in provable damages. The company lost this lawsuit on a contested technicality, and also lost its appeal.

In November 2018 the company filed a lawsuit in Pennsylvania court against Conductive Technologies, Inc. (CTI) and Shasta Technologies LLC, alleging, among other things, that these two former partners colluded along with Lifescan, Inc. to illegally embargo the company’s GenUltimate! product and technology, and to attempt to seize this product and associated Intellectual Property. The suit emerged as a result of a settlement the former partners entered into with Lifescan, Inc. and Johnson & Johnson to settle their issues (at our expense) in the above discussed patent infringement lawsuits of 2011 and 2012. On December 31, 2018 the Pennsylvania court granted the company a judgment in the amount of \$3,600,000 against Shasta Technologies LLC. The company had been in the process of enforcing the judgment in the states of Minnesota, Oregon (Shasta’s domicile), and California. In late April 2019 the company filed and received a Writ of Attachment from the State of California Superior Court and proceeded to execute on this Writ.

Activities to enforce the judgment against Shasta in Minnesota and California ended the litigation and collection activities against Shasta as of the period ended June 30, 2019. The company, upon conclusion of the litigation then valued its acquisition of technology and Marks in the financials for the period ended June 30, 2019. The company shows a one-time gain in the 2Q 2019 period. Litigation against CTI continues. Recently the company was made aware of a conflict that involved a sister company of CTI, whereby this sister company had extensive undisclosed contract dealings with J&J. At the time of the Settlement by Shasta and CTI with J&J, CTI had recently appointed a new Chairman, the then CEO of the sister corporation. The company believes that this new Chairman, in an effort to preserve another agreement with J&J immediately ordered settlement with J&J and as a result of this settlement with J&J became the architect of the embargo against the company and its products, forcing the company to redevelop GenUltimate in Korea, at a cost of \$660,000. CTI also used the company’s client list obtained as a part of the J&J litigation and hired a company distributor to distribute the company’s products to other of the company’s distributors. The company is seeking settlement with CTI but will be forced going forward to expand its suit against CTI to add the sister corporation and its Chairman to the expanded lawsuit.

- B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

The company has five wholly owned subsidiaries, Decision IT Corp., PharmaTech Solutions, Inc. PharmaTech Direct Corp., PDA Services Inc., Pharmatech Sensor Development Corp. All of the subsidiary corporations reside in the same building that hosts Decision Diagnostics Corp. We report on a consolidated basis.

- C. Describe the issuers’ principal products or services, and their markets

Decision Diagnostics Corp. is a worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose, the PetSure! glucose test strip for the glucose testing of dogs and cats, a test strip designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter, and the GenUltimate! 4Pets Glucose system a proprietary glucose measuring system inclusive of the company’s GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats and horses. The company also has its GenSure! glucose test strip, a product for off-shore sales which is complete and available for sales, but will primarily be sold as an international private label market entry. GenSure! and the legacy glucometers that accept this test strip no longer meet most International (ISO) standards.

## 6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is \$3000.00 per month on a month-to-month basis. We also maintain a Quality Assurance office in at the facility of our exclusive manufacturer's representative in Seoul, Korea. We contract for space in a specialty public warehouse in Miami, FL, which serves as our importing, exporting and shipping and receiving terminal.

## 7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information regarding any person or entity owning 5% of more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own.

**If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

See below

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Keith M. Berman	CEO & CFO	Westlake Village, CA	480,103	Common	<1%	
Robert G. Jagunich	Chairman	Palo Alto, CA	929,301	Common	<1%	
Barbara P. Asbell	Founder	Ventura, CA	1,409,404	Common	<1%	

Our executive officers, directors, and key employees are:

<u>Name</u>		<u>Age</u>
Keith Berman	CEO, CFO, Director	66
Robert Jagunich	Chairman, Director	73

Our shareholders elect our directors and our Board of Directors appoints our officers. As of the date of this filing, we have not held an annual meeting. All current directors have been held over until such time the annual meeting is held. Vacancies in our board are filled by the board itself. Set forth below are brief descriptions of the recent employment and business experience of our executive officers and directors.

**Keith Berman** has served as Chief Financial Officer, Secretary, Treasurer and Director of the Company since January of 2003. He was elected CEO in July 2017. Mr. Berman has been involved in the development of in-vitro diagnostic products, dry chemistry products, and healthcare software including Intranet and Internet systems for the past 43 years. From July 1999 to present, Mr. Berman has held the position of President, founder and director of Caredecision.net, Inc. a private company engaged in e-health technology development. From March 2001 through June 2002 Mr. Berman also held the Position of President and Director of Medicus, Inc. From January 1996 to June 1999 Mr. Berman was the President and founder of Cymedix, the operating division of Medix Resources, Inc., later Ramp Corp. (RCO). Cymedix was a pioneer company in what was then known as i-health (Internet healthcare) now the e-health industry. Mr. Berman's professional background provides the Company with business management experience and an in depth knowledge of our industry. Mr. Berman received a BA in 1975 and an MBA in 1977, from Indiana University.

**Robert Jagunich** has served as a Director of the Company since January of 2003. Mr. Jagunich has 28 years of experience in the medical systems and device industry. From August 1992 to present, he has held the position of President at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. He also provides consulting services to companies such as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. From April 1996 to December 1997 Mr. Jagunich acted as a director of Cymedix Corporation, the operating entity of Medix Resources, Inc., and later, Ramp Corp. (formerly AMEX:RCO). Mr. Jagunich's professional focus on medical devices as well as the professional relationships he has developed throughout his career provides the Company with opportunities to expand current markets and utilize additional product resources not previously available. He received his BS in 1969, and his MS and MBA in 1971, from the University of Michigan.

Mr. Berman, officer and director, works full-time for the company. Mr. Jagunich attended meetings of the board of directors when held and provides 10% and 15% respectively of his business time in professional capacities to the Company. Mr. Jagunich left the Board of Directors in January 2020 effective February 2020.

The following table sets forth information the remuneration of our Principal Executive officer for the years ended December 31, 2018, 2017 and 2016:

#### Summary Compensation Table

<u>Name and Principal Position</u>	<u>Year</u>	<u>Salary Bonus</u>		<u>Stock</u>	<u>Option</u>	<u>Non-</u>	<u>Nonqualified</u>	<u>All</u>	<u>Total (\$)</u>
		<u>(\$)</u>	<u>(\$)</u>	<u>Awards</u>	<u>Awards</u>	<u>Equity</u>	<u>Deferred</u>	<u>Other</u>	
				<u>(\$)</u>	<u>(\$)</u>	<u>Compensatio</u>	<u>Compensatio</u>	<u>Compensatio</u>	
						<u>n</u>	<u>n</u>	<u>n</u>	
						<u>(\$)</u>	<u>Earnings (\$)</u>	<u>(\$)</u>	
Keith Berman,	2017	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-
CFO and PEO	2018	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-
	2019	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-	\$ -0-

Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August 2006. During the fiscal years ended December 31, 2016 and 2017 and through December 31, 2018 Mr. Berman has received no cash compensation. Mr. Berman has not received any form of cash compensation as a result of our limited cash flow; Mr. Berman has agreed to accept stock option awards from time to time as his compensation until such time the Company has the necessary resources available to provide a traditional compensation plan.

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

## 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

### Securities Counsel

Name:

**Firm: Law Offices of Thomas C. Cook**  
**Address 1: 8250 W. Charleston Blvd. Ste. 120**  
**Address 2: Las Vegas, NV 89117**  
**Phone: (702) 242-0099**  
**Email: tcesq@aol.com**

Firm: see above

Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Accountant or Auditor

Name: none  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Investor Relations Consultant

Name: none  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

Other Service Providers

Provide the name of any other service provider(s), including, counsel, advisor(s) or consultant(s) **that assisted, advised, prepared or provided information with respect to this disclosure statement**, or provided assistance or services to the issuer during the reporting period.

Name: none



## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Keith M. Berman certify that:

1. I have reviewed this Annual Report for the period ended December 31, 2019, of Decision Diagnostics Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 30, 2020

Chief Executive Officer

/s/ Keith M. Berman

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, Keith M. Berman, CFO certify that:

1. I have reviewed this Annual Report for the period ended December 31, 2019 of Decision Diagnostics Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 30, 2020

Chief Financial Officer

/s/ Keith M. Berman

(Digital Signatures should appear as "/s/ [OFFICER NAME]")



# **Decision Diagnostics Corp.**

## **OTC Pink Balance Sheet, Statements of Equity & Cash Flows, Footnotes to Balance Sheet Annual Report for Years Ended December 31, 2019 and 2018**

**The following pages present the unaudited financial statements along with Statements of Equity and Cash Flows, and the Footnotes to the Balance Sheet for Decision Diagnostics Corp., for the years ended December 31, 2019, and 2018. The financial statements have been prepared in accordance with generally accepted accounting principles.**

**Trading Symbol: DECN  
CUSIP Number: 243443 108**

**Decision Diagnostics Corp.**  
**Condensed Consolidated Balance Sheets**  
(Unaudited)

	December 31, 2019	December 31, 2018
<b>Assets</b>		
Current assets:		
Cash	\$ 114,334	\$ 358,757
Accounts receivable, net	1,045,166	949,797
Inventory	166,635	250,716
Prepaid expenses	2,249	106,988
Total current assets	1,328,384	1,666,258
Fixed assets:		
Specialty manufacturing equipment	802,315	802,315
	802,315	802,315
Less accumulated depreciation	-	-
Fixed assets, net	802,315	802,315
Other assets:		
Intellectual property	683,550	567,175
Patent licenses, net value	2,490,825	1,150,825
Total other assets	3,174,375	1,718,000
Total assets	\$ 5,305,074	\$ 4,186,573
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable and accrued liabilities	\$ 1,253,892	\$ 1,030,270
Accrued interest	348,549	48,462
Contingent legal fees	240,000	240,000
Short term inventory financing	335,304	108,000
Notes payable and short term debt with warrants (Note 5)	2,794,673	1,422,680
Total current liabilities	4,972,419	2,849,412
Contingencies	245,069	245,069
Stockholders' equity (deficit):		
Preferred stock, \$0.001 par value, 3,738,500 shares authorized, no shares issued and outstanding as of December 31, 2019 and December 31, 2018	-	-
Preferred series "B" stock, \$0.001 par value, 2,500 shares authorized, 2,000 and 1,000 shares issued and outstanding as of December 31, 2019 and December 31, 2018	2	2
Preferred series "C" stock, \$0.001 par value, 10,000 shares authorized, 9,453 and 7,458 shares issued and outstanding as of December 31, 2019 and December 31, 2018	8	7
Preferred series "D" stock, \$0.001 par value, 500 shares authorized, 210 and 100 shares issued and outstanding as of December 31, 2019 and December 31, 2018	-	-
Preferred series "E" stock, \$0.001 par value, 1,250,000 shares authorized, 1,072,540 and 847,540 issued and outstanding as of December 31, 2019 and December 31, 2018	1,072	847
Common stock, \$0.001 par value, 494,995,000 shares authorized, 159,399,161 and 134,551,840 shares issued and outstanding as of December 31, 2019 and December 31, 2018	159,190	134,343
Common stock unissued, 1,410,000 shares as of December 31, 2019 and December 31, 2018	1,411	1,411
Subscription receivable	(82,250)	(82,250)
Unit offering finders' fees	(321,344)	(321,344)
Additional paid-in capital	50,059,420	47,956,705
Retained (deficit)	(49,729,924)	(46,597,629)
Total stockholders' equity	87,584	1,092,091
Total liabilities and stockholders' equity	\$ 5,305,074	\$ 4,186,573

OTC Markets Group Inc. The accompanying Notes are an integral part of these financial statements.  
OTC Pink Basic Disclosure Circulars 1201 February 2020

**Decision Diagnostics Corp.**  
**Condensed Consolidated Statements of Operations**  
**(Unaudited)**

	Year Ended	
	December 31,	
	2019	2018
Revenue	\$ 2,379,234	\$ 2,235,989
Cost of sales	1,528,882	1,454,819
<b>Gross profit</b>	<b>850,352</b>	<b>781,169</b>
<b>Expenses:</b>		
General & administrative expenses	952,123	541,950
Consulting	200,269	130,658
Compensation expense	416,527	473,973
Professional fees	575,815	1,487,750
Total expenses	2,144,735	2,634,331
<b>Net operating (loss)</b>	<b>(1,294,382)</b>	<b>(1,853,162)</b>
<b>Other income (expense):</b>		
Financing costs	(348,655)	(195,877)
Interest expense, net	(2,666,898)	(190,210)
Loss on write-down of obsolete inventory	(162,359)	(902)
Gain on intellectual property	1,340,000	-
Total other income (expense)	(1,837,913)	(386,989)
<b>Taxes:</b>		
State	-	(70)
<b>Net income/loss</b>	<b>\$ (3,132,295)</b>	<b>\$ (2,240,220)</b>
Add: Dividends declared on preferred stock	-	
<b>Income available to common shareholders'</b>	<b>\$ (3,132,295)</b>	<b>\$ (2,240,220)</b>
Weighted average number of common shares outstanding - basic and fully diluted	150,367,632	124,989,890
<b>Net loss per share - basic and fully diluted</b>	<b>\$ (0.02)</b>	<b>\$ (0.02)</b>

The accompanying Notes are an integral part of these financial statements.

**Decision Diagnostics Corp.**  
**Statements of Shareholders' Equity**  
(Unaudited)

Date	Shareholder	Preferred "B"		Preferred "C"		Preferred "D"		Preferred "E"		Common Stock		APIC	Authorized Unissued	Subscription Receivable	Finders' Fees	Retained (Deficit)	Total
		# Shares	Amt	# Shares	Amt	# Shares	Amt	# Shs	Amt	# Shs	Amt						
<b>BALANCE DECEMBER 31, 2017</b>		<b>1,000</b>	<b>2</b>	<b>6,473</b>	<b>6</b>	<b>40</b>	<b>-</b>	<b>813,240</b>	<b>813</b>	<b>110,231,610</b>	<b>110,032</b>	<b>46,288,346</b>	<b>1,411</b>	<b>(82,250)</b>	<b>(321,344)</b>	<b>(44,357,408)</b>	<b>1,638,608</b>
1/8/18	New Issuance-Alpha Capital Anstalt									1,504,281	1,504	151,932					153,437
1/18/18	New Issuance-Robert Herskowitz							100,000	100	-	-	5,900					6,000
2/9/18	New Issuance-Alpha Capital Anstalt									1,496,661	1,497	151,163					152,659
2/23/18	New Issuance-Robert Herskowitz							(100,000)	(100)	1,400,000	1,400	(1,300)					-
2/23/18	New Issuance-Chase Financing Inc Profit Sh.							(70,000)	(70)	980,000	980	(910)					-
3/5/18	New Issuance-Alpha Capital Anstalt									1,510,797	1,511	152,590					154,101
3/31/18	New Issuance-Alpha Capital Anstalt									1,521,904	1,522	153,712					155,234
4/3/18	New Issuance-Mark Herskowitz									849,123	849	85,761					86,611
4/16/18	New Issuance-Alpha Capital Anstalt									1,513,789	1,514	152,893					154,406
4/16/18	New Issuance-Chase Financing Inc Profit Sh.							100,000	100	-	-	5,900					6,000
4/23/18	New Issuance-Alpha Capital Anstalt									1,039,571	1,040	104,997					106,036
5/11/18	New Issuance-LICGO Partners			420	-					-	-	-					-
5/11/18	New Issuance-Chase Financing Inc Profit Sh.							100,000	100	-	-	5,900					6,000
5/29/18	New Issuance-Alpha Capital Anstalt									1,985,374	1,985	200,523					212,508
5/29/18	New Issuance-Robert Herskowitz									1,550,000	1,550	156,550					158,100
6/11/18	New Issuance-Chase Financing Inc Profit Sh.							(75,000)	(75)	1,050,000	1,050	(975)					-
	Immaterial reconciling items							14,300	14	10,000	-	(14)					-
7/3/18	New Issuance-Alpha Capital Anstalt									1,520,646	1,521	153,985					155,106
7/30/18	New Issuance-Navesink Device Initiatives			(125)	-					625,000	625	(625)					-
7/30/18	New Issuance-Navesink Device Initiatives			(125)	-					625,000	625	(625)					-
7/31/18	New Issuance-LICGO Partners			710	1					-	-	-					1
7/31/18	New Issuance-Sovereign Partners LLC			105	-					-	-	-					-
7/31/18	New Issuance-Navesink Device Initiatives					50	-			-	-	-					-
7/31/18	New Issuance-Paradigm Capital					10	-			-	-	-					-
7/31/18	New Issuance-Chase Financing Inc Profit Sh.							200,000	200	-	-	7,800					8,000
8/23/18	New Issuance-Chase Financing Inc Profit Sh.							(35,000)	(35)	490,000	490	(465)					-
8/23/18	New Issuance-Chase Financing							(50,000)	(50)	700,000	700	(650)					-
8/27/18	New Issuance-Mark Herskowitz									816,326	816	82,449					83,265
10/9/18	New Issuance-Alpha Capital Anstalt									1,031,758	1,032	104,238					105,299
11/26/18	New Issuance-Chase Financing Inc Profit Sh.							(50,000)	(50)	700,000	700	(650)					-
11/26/18	New Issuance-Chase Financing Inc Profit Sh.							(100,000)	(100)	1,400,000	1,400	(1,300)					-
	Rounding adjustment										1						(1)
	<b>Net loss</b>																<b>(2,240,220)</b>
<b>BALANCE DECEMBER 31, 2018</b>		<b>1,000</b>	<b>2</b>	<b>7,458</b>	<b>7</b>	<b>100</b>	<b>-</b>	<b>847,540</b>	<b>847</b>	<b>134,551,840</b>	<b>134,343</b>	<b>47,956,705</b>	<b>1,411</b>	<b>(82,250)</b>	<b>(321,344)</b>	<b>(46,597,629)</b>	<b>1,092,091</b>
12/19	New Issuance-LICGO Partners			420	-					-	-	-					-
12/19	New Issuance-Sovereign Partners LLC			140	-					-	-	-					-
12/19	New Issuance-Paradigm Capital					10	-			-	-	-					-
2/5/19	New Issuance-Alpha Capital Anstalt									5,004,562	5,005	505,460					510,464
2/13/19	New Issuance-Mark Herskowitz									600,000	600	11,400					12,000
3/12/19	New Issuance-Chase Financing Inc Profit Sh.							(100,000)	(100)	1,400,000	1,400	(1,300)					-
4/1/19	New Issuance-Alpha Capital Anstalt									4,139,272	4,139	418,066					422,206
4/5/19	New Issuance-Mark Herskowitz									600,000	600	60,600					61,200
5/1/19	New Issuance-Chase Financing Inc									413,218	413	41,735					42,148
5/1/19	New Issuance-Robert Herskowitz									1,091,718	1,092	110,264					111,355
5/1/19	New Issuance-Chase Financing Inc Profit Sh.									1,395,555	1,396	140,951					142,347
5/8/19	New Issuance-LICGO Partners			420	-					-	-	-					-
5/8/19	New Issuance-Sovereign Partners LLC			140	-					-	-	-					-
5/8/19	New Issuance-Paradigm Capital					10	-			-	-	-					-
5/8/19	New Issuance-Thomas Nelson					30	-			-	-	150,000					150,000
5/8/19	New Issuance-JAN Stock Trust					15	-			-	-	75,000					75,000
5/8/19	New Issuance-KEN Stock Trust					15	-			-	-	75,000					75,000
5/8/19	New Issuance-Robert Herskowitz							175,000	175	-	-	6,825					7,000
5/8/19	New Issuance-Kenneth Schaefer							150,000	150	-	-	5,850					6,000
6/11/19	New Issuance-Mark Herskowitz									600,000	600	60,600					61,200
6/19/19	New Issuance-Alpha Capital Anstalt									4,083,006	4,083	412,384					416,467
7/11/19	New Issuance-Chase Financing Inc Profit Sh.							(200,000)	(200)	2,800,000	2,800	(2,600)					-
7/16/19	New Issuance-LICGO Partners LLC			400	-					-	-	-					-
7/16/19	New Issuance-Sovereign Partners LLC			210	-					-	-	-					-
7/16/19	New Issuance-Paradigm Capital Holdings			130	-					-	-	-					-
7/16/19	New Issuance-Navesink Device Initiatives LLC			260	-					-	-	-					-
7/16/19	New Issuance-LICGO Partners					210	-			-	-	-					-
7/16/19	New Issuance-Sovereign Partners LLC					70	-			-	-	-					-
7/16/19	New Issuance-Paradigm Capital							10	-	-	-	-					-
10/9/19	New Issuance-Chase Financing Inc Profit Sh.							300,000	300	-	-	8,700					9,000
10/11/19	New Issuance-LICGO Partners			210	-					-	-	-					-
10/11/19	New Issuance-Sovereign Partners LLC			105	-					-	-	-					-
10/11/19	New Issuance-Paradigm Capital							10	-	-	-	-					-
10/29/19	Conversion-Chase Financing Inc Profit Sh.							(100,000)	(100)	1,400,000	1,400	(1,300)					-
11/15/19	New Issuance-Mark Herskowitz									600,000	600	11,400					12,000
12/31/19	New Issuance - Thomas Nelson									360,000	360	6,840					7,200
12/31/19	New Issuance - KEN Stock Trust									180,000	180	3,420					3,600
12/31/19	New Issuance - JAN Stock Trust									180,000	180	3,420					3,600
12/31/19	New Issuance-LICGO Partners			210	-					-	-	-					-
12/31/19	New Issuance-Sovereign Partners LLC			70	-					-	-	-					-
12/31/19	New Issuance-Paradigm Capital					10	-			-	-	-					-
	Rounding adjustment					1	-			-	(1)	1					1
	<b>Net loss</b>																<b>(3,132,295)</b>
<b>BALANCE DECEMBER 31, 2019</b>		<b>2,000</b>	<b>2</b>	<b>9,453</b>	<b>8</b>	<b>210</b>	<b>-</b>	<b>1,072,540</b>	<b>1,072</b>	<b>159,399,161</b>	<b>159,190</b>	<b>50,059,420</b>	<b>1,411</b>	<b>(82,250)</b>	<b>(321,344)</b>	<b>(49,729,924)</b>	<b>87,584</b>

**Decision Diagnostics Corp.**  
**Consolidated Statements of Cash Flows**  
(Unaudited)

	Year Ended	
	December 31,	
	2019	2018
Cash flows from operating activities		
Net loss	\$ (3,132,295)	\$ (2,240,220)
Adjustments to reconcile net loss to net cash (used) by operating activities:		
Amortization of prepaid legal fees	101,239	750,000
Shares and options issued for services	25,000	-
Shares issued for financing fees	348,654	195,876
Bad debt	175,000	-
Loss on write-down of obsolete inventory	162,363	-
Gain on intellectual property settlement	(1,340,000)	-
Changes in operating assets and liabilities		
Accounts receivable	(270,370)	(511,893)
Inventory	(78,282)	65,943
Prepaid and other assets	3,500	2,425
Accounts payable and accrued liabilities	223,622	224,715
Accrued interest	2,666,898	190,210
Net cash (used) by operating activities	(1,114,671)	(1,322,946)
Cash flows from investing activities		
Fixed assets	-	(75,000)
Intellectual property	(116,375)	(15,300)
Net cash (used) by investing activities	(116,375)	(90,300)
Cash flows from financing activities		
Proceeds from notes payable	769,318	683,242
Payments on notes payable	(82,696)	-
Proceeds from sale of stock	300,000	-
Net cash provided by financing activities	986,622	683,242
Net decrease in cash	(244,424)	(730,004)
Cash - beginning	358,757	1,088,761
Cash - ending	\$ 114,333	\$ 358,757
Supplemental disclosures:		
Interest paid	\$ -	\$ -
Income taxes paid	\$ -	\$ 70
Non-cash transactions:		
Shares and options issued for services	\$ 25,000	\$ -
Shares issued for financing activities	\$ 348,654	\$ 195,876
Options issued for compensation	\$ -	\$ -
Shares issued for debt and derivative liabilities	\$ 1,454,133	\$ 1,496,827

The accompanying Notes are an integral part of these financial statements.

## DECISION DIAGNOSTICS CORP.

### NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

#### NOTE 1 – Basis of presentation and accounting policies

##### Organization

We were organized July 6, 2000 under the laws of the State of Nevada. As a part our efforts to transition the company toward a full service and vertically integrated provider of at-home diagnostics, on November 1, 2011, as a condition of the acquisition of Diagnostics Newco, LLC, from its sole owner, the company completed a name change action through the office of Nevada Secretary of State (NVSOS). The surviving entity is known as Decision Diagnostics Corp. or the Company. This action through the office of the NVSOS was effective as of November 25, 2011.

As part our efforts to secure a listing on a new stock exchange, we completed another action with the NVSOS, where a previously approved board resolution to reverse split our shares was finalized. Our stock was split whereby one new share of the company's common stock was exchanged for every fourteen previously issued and outstanding shares of our \$.001 par value common stock. This action was effective as of November 25, 2011. All share references included herein have been retroactively restated to reflect that 1:14 reverse split.

##### Principles of Consolidation

The financial statements include those of: Decision Diagnostics Corp. ("Decision Diagnostics"); and nearly wholly owned (99.93%) owned subsidiaries, PDA Services, Inc. and PharmaTech Solutions, Inc., and its wholly owned subsidiaries Pharmtech Direct Corp, PharmaTech Sensor Development Corp., and Decision IT Corp. All significant inter-company transactions and balances have been eliminated. Decision Diagnostics and its subsidiaries are collectively referred to herein as the "Company." Investments in unconsolidated subsidiaries representing ownership of at least 20% but less than 50% are accounted for under the equity method. Non-marketable investments in which the Company has less than 20% ownership and in which it does not have the ability to exercise significant influence over the investee are initially recorded at cost and periodically reviewed for impairment. As of December 31, 2019 and 2018, we did not have non-marketable investments.

##### Cash and cash equivalents

Cash and cash equivalents include all cash balances in non-interest bearing accounts and money-market accounts. We place our temporary cash investments with quality financial institutions. At times, such investments may be in excess of Federal Deposit Insurance Corporation (FDIC) insurance limit. Our bank is a money market bank and as such, we do not believe it is exposed to any significant credit risk on cash and cash equivalents. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. There are no cash equivalents as of December 31, 2019 and 2018.

##### Credit Risks

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (FDIC) up to \$250,000. At December 31, 2019 we had no bank balances which exceeded the FDIC insured limit.



### Accounts receivable and Allowance for Doubtful Accounts Receivable

Trade accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable.

Credit is extended to customers based on an evaluation of their financial condition and other factors. The Company generally does not require collateral or other security to support accounts receivable. The Company performs ongoing credit evaluations of its customers and maintains an allowance for doubtful accounts.

The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations, such as bankruptcy proceedings and receivable amounts outstanding for an extended period beyond contractual terms. In these cases, the Company uses assumptions and judgment, based on the best available facts and circumstances, to either record a specific allowance against these customer balances or to write off the balances. Since the Company's customers have been subject to new and on-going draconian government reduction of healthcare reimbursement, previous rules regarding creditworthiness are changing. In addition, the Company calculates an overall reserve based on a percentage of the overall gross accounts receivable. This percentage is based on management's assessment of the aging of accounts receivable, historical write-offs of receivables and the associated risk profile of the Company's customer base. Healthcare, particularly the medical device products, are primarily paid for by Medicare, Medicaid, and large health insurers. Payments, particularly in several regional areas, are "slow pay." This tends to trickle to all levels of retail, sales and distribution networks, and is taken into account by the Company.

### Revenue recognition

We recognize revenue in accordance with ASC subtopic 605-10 (formerly SEC Staff Accounting Bulletin No. 104 and 13A, "Revenue Recognition") net of expected cancellations and allowances. As of December 31, 2019 and 2018, we evaluated evidence of cancellation in order to make a reliable estimate and determined there were no material cancellations during the years and therefore no allowances has been made.

We recognize revenue from our sales of pharmaceutical supplies upon delivery to its customer where the fee is fixed or determinable, and collectability is probable. Cash payments received in advance are recorded as deferred revenue. We are not generally obligated to accept returns, except for defective products, or should FDA or Medicare regulations change after delivery is made. The advent of Medicare's competitive bidding program that covers the products the Company manufactures has added to regulatory issues faced by the Company.

Revenue from proprietary software sales that does not require further commitment from the company is recognized upon shipment. Consulting revenue is recognized when the services are rendered. License revenue is recognized ratably over the term of the license.

### Advertising costs

We expense all costs of advertising as incurred. Advertising costs of \$11,719 and \$32,984 were included in general and administrative expenses as of December 31, 2019 and 2018, respectively. Television, radio and other media advertising has been treated as professional expense since the Company places its television, radio and social media ads through licensed advertising aggregators.

### Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. As of December 31, 2019 and 2018, we have accrued contingent legal fees and product liability fees totaling \$485,069, respectively.

### Fair value of financial instruments

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2019 and 2018. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values. These financial instruments include cash, accounts receivable, accounts payable, accrued liabilities and notes payable. Fair values were assumed to approximate carrying values because they are short term in nature and their carrying amounts approximate fair values or they are payable on demand.

#### Impairment of long-lived assets

The Company reviews its long-lived assets and intangibles periodically to determine potential impairment by comparing the carrying value of the long-lived assets with the estimated future cash flows expected to result from the use of the assets, including cash flows from disposition. Should the sum of the expected future cash flows be less than the carrying value, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived assets and intangibles. The Company recognized no impairment losses during the years ended December 31, 2019 and 2018.

#### Earnings per share

Earnings per share are provided in accordance with ASC Topic 260 “Earnings per Share” (as amended). The Company presents basic earnings per share (“EPS”) and diluted EPS on the face of consolidated statements of operations. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. Basic loss per share is computed by dividing losses available to common stockholders by the weighted average number of common shares outstanding during the period. Basic earnings per common share are based on the weighted average number of common shares outstanding during the year. Diluted earnings per share is based on the weighted average number of common shares, plus all stock options and warrants convertible into common stock for an additional 32,639,041 common shares; and all preferred stock (issued or authorized and unissued) convertible into common stock for an additional 70,215,560 common shares. Most of the Company’s authorized Preferred shares remain unissued.

#### Income Taxes

The Company follows ASC subtopic 740-10 (formerly Statement of Financial Accounting Standard No. 109, “Accounting for Income Taxes”) for recording the provision for income taxes. ASC 740-10 requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change.

Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.

#### Concentrations

In 2019, three customers accounted for approximately 95% of net sales compared to three customers accounting for approximately 95% of net sales in 2018. However, it should be noted that all three of the Company’s largest customers make use in large part to on-line sales through Amazon, Walmart, Sears, Jet.com (“marketplaces”) and at least 1,000 other on-line sellers and aggregators. These customers use the distribution services and resources of the marketplaces.

Historically the Company’s operations require maintaining strategic relationships with customers whereby delivering product and services directly to the patient base that underlies strategic relationships, accepting assignment of insurance benefit through a series of strategic partnerships with licensed pharmacies for the billing and future servicing of these patients. We also maintain relationships with the entities where the patients reside. As of December 31, 2019 and 2018, we obtained the majority of our pharmaceutical products from two contract manufacturers and three other major suppliers. There can be no assurance that our major customers will continue to purchase products. The loss of our largest customers or a decrease in product sales would have a material adverse effect on our business and financial condition.

## Reclassifications

Certain reclassifications have been made to the prior years' financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or retained earnings.

## Recent Accounting Pronouncements

Management has analyzed all pronouncements issued during the year ended December 31, 2019 by the FASB or other authoritative accounting standards groups with future effective dates, and have determined that they are not applicable or are not expected to be significant to the financial statements of the Company.

Previous year financial information has been presented to conform to current year financial statement presentation.

## Year-end

We have adopted December 31 as our fiscal year end.

## **NOTE 2 – Going concern**

The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. Our ability to continue as a going concern is dependent upon attaining profitable operations based on the development of distribution platforms and channels through which our products that can be sold. We intend to use borrowings and security sales to mitigate the effects of our cash position, however, no assurance can be given that debt or equity financing, if required, will be available. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and classification of liabilities that might be necessary should we be unable to continue in existence.

## **NOTE 3 – Fair value**

Our financial instruments consist principally of notes payable and lines of credit. Notes payable and lines of credit are financial liabilities with carrying values that approximate fair value. Management determines the fair value of notes payable and lines of credit based on the effective yields of similar obligations and believe all of the financial instruments' recorded values approximate fair market value because of their nature and respective durations.

We comply with the provisions of ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements required under other accounting pronouncements. ASC 820-10-35, "Fair Value Measurements and Disclosures - Subsequent Measurement" ("ASC 820-10-35"), clarifies that fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820-10-35 also requires that a fair value measurement reflect the assumptions market participants would use in pricing an asset or liability based on the best information available. Assumptions include the risks inherent in a particular valuation technique (such as a pricing model) and/or the risks inherent in the inputs to the model. The Company also follows ASC 825 "Interim Disclosures about Fair Value of Financial Instruments", to expand required disclosures.

ASC 820-10-35 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under ASC 820-10-35 are described below:

Level 1. Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.

Level 2. Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

Level 3. Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

We utilize the best available information in measuring fair value. The following table summarizes, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of December 31, 2019:

	2019 Fair Value Measurements			
	Level 1	Level 2	Level 3	Total Fair Value
Assets				
Intellectual property	\$ -	\$ -	\$ 3,174,375	\$ 3,174,375
Liabilities				
Notes payable	-	(2,794,673)	-	(2,794,673)
Total	\$ -	\$ (2,794,673)	\$ 3,174,375	\$ 379,702

#### NOTE 4 – Equipment – Specialty Manufacturing Instruments

On June 1, 2015, we entered into a wide-ranging manufacturing and product development agreement with a large venture funded Korean concern. On July 8, 2015, we enhanced its role in this agreement through the purchase of, and investment in, computer controlled, specialty manufacturing equipment for our GenUltimate! products that is now located in the Korean facility of the Company's R&D and contract manufacturing partner. In the summer of 2016 we augmented this equipment by adding additional equipment capable of manufacturing our GenChoice!, GenAccord! and GenCambre! products that make use of different molds and chemical processes. This same contract manufacturer will manufacture, to our specifications, our new GenViro! products.

During the quarter ended March 31, 2017, we acquired \$64,890 in fixed assets pursuant to the manufacturing and product development agreement dated June 1, 2015. We expensed an additional \$380,000 for the development of our GenChoice! product which will make use of the Specialty Manufacturing equipment located in Korea. We continue to incur great expense due to development of our GenChoice! and GenUltimate Precis! And GenUltimate! TBG products during the year ending December 31, 2019.

#### NOTE 5 – Patents

During the years ended December 31, 2019 and 2018, we amortized formerly capitalized attorney fees related to the continued development and perfection of our patents totaling \$101,239 and \$750,000, respectively. We did not amortize any intellectual property or patents during the years ended December 31, 2019 and 2018.

During the year ended December 31, 2019, we settled out of court with Shasta Technologies, LLC, whereby we have retained all unobscured rights to acquire certain intellectual properties (see Note 6 below). We have expensed \$660,000 in legal fees over the past several years pursuant to the litigation. We have capitalized and recorded a "Gain on Intellectual Property" of \$1,340,000.

#### NOTE 6 – Acquisition of Certain Properties

In March 2014, we agreed to acquire certain properties from Shasta Technologies LLC. The agreement covering this acquisition became the subject of two litigations, one litigation related to the remaining proceeds of an IP defense insurance policy, subsequently settled, the other litigation concerning damages the company is trying to collect from Shasta Technologies LLC owing to Shasta's subsequent undisclosed issues with the U.S. FDA. The damages sought by the company, and other damages, became a part of allegations made in a suit filed in Pennsylvania where we will also litigate damages incurred as a result of a 2015 collusion between Shasta and our former contract manufacturer Conductive Technologies, Inc., who conspired with Johnson and Johnson during the settlement of the first patent litigations. On December 31, 2018 the court in Pennsylvania ordered judgement against Shasta in the amount of \$3,600,000.

The original purchase price for this "Shasta" property was expected to be \$2,000,000 (cash). Earlier in 2019 the company filed a Writ of Execution, owing to the \$3,600,000 judgement that migrated from Pennsylvania. The Writ became final in April 2019, and was used, among other things, as offset against Shasta in the California litigation. Our business with Shasta is now completed.

We did register our FDA cleared product under our FDA Establishment registration (with the US FDA) in 2014, 2015, 2016, 2017, 2018, 2019 and in 2020. In September 2016 we became fully compliant with the then newly implemented FDA UDI product identification initiative.

#### **NOTE 7 – Notes payable**

During the course of a year-end review of our debt with our noteholders, we mutually identified Original Issue Discounts (“OID’s”) associated with the notes totaling \$3,332,189. We have recorded these OID’s by increasing notes payable and interest expense as of the year ended December 31, 2019. \$537,516 of OID remained unamortized to interest expense as of December 31, 2019.

On March 22, 2019 the company closed additional financing in the form of OID Notes and Warrants in the amount of \$250,000 face value (OID of \$37,500), with Alpha Capital Anstalt, the company’s primary financier. The Notes were funded and recorded on our books during the year ended December 31, 2019.

We have recorded financing expense in connection with our notes payable totaling \$348,655 and \$195,877 for the years ended December 31, 2019 and 2018, respectively.

#### **NOTE 8 – Stockholder’s equity**

We are authorized to issue up to 494,950,000 shares of \$0.001 par value common stock and 5,000,000 shares of various classes of \$0.01 par value preferred stock. In March of 2011, we amended our preferred stock designations as follows: 1) withdrawal of Series “A” designation on 750,000 shares of preferred stock, 2) Amendment of Series “C” designation on to 10,000 shares of preferred stock, 3) Designation of Series “B” on 2,500 shares of preferred stock, 4) Designation of Series “D” on 1,250 shares of preferred stock and its amendments; 5) increased the number of preferred shares designated as Series “E” from 1,000,000 to 1,250,000. All presentation of preferred stock contained herein has been retroactively presented to reflect the designations and amendments; 6) increased the number of preferred shares designated as Series “D” from 500 to 1,250.

##### Series “B” convertible preferred stock

We have designated 2,500 shares of our \$0.001 preferred stock as Series “B”. Holders of series “B”: convertible stock shall not have the right to vote on matters that come before the shareholders. Each share of Series “B” Preferred stock is valued at \$10,000. Series “B” convertible preferred stock may be converted, the number of shares into which one share of Series “B” Preferred Stock shall be convertible into common stock shares shall be 15,000. Series “B” convertible stock shall rank senior to common stock in the event of liquidation. Holders’ of Series “B” convertible stock shall not be entitled to a mandatory monthly dividend. Series “B” convertible stock shall have a redemptions price equal to 101% of the purchase price per share, subject to adjustments resulting from stock splits, recapitalization, or share combination.

##### Series “C” convertible preferred stock

We have designated 10,000 shares of our \$0.001 preferred stock as 2011 Series “C”. Each share of 2011 Series C Preferred stock is valued at \$1,000. Holders of series “C”: convertible stock shall not have the right to vote on matters that come before the shareholders. 2011 Series “C” convertible preferred stock may be converted after 36 months, but not before unless by Board Resolution, the number of shares into which one share of 2011 Series “C” Preferred Stock shall be convertible on a pro-rata basis into common stock shares, each share of common stock valued at \$0.20. 2011 Series “C” convertible stock shall rank junior to all other classes of Preferred stock in the event of liquidation. Holders of 2011 Series “C” convertible stock shall not be entitled to a mandatory monthly dividend.

##### Series “D” convertible preferred stock

We have designated 1,250 shares of our \$0.001 preferred stock as 2012 Series “D”. As of this date, we have not issued any shares of this issue of Preferred stock. Holders of series “D” convertible stock shall not have the right to vote on matters that come before the shareholders. 2012 Series “D” convertible preferred stock may be converted three years (36 months) after distribution. The number of shares into which one share of 2012 Series “D” Preferred Stock shall be convertible into common stock shares is 1 for 120,000 shares of \$0.001 par value common stock. In 4Q 2016 and 1Q 2017 the company amended the Designations of its 2012 Series “D” convertible stock in anticipation of a large investment by a private non-fund related party. Should this investment occur, the majority of or all of the 1,250 shares would be subscribed to. 2012 Series “D” convertible stock shall rank junior to all other classes of Preferred stock in the event of liquidation. Holders of 2012 Series “D” convertible stock shall not be entitled to a mandatory monthly dividend. Holders of 2012 Series “D” shares may not convert these shares into common stock until the expiration of a 36 month holding period, unless the holder has received an extraordinary allowance to convert shares earlier by the company’s Board of Directors.

## Series E convertible preferred stock

We have designated 1,250,000 shares of our \$0.001 preferred stock as Series “E”. Holders of series “E”: convertible stock shall not have the right to vote on matters that come before the shareholders. Series “E” convertible preferred stock may be converted, the number of shares into which one share of Series “E” Preferred Stock shall be convertible into common stock shares shall be 14. Series “E” convertible stock shall rank senior to common stock in the event of liquidation. Holders’ of Series “E” convertible stock shall not be entitled to a mandatory monthly dividend. Series “E” convertible stock shall have a redemptions price equal to 101% of the purchase price per share, subject to adjustments resulting from stock splits, recapitalization, or share combination.

## **2019 Issuances**

### Preferred “B”

During the year ended December 31, 2019, we issued 1,000 preferred series “B” shares to certain existing shareholders pursuant to our quarterly bonus stock initiative. The fair market value of the shares are \$nil on the date of issuance.

### Preferred “C”

During the year ended December 31, 2019, we issued 1,995 preferred series “C” shares to certain existing shareholders pursuant to our quarterly bonus stock initiative. The fair market value of the shares are \$nil on the date of issuance.

### Preferred “D”

During the year ended December 31, 2019, we issued 50 preferred series “D” shares to various consultants for services provided. The fair market value of the shares and services are \$nil on the date of issuance.

During the year ended December 31, 2019, we issued 60 preferred series “D” shares to investors for cash totaling \$300,000.

### Preferred “E”

During the year ended December 31, 2019, we issued 625,000 preferred series “E” shares to various consultants for services rendered. The fair market value of the shares and services is \$22,000 on the date of issuance.

During the year ended December 31, 2019, certain holders of preferred series “E” shares converted 400,000 shares elected to convert their shares into 5,600,000 shares of \$0.001 par value common stock.

### Common

During the year ended December 31, 2019, we issued 14,318,548 shares of \$0.001 par value common stock for conversion of debt and accrued interest totaling \$1,454,133.

During the year ended December 31, 2019, we issued 418,250 shares of \$0.001 par value common stock for financing costs totaling \$321,923.

During the year ended December 31, 2019, we issued 5,600,000 shares of \$0.001 par value common stock in exchange for 400,00 shares of preferred series “E” stock.

## *2018 Issuances*

### Preferred

During the quarter ended December 31, 2018, holders of our preferred series “E” shares elected to convert 150,000 preferred series “E” shares into 2,100,000 shares of our \$0.001 par value common stock.

During the quarter ended September 30, 2018, we issued 815 shares of preferred series “C” shares for financing costs valued at less than \$1.

During the quarter ended September 30, 2018, we issued 60 shares of preferred series “D” shares for financing costs valued at less than \$1.

During the quarter ended September 30, 2018, we issued 200,000 shares of preferred series “E” shares for financing costs valued at \$8,000.

During the quarter ended September 30, 2018, holders of our preferred series “E” shares elected to convert 95,000 preferred series “E” shares into 1,190,000 shares of our \$0.001 par value common stock.

During the quarter ended June 30, 2018, we issued 420 shares of preferred series “C” shares for financing costs valued at less than \$1.

During the quarter ended June 30, 2018, we issued 200,000 shares of preferred series “E” shares for financing costs valued at \$12,000.

During the quarter ended June 30, 2018, holders of our preferred series “E” shares elected to convert 75,000 preferred series “E” shares into 1,050,000 shares of our \$0.001 par value common stock.

During the quarter ended March 31, 2018, we issued 100,000 shares of preferred series “E” shares for services valued at \$6,000.

During the quarter ended March 31, 2018, holders of our preferred series “E” shares elected to convert 170,000 preferred series “E” shares into 2,380,000 shares of our \$0.001 par value common stock.

### Common

During the quarter ended December 31, 2018, we issued 1,031,758 shares of \$0.001 par value common stock for conversion of debt and accrued interest totaling \$105,239.

During the quarter ended September 30, 2018, we issued 1,520,646 shares of \$0.001 par value common stock for conversion of debt and accrued interest totaling \$155,106.

During the quarter ended September 30, 2018, we issued 816,326 shares of \$0.001 par value common stock for financing costs of \$83,265.

During the quarter ended June 30, 2018, we issued 6,088,734 shares of \$0.001 par value common stock for conversion of debt and accrued interest totaling \$621,051.

During the quarter ended June 30, 2018, we issued 849,123 shares of \$0.001 par value common stock for financing costs of \$86,611.

During the quarter ended March 31, 2018, we issued 6,033,643 shares of \$0.001 par value common stock for conversion of debt and accrued interest totaling \$615,432.

## NOTE 9 – Stock options

### 2017 Stock Option Plan

During the quarter ended March 31, 2017, we adopted the “2017” Executive and Key Man/Woman Stock Option Plan and granted incentive and nonqualified stock options with rights to purchase 20,000,000 shares of \$0.001 par value common stock at the variable strike prices per share based on share fair market value on the date of grant. As of December 31, 2019, all options allowed under the plan have been granted and are exercisable at the election of the holder.

The following is a summary of activity of outstanding stock options under all Stock Option Plans:

	<u>Number of Shares</u>	<u>Weighted Average Exercise Price</u>
Balance, January 1, 2018	9,050,000	\$ 0.10
Options granted	-	-
Options cancelled	-	-
Options exercised	-	-
Balance, December 31, 2018	<u>9,050,000</u>	<u>\$ 0.10</u>
Balance, January 1, 2019	9,050,000	\$ 0.10
Options granted	17,300,000	0.013
Options cancelled	-	-
Options exercised	-	-
Balance, December 31, 2019	<u>26,350,000</u>	<u>\$ 0.05911</u>

## NOTE 10 – Warrants

The following is a summary of activity of outstanding warrants:

	<u>Number of Shares</u>	<u>Weighted Average Exercise Price</u>
Balance, January 1, 2018	2,603,143	\$ 0.56
Warrants granted	-	-
Warrants cancelled	-	-
Warrants exercised	-	-
Balance, December 31, 2018	<u>2,603,143</u>	<u>\$ 0.56</u>
Balance, January 1, 2019	2,603,143	\$ 0.56
Warrants granted	3,685,898	.0195
Warrants cancelled	-	-
Warrants exercised	-	-
Balance, December 31, 2019	<u>6,289,041</u>	<u>\$ 0.2432</u>



## **NOTE 11 – Commitments and Contingencies**

### Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our GenStrip 50 and GenUltimate! products required initial regulatory approval by the US FDA as well as on-going US FDA oversight and inspection during the product life cycle. We also import product from Korea manufactured by our Korean contract manufacturer. This product is also subject to FDA inspection. We are also subject to new FDA regulation and post market overview. In 2016, we had to meet new FDA Guidelines for product identification, tracking and standardization. Our new GenChoice! and GenUltimate! TBG and the later upcoming GenAccord! and GenCambre! products will follow the same pathway with the U.S. FDA. The FDA calls its new product identification program, the UDI initiative, and the new packaging required, and met by us, approximates a similar standard implemented in the European Union in 2013, and then adopted in other countries, Korea for example. We are now filing for approvals in the EU and the Russian Federation after having received certain approvals in Central and South America.

Further, our products required medical patient trials and several compete directly with a major platform manufacturer. Healthcare, especially those segments where the company competes, is a very litigious. Competing companies often use litigation as a marketing (market depriving) tool, bringing litigation as a means to protect market share and limit market exposure even though market limitation through litigation is illegal. We have in the past (and currently) defended cases brought by Plaintiffs asserting these types of claims.

The medical industry is also intertwined. From time to time, we have become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, payment disputes both as a seller and a buyer, and litigation that arises over claims of fair value. We have also had to defend trade dress claims filed solely because of the cost to defend these claims, real or not. For instance, we have been sued in several jurisdictions over a single business transaction. Often these cases involve substantial over-prosecution where we and our have been held accountable by Plaintiffs for a myriad of things including words written or posted in public forums by anonymous persons.

We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers, people or entities that we may not be familiar with. We maintain substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. We have also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, we accrue contingent legal fees and product liability fees. As of December 31, 2019, our contingent legal fees accrual was \$240,000 and our general contingencies accrual was \$245,069. Contingencies total \$485,069 and are reflected herein.

From time to time, we may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered material or potentially material.

### Leases

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is \$3,000 per month (increased from \$2,170 on October 1, 2019) on a month-to-month basis. We also maintain space in a public warehouse in Miami, FL, for our import, export and storage and pick and pack needs. Also, we are granted space indirectly in Seoul, South Korea for the completion of necessary clinical trials.

Rent expense totaled \$30,700 and \$26,040 for the year ended December 31, 2019 and 2018, respectively.

## **NOTE 12 – Subsequent events**

In accordance with ASC 855, management evaluated all of our activities through the issue date of the financial statements and concluded that except as described below, no other subsequent events have occurred that would require recognition or disclosure in the financial statements. We do however discuss all subsequent events in our Managements' Discussion and Analysis documents and filings.

In February 2020 the company began the development of a new product line for the detection of the coronavirus using a special electronic analysis method known as impedance. The company's application makes use of a special test strip, in many ways similar to the company's GenUltimate TGB product, to which whole blood from a finger prick is applied to the special test strip in order to achieve a test result for Covid-19. During the patient testing process, the strip will lyse the whole blood applied, using a chemical lysing agent to eliminate all (or almost all) of the patient's red blood cells from the blood sample, leaving only plasma for measurement. This plasma is then run through the impedance "chamber" and in an expected 15 seconds (or less) a coronavirus result will emerge, either a Positive For or a Negative For the coronavirus. The company's new product will also employ algorithms for the attempted detection of false Negative results. Positive and suspected false Positive results are expected to be referred to a hospital or commercial laboratory for confirmation testing.

In March 2020 the company confirmed that it had begun work on a second Covid-19 test strip, this strip employing a different chemistry process. The company anticipates making and selling this test strip as a confirmation test either tested Positive For or Negative For in previous tests. The company will not begin funding the confirmation test development until 2Q 2020.

In March 2020 the company entered into four Notes (loans) with its main investor, Alpha Capital Anstalt for a total of \$1 million. As of this writing, Alpha has rendered \$700,000 in loans, based on Alpha's funding and fulfillment of three of these Notes. The remainder of the \$1 million in loans from Alpha is anticipated during the week beginning March 30, 2020.

Beginning in mid-February and running through March 25, 2020, the company's contract manufacturer, The Bio Co. Ltd., was on full, and then partial lockdown at its Daegu, South Korea facility due to coronavirus outbreaks in Daegu, Korea. Shipments of the company's GenUltimate and PetSure products were halted during 1Q 2020, but have resumed.

#### Error Repair

The company will endeavor to repair any and all errors that new sets of eyes find in this document after its posting, whether these errors are in spelling, grammatical, punctuational or numeric. We are not perfect and we remind the readers of this document that they are not perfect either.

# **ANNUAL 2019 MANAGEMENT'S DISCUSSION & ANALYSIS**



**DECISION DIAGNOSTICS CORP.**

**ANNUAL REPORT FOR OTC PINK**

**MANAGEMENT'S DISCUSSION & ANALYSIS**

**Report for the Year Ended**

**December 31, 2019**

**Trading Symbol: DECN**

**CUSIP Number: 243443 108**

# MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

## Overview

Decision Diagnostics Corp. is a necessary services worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose, the PetSure! glucose test strip for the glucose testing of dogs and cats, a test strip designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter, the GenUltimate! 4Pets Glucose system a proprietary glucose measuring system inclusive of the company's GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats and horses. The company also has its GenUltimate! Sure and GenUltimate! Precis test strips, products for off-shore sales. The company has begun Definitive Agreement writing with a large Eastern European distributor for their distribution in the Russian Federation and aligned countries. Both of these products will primarily be sold as an international private label market entry. Export Certificates for GenUltimate! Sure and GenUltimate! Precis have been allowed, and manufacturing and sales were scheduled to begin in February 2020, until the advent of the Coronavirus shut down of our Korean contract manufacturer. There is no domestic or North American markets for these products.

In addition, the company's GenChoice! glucose test strip has completed its clinical trials and filed a 510K application with the U.S. FDA for its clearance. The company has had eleven formal communications with the FDA, inclusive of a face-to-face meeting with FDA management and the review staff. We expect clearance of this product, although we have moved the completion and shipment of our Covid-19 products, due to emergency, ahead of our GenChoice. The explanation below is a done in a manner that all readers will understand.

In mid-February 2020 we were first advised of the large outbreak of Coronavirus in Korea, and in particular in the city of Daegu, Korea. Daegu is the Korean city where since 2016 the company's manufacturing facility and patient trials hospital are located. At first it was difficult to receive information as to the severity of the virus and how it was affecting the company's facility in Daegu, Korea. Subsequently we learned for the first time the use of words "lock down" and lock up." Our contract manufacturer The Bio Co., Ltd. ("The Bio") was eventually described to us as locked down and locked up and was unable to manufacture or ship to us our diabetic testing products from February 22 through March 27, 2020. It was explained that even though The Bio had reopened for business in early March 2020, some of their suppliers, both locally, and in other parts of Korea, and outside of Korea, were still locked down.

As this Coronavirus spread, and with time on their hands during the lock down, we asked The Bio several days after their mid-February 2020 lock down, to look into whether some of our diabetic detection and management technologies could be put to use to develop a coronavirus test.

We had decided that if such a test methodology were possible it was worthwhile from a humanitarian standpoint to use our limited resources at least to try to develop such a test. A few days later we received three cites from The Bio regarding technical papers written in the last five years where the researchers and scientists discussed in those white papers the ability to use a method called impedance to identify and classify certain (now familiar) classes of virus. All three papers described their methodologies in detail and included sample data sets.

In all three cases the researchers designed and built a bench level chemistry methodology and their version of an identification device, and then performed tests on live patients. In all cases the number of patients (subjects) tested was statistically significant. The importance of these publications indicated that a testing device and chemistry method, using impedance (better described as an energy pulse with traits somewhat similar to an electric current and a radio wave pulse), could be created in short order to measure the presence or absence of such a virus (of interest) such as influenza and H1N1 influenza, and of course SARS and Covid-19. The company's GenUltimate TBG product makes use of impedance technology to measure the number of red blood cells in a patient blood sample, information relevant to a glucose measurement in that same patient. Mr. Berman, the company's CEO, became convinced that a similarly configured device could be built for the determination of Covid-19.

As quickly as it could the company engaged Matthew Musho, PhD (holder or collaborator in 32 patents published in parallel fields) and his wife Leslie to assist in the design of a testing method and device for the measurement of Covid-19.


<https://patents.justia.com/inventor/matthew-k-musho>

The company also engaged FDA practice counsel to prepare the company and its new product for submission for emergency use authorization (EUA) by the FDA. Counsel, already familiar with the company's products and technologies, understood almost immediately what the company was trying to achieve and during the last week in February counsel contacted the FDA. This contact was made a day or two prior to the FDA's eased guidance for EUA, published on February 27, 2020. A subsequent further easing of FDA past policy appeared in a March 16, 2020 guidance policy.

The specifications guidelines set down by Mr. Berman, for creating this Covid-19 testing device and its important chemistry, were that the test must be measured on the company’s existing Precise or Avantage glucometers, because they were completed products, having been tested to great length, and now to be adapted for detection of Covid-19 instead of whole blood glucose. In addition, the resulting chemistry would necessarily run using a patients (small sample of) whole blood taken from a finger prick, and later defined as 1-2 microliters (a small drop on a finger tip), and perform the test and provide a result in one minute or less (later redefined as 15 seconds or less), with at least a 95% accuracy. Mr. Berman believed this device was capable of 97-98% accuracy. Three alternative designs were provided and given to the company on March 2. Two of the designs were diagrammed by Mathew Musho, PhD, the third design by a chemist and engineer from The Bio in Korea. The chosen of the three alternative product designs would bear the trade name GenViro! Swift.

The company then set to work, along with Matthew Musho, PhD (“Musho”), to evaluate the designs, keeping in mind the desired specifications of the DECN CEO and product Program Director, which included availability of components without wait time, time to market (assuming FDA EUA), whether the chosen method was applicable to use in point of care and at-home environments, time of assay from commencement of test and until result, size of the blood sample, and finally cost to produce. Given the company’s experience in working with biosensors and with electrode technology, the design review process took less time than originally expected. The entire process took 13 days. The last of these days used to determine which of the two Musho specifications was to be chosen. The design provided by The Bio was discarded because it could not be read on the existing company meter technology, and therefore would require additional development. At the end of this process, the company chose to produce the product shown in the illustrations, the second of the two Musho alternative versions, but shortly thereafter to begin work on the other Musho specification, to be used as a confirmation tool.


**Product Design 1 (chosen)**



The design above is in many regards similar to the direct antibody antigen approaches favored by some of the competitive companies in the Covid-19 testing field. But the major difference (magic) is that the approach used by the company in its GenViro! product allows for swift (15 seconds or less) results using a minimum of blood from a finger prick. As of this writing, work has commenced on the product specification above with components such as the platinum electrodes, platinum carbon paste, industrial films (several types) to make the biosensor, and perhaps a new impedance chip for the meter. The company is operating on an 8-week development schedule and is some 10 days into this schedule. The current development cycle is considered advanced development. For FDA EUA filing and the granting of a Pre-EUA by the FDA, the company is preparing its final working concept filing, to be completed within days of this writing.

On April 1, 2020 the company plans to begin development work on its second product design, a confirmation test for Covid-19. This test, a hybrid but direct antibody/antigen (IGG) method, again making use of the company’s expertise in biosensors, will be designed to be used on those the tested Positive Covid-19, and those that tested Negative but are suspected to be false Negatives. This product design is not yet in the advanced development cycle.

## Product Design 2 (confirmation)



As stated, the company anticipates filing its latest and complete EUA documents with the FDA during the week beginning March 30, 2020, for the registration of its Covid-19 test for Point of Care and At-Home use. The company is unsure if the At-Home use application can be cleared for Pre-UEA at this point, owing to the historical use of EUA being limited to Point of Care uses. However, the company is in the process of completing packaging and package inserts for three versions of its GenViro! Product, GenViro! Point of Care, GenViro! At-Home use, and GenViro! International in English, Spanish, French, German and Russian languages. The most immediate request made to the FDA will be for Pre-UEA, the new accepted standard for emergency diagnostic products.

Regarding additional product development, the company has completed advanced development work and third party testing of its GenUltimate! TBG test strip and TGB Precise meter and are ready to begin patient testing (clinical trials) in Korea. A clinical site at a prestigious Korean research hospital has been identified and appropriate documentation filed with the Korean FDA. This application was delayed for 30 days beginning in August 2019 when DECN CEO Berman requested the development engineers for the TGB product to change the active enzyme in the chemistry to a variant of Glucose Dehydrogenase (GDH), which provided the TGB product an added precision in use. Earlier in 2019, and in association with the company's advanced development engineers, company CEO Keith Berman asked for a change to the engineering foundation of the GenUltimate! TBG system to work in an identical manner with the company's GenUltimate test strip, same chemistry, same family of meters, thereby allowing the company to offer three essentially identical products, each serving its own somewhat unique purposes, all running on the same test strip foundation, an FDA cleared device. The TGB enhanced version of GenUltimate! is named GenUltimate! Premier and will go on sale commercially just as soon as the company's FDA registered contract manufacturer recovers from the Korean experience with the Covid-19 virus that began in Korea in late January 2020 and reached critical proportions in February 2020. The main needs now to begin manufacturing of this new version (Version 3) test strip is certain tooling needed to be added at the company's manufacturing facility. Gen Premier! owing to its near analyzer level precision (in a handheld device) will carry a substantially higher MSRP, Big Box, and wholesale pricing. The company will continue to sell its GenUltimate! product in existing markets.

**GenUltimate!®**  
& **GenUltimate!®**  
**TBG**



As off-shore products GenUltimate! Sure and GenUltimate! Precise are test strips that run on four existing Platinum/Lifescan legacy meters, and will only be sold in select international markets, primarily in the Russian Federation. There are no USA markets for either test strip. The International roll-out decisions were to choose those markets where the products will not encounter certain performance criteria issues created by the legacy metering platforms that the GenUltimate! Sure and GenUltimate! Precise test strips run on. The GenUltimate! Sure product in particular, although sharing many similarities with the company's GenUltimate! product, does not have the capability for future improvement or upgrade and as a result is viewed in the market and by DECN as a small niche product. Thus, most of the company's attention for International markets will be focused on GenUltimate! Precise. However, manufacturing of the GenUltimate! Sure product will allow the company to continue manufacturing the existing GenUltimate! test strip which uses the same manufacturing line. The GenUltimate! Precise product has more potential in that it is capable of having portions of the company's TGB

technology added-on at a later date. Thus, the conclusion was that having two finished products is better than having no product at all, so the company will continue to perform compatibility testing with the family of legacy meters as we grow our relationship with the large Eastern European distributor.

Resources permitting, as 2019 transitions into 2020, we intend to register the company's GenChoice! and GenUltimate! TBG products in the EU, because these products do meet ISO guidelines without further development. The GenUltimate! TBG meter, which will undergo 510K prosecution for its metering system, is next up of our diabetes related products for FDA clearance. The test strip, a close relative of the company's GenUltimate! test strip which is already FDA cleared. The company has contracted with the same expert organization that wrote the 510K document and a credentialed IRB who completed the GenChoice! clinical trial data and who will follow the same clearance path for the GenUltimate! TBG system.

### Our Current Business Foundation

Our subsidiaries, Pharma Tech Solutions, Inc., PDA Services, Inc. and PharmaTech Sensor Development Corp. operate in several healthcare products channels. In addition our subsidiary Decision IT Corp. engages in the acquisition and holding of Intellectual Property including Patents and Trademarks and specialty manufacturing equipment acquired for our Korean contract manufacturer of our GenUltimate! as well as our GenSure! and GenChoice! products. Our newest subsidiary Pharmatech Sensor Development Corp. manages our investment in specialty manufacturing machinery and testing laboratories, as well as an inventory credit line to finance inventory purchases of our GenUltimate! and PetSure! products. The company will endeavor to expand the credit line for the management of our GenChoice! and GenUltimate! TBG products in 2019. The company has discontinued its earlier GenStrip 50 product and ended the selling of the last of the inventory in November 2016. All of the GenStrip 50 test strips have subsequently reached expiration dates.

In March 2017 the company was approached by its Korean partner, The Bio Co., Ltd to design and fund a new product which the company calls GenUltimate! TBG. This product represents a major improvement in diabetic glucose monitoring. The GenUltimate! TBG system will be the first of its kind +/- 7% system. Current ISO (2015) and FDA (2014) guidelines call for glucose monitoring systems to meet a +/- 15% standard, whereby the meter and strip must be within +/- 15% of a reference method in repeated testings 95% of the time. GenUltimate! and GenChoice! are +/- 15% test strips, with GenChoice! perhaps a little bit better, but in each case 97+% of the time in repeated samplings. GenUltimate! TBG is designed to meet the written standards of the ISO and FDA at +/- 7%, 97% of the time – effectively setting a new standard. The company has been funding the development of this system product since 2017, as well as a test strip only derivative version for use with a legacy meter sold overseas. In October 2018 the company implemented a strategic change to its development and manufacturing processes whereby we will standardize around two technology foundations, our GenUltimate! technology and our GenChoice! technology. PetSure! was the first marketable product to make use of the GenChoice! technology foundation, and is currently selling in pet testing channels in the USA, Canada and the EU. GenUltimate! TBG will be the first enhancement of our GenUltimate! technology foundation. The company believes that these changes in our product development processes will lead to quicker to market products and streamlined and less costly manufacturing processes. .



As of this writing, GenUltimate! Precis and GenChoice! products are not yet available for sale in the U.S. or Puerto Rico.

### Historical Construct

Shasta Technologies LLC, the original specifications provider of GenStrip, had an extremely difficult relationship with the US FDA and was the subject of a detailed and damning FDA (Enforcement) Warning Letter on April 8, 2014, and when they refused to respond to this Warning Letter in an expected fashion, the FDA then broadcast a worldwide Safety Notice on April 29, 2014, the FDA version of the Death Penalty. This second letter effectively ended Shasta's ability to be a product design specifier and manufacturer, due to a total lack of regulatory adherence in the highly regulated medical device industry. It is confusing to consider what Shasta could have possibly been thinking. The company's acquisition of Genstrip (now GenUltimate!) was fortuitous in its timing given the finality and outcome of Shasta Technologies' fatal troubles with the FDA. Shasta contested our acquisition and took other legal steps against their FDA lawyer and in retaliation against the company. During the efficacy of these litigations we had success in the courts. In OTC Markets Group Inc. OTC Pink Basic Disclosure Guidelines (v2.0 February 2019)



December 2018 we received a grant of a judgment against Shasta for \$3.6 million. We perfected this judgment in California, Pennsylvania, Oregon (Shasta's domicile) and Minnesota. As we began levy against Shasta we accepted their offer of Settlement. As a result of this Settlement we were able to value our acquisition of GenStrip under our 2014 Agreement. A substantial gain occurred and is fully described in our financial report.

The worldwide market for at-home blood glucose testing is an estimated \$17.6 billion as of 2018, inclusive of the 2013 and 2016 changes to the Federal Medicare programs which gutted almost one-third of the U.S. market. The current GenUltimate! competes directly with one of the largest worldwide platform manufacturers the venerable Platinum (formerly Johnson & Johnson) Lifescan Inc. Ultra legacy product. J&J, which had owned Lifescan for more than 25 years, sold its Lifescan division and its venerable products to Platinum, a private equity firm. GenUltimate! (and the earlier GenStrip 50) were developed for use with the Lifescan OneTouch Ultra legacy system for at-home blood glucose testing, a system currently used daily by over 3 million diabetes afflicted Americans and 5.8 million diabetics world-wide. GenUltimate! competes in the overall at-home testing market by offering an economical solution to former users of the legacy platform provider's product. The company's GenUltimate! product is a much improved version. Our business model is unique to this market channel as our major business focus is directed toward diabetics who have attempted a change of their glucose monitoring platforms (systems) or those currently using the Lifescan legacy products but are dealing with escalating prices and lower (if any) insurance reimbursements. At the time of the introduction of GenStrip in March 2013, Lifescan controlled just under 40% of this market and 100% of its own Lifescan, Inc. OneTouch Ultra market. Their overall market share has since dropped below 30%. In October 2018 Lifescan, Inc. was sold to a large California based private equity firm in an asset sale arrangement. This event gave impetus to the changes we have made to our GenUltimate! TBG system, the first and only evolutionary enhancement to be offered to the Lifescan Ultra family of products still in use by over 4 million diabetics worldwide (see Litigation section).

We began our transition into these medical products channels on November 1, 2011 when we completed the acquisition of Diagnostic Newco LLC from its owner Kimberly Binder. Diagnostic Newco LLC was a design company that specialized in product packaging design, medical products advertising design and graphic art. Ms. Binder subsequently joined the staff of the company's Pharma Tech Solutions, Inc. subsidiary specifically for these purposes, and has worked closely with the contract manufacturers for GenUltimate!, making subtle changes to packaging design and more recently integrating the new FDA UDI product identification data system, among other responsibilities. She is also responsible for the package design for new diagnostic products the company is currently working on, including the GenSure! and the upcoming GenChoice! and GenUltimate! TBG products. Ms. Binder is also owner of Genstrip Direct LLC and Full Circle Diabetes LLC, her own distribution companies, which she operates separately from her (Decision Diagnostics Corp. and Pharma Tech Solutions, Inc.) company related responsibilities.

The original Shasta product was acquired by our Pharma Tech subsidiary on March 20, 2014, and fits into a diagnostic product niche, fitting nicely into the world-wide self-test (home test) market that has been growing at a 15% annual rate. Since GenUltimate! is a rather unique product offering, employing a brand name razor blade only model (diagnostic test strip) into a razor (diagnostic meter) -- razor blade (diagnostic test strip) market, the Genstrip 510(k) application made for unusual challenges for the FDA and an educational challenge and opportunity for the company. In fact, the company only concluded its dealings with the FDA in March 2016, but has had subsequent issues pre and post market review staff, an on-going process that was begun on a very sour note by Shasta in October 2009 and ended even more sourly in early 2014. The company believes that upcoming product offerings such as the GenChoice! and GenUltimate! TBG products, which will also be regulated by the FDA but we hope will go through the rigorous comment process, particularly since receipt of a directed landmark ruling by the U.S. FDA, covering our third party developed diagnostics (developed, in development and to be developed). The FDA, however, is accountable to no third party and while we did win major victories and we did deal with certain biases and retaliation during the GenStrip 510K prosecution, we have seen this same type of treatment for our GenChoice! product. However, we remain ever vigilant and continue to retain litigation counsel.

Until our receipt of the March 2016 ruling from the FDA, two years (and growing) was a standard development to market timeline for in-vitro diagnostic products similar to Genstrip / GenUltimate! In fact the long review periods and stifling performance standards established have contributed to a large decline in new products offerings in the USA and the industry since 2014.

In 2019 we again improved GenUltimate!. GenUltimate! has become the only version of the original Genstrip line that will be packaged to conform with the FDA UDI standards, and was released as UDI compliant as of September 24, 2016. Manufacturing of Genstrip 50 ended and on-going sales continued under the GenUltimate! brand, and includes the FDA UDI packaging.

On the business side, in June 2010 the company was approached by the largest retailer in the world for the distribution and sale of the Genstrip product, then about to enter the 510k regulatory review process, at over 5,000 retail stores worldwide. A contract with this retailer was negotiated in September 2010 and subsequently renegotiated and renewed in April 2011 and then for a third time Beginning in November 2016, and as soon as the retail contract was agreed to and as a means to conduct market research, the company began seeking pre-conditioned letters of intent (pre-orders) for Genstrip, while continuing the prosecution of the 510(k) application on behalf of Shasta Technologies before the FDA.

Lifescan Inc., until October 2018, then the diabetes testing division of Johnson & Johnson, sued the company in three separate suits, all in Federal court, beginning in September 2011. These suits proved costly in that their intended purpose was to keep the Genstrip product off of retail market shelves. Until these suits were settled in May 2016, the company's marketing abilities were severely limited. In fact, even as of this writing, the company faces market obstacles brought about by the original litigation with Lifescan, Inc. However, it should be noted that Johnson & Johnson announced in January 2018 that their entire diabetic business (three divisions, multiple products) had been put up for sale, and offers for some or all of their businesses had been received. The sale closed in October 2018 with the completion of an asset sale to a large California based private equity firm, Platinum Private Equity.

The settlements we did achieve with J&J provided a hard-fought victory for the company, particularly since in 2015 Shasta had admitted to patent infringements of all three J&J diabetic medical device patents that were being adjudicated. We settled these lawsuits in a novel manner, where Johnson & Johnson paid the company a settlement amount in cash, in those lawsuits where the company was a defendant, a rarity in matters where the Plaintiff (J&J) had initiated the strike suit in the first place. J&J, as a part of the settlement, also granted the company licenses to three J&J patents (including one patent that J&J subsequently lost as a result of 3<sup>rd</sup> party prosecution by the company, through final action by the US Supreme Court), the larger value gained from this 5-year legal battle. In March 2016, prior to its settlement, the company's Pharma Tech Solutions, Inc. and Decision IT Corp. subsidiaries brought suit against Johnson & Johnson and Lifescan, Inc. in Nevada Federal court for patent infringement, the company alleging that Lifescan, Inc.'s OneTouch Ultra product was and had been infringing both of the company's patents. In March 2017, after a protracted battle with J&J where they tried to invalidate the company's lawsuit, the court in a major ruling agreed that the company will be allowed to move forward (a major victory so early in the suit) and will also be allowed to allege the Doctrine of Equivalents, a legal doctrine that would preclude J&J from twisting words through its pleadings and expert reports to escape justice. In April 2016 the company amended its original suit to include allegations under the Doctrine of Equivalents.

*“The doctrine of equivalents is a legal rule in many (but not all) of the world's patent systems that allows a court to hold a party liable for patent infringement even though the infringing device or process does not fall within the literal scope of a patent claim, but nevertheless is equivalent to the claimed invention(s).”*

Further, in January 2016 the US Supreme Court ruled that the Doctrine of Laches, a defense used by many Defendants in patent infringement suits could no longer be used. This ruling further deprived J&J of one of its most important defenses against the company's current patent infringement claims. All of this action did not dissuade the Nevada District Court trial judge from granting J&J a Motion for Summary Judgment in October 2018. As a result of this ruling, the company filed an appeal to the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit court”) in Washington, DC (the patent court). The company's appeal was ruled against by the Federal Circuit court in 4Q 2019. The company, with many other irons in the fire, decided not to avail ourselves of further appeal, thus ending this litigation.

## The Current Business

In the next 120 days the company expects to enter the Covid-19 test kit market with unique, cost effective, accurate and wholly proprietary products. Almost all available resources are being directed to the Covid-19 products (see Business Introduction). It is unknown how big this market will eventually grow to encompass, but given the severity of the Covid-19 pandemic, the fact that the company is developing screening tests, we expect to make a big market entry as we finish our product, manufacture it, and achieve FDA initial and then complete clearance.

The current foundation business is focused on the diabetes testing market, a market dominated by four large pharmaceutical manufacturers who provide very similar and equally focused products, selling at essentially equal prices. Our Genstrip's original introduction, even with the fits and starts, employed a business model different than those models employed by the major market players. Recent successes in the on-line marketplace has allowed the company to alter the market dynamics, lowering average price (which has occurred) or allowing for increased testing by diabetics for a lesser price, thereby affecting all market segments. The company's major current market focus is to pharmacy chains, grocery chains with in-store pharmacies, large all-purpose retailers with in-store pharmacies, and group buying and chain pharmacy organizations, and for its pet testing products, on-line sales and chain pet supply stores and retail pet outlets. Although this has been part of the company's plans in the recent past, the difficult litigation with Johnson & Johnson as well as the advent of the July 2013 and July 2016 changes to Medicare reimbursement (and followed by private insurers) and the October 2016 reimbursement engineering, pharmacy business models are now blurred. Thus the company successfully added on-line sales to its business model.

The company has also implemented a successful “direct to diabetic” business model and has (independently or along with our distributors) executed on-line agreements with several of the largest retail chains, diabetic supply co-operatives, group purchasing

organizations, as well as on-line mass merchandisers such as Amazon.com, EBay, Walmart, Sears, Jet.com and approximately 1050 other on-line cooperatives and product aggregators. The company considers this rapid adoption to be a success gained in a very short period of time.

In June 2017 we were notified by Amazon.com, the largest retail portal for our products where we now currently sell approximately 35,000 boxes of GenUltimate per month, that the listings for our products had been “hacked” by ghost sellers -- individuals and people who listed our products, accepted orders and cash money from diabetics, but were unknown to the company. Oftentimes product was never delivered to the diabetic even after receipt of payment. This practice called freeloading (by Amazon) is not rare, but once started it is difficult to eradicate. The company had to replace almost 6,500 units of GenUltimate as a result of the freeloading. In March 2018 another 3,000 boxes were replaced, leading to lower sales margins in the periods where the replacements too place. The company is in on-going friendly negotiations with its distributors to provide compensation for the effect of the freeloaders. While freeloaders had a cost basis of zero, legitimate sellers and distributors were forced to compete with these zero cost sellers. Prices for GenUltimate plummeted and by October 2017 the product in its largest portal showed a price decline on average of 35%.

With the assistance of Amazon, who themselves became a distributor of GenUltimate!, the company was able to overcome some of these issues. With the assistance of Amazon we reordered our selling practice, implementing base (floor) pricing and implementing real-time policing of listings. As a result, we were able to overcome this freeloading practice. Prices have recovered about one half of the Fall 2017 decline. We are currently in the process of raising prices again. Also, as a result of the “Amazon debacle,” the company also eliminated many small distributors of GenUltimate! from the Amazon portal. In 1Q 2019 we further eliminated a group of our wholesalers who may still sell our products, but not on Amazon. While these actions had the effect of lowering sales throughout 2018 and into 2019, our margins and our sales levels are recovering, as our sales increase. The effect of barring wholesalers from selling on Amazon cost the company \$90,000 to \$120,000 in sales for 1Q 2019, mostly through lower inventory levels by our wholesalers. Subsequently, the advent of Covid-19 closed down our Korean contract manufacturer from mid-February through March 27. Our Korean contract manufacturer was the only finished goods producer of our GenUltimate! and PetSure! products. This bottleneck was alleviated as of March 27, but sales were greatly impaired during 1Q 2020.

In March 2017 the company was contacted by the retail giant Walmart, who along with their acquired on-line retailer Jet.com, are attempting to duplicate and surpass the Amazon portal. Our GenUltimate! products have been sold on Walmart’s (and Jet.com’s) portals since November 2016. In the 2018 discussions Walmart offered us preferential listings on portals and Walmart Depot stocking at their regional transit facilities. We also began discussions, now in process, for the manufacturer of a Walmart house brand version of our GenUltimate! As a result of our agreements with Walmart, GenUltimate! is now sold and fulfilled directly by Walmart. In addition, Walmart has implemented a large on-line store pickup, allowing GenUltimate! users to pick their GenUltimate! product up at Walmart stores. We accepted Walmart’s offer (who wouldn’t) and changed our distribution agreement with Walmart (and Jet) so that Walmart would sell and fulfill our products directly. We accomplished this while still selling our products directly through Walmart. This business model is called cannibalization with the goal of overall sales maximization. Walmart customers who previously received standing orders for their legacy J&J Lifescan test strips are a part of this new program. The company believes this to be a market enhancing deal since Walmart will become both a “push” and a “pull” retailer. No special pricing of our GenUltimate! products was required to implement this plan, owing, no doubt, to the footprint we have established on the other large on-line portals. Walmart purchase orders for Walmart sales of our products have increased dramatically. We continue to evaluate our prospects with Walmart and we believe we will move toward a global agreement with Walmart for our GenUltimate!, PetSure! and GenChoice! (when cleared) and GenUltimate! TBG products. Meetings were scheduled in the month of May 2019 at both Walmart and CVS pharmacies, primarily for our GenUltimate TBG products. Subsequently we are gearing up our Covid-19 kit business quickly, albeit because of the times, using remote capabilities to reach out to Walmart, CVS, many, many others in the USA, Canada, and internationally.

In March 2016 we also retained a product source company called Retail Monster, to represent our products to large drug chains (“big box pharmacy”), large retailers, chain grocers and the like. Unfortunately the arrangement with Retail Monster did not succeed, primarily because a group of company shareholders and persons claiming to be shareholders poisoned our relationship with Retail Monster early in our contract term, by advocating during repeated calls, a “palace coup.” After these incursions by shareholders and persons claiming to be shareholders, our relationship with Retail Monster remained cordial but was, unfortunately, destined to fail. The two companies decided to end the engagement on December 31, 2016.

The efforts being expended in the “big-box” arena are greatly aided by the company’s recent success with the explosively growing on-line Marketplaces, many sponsored by the large retail pharmacies and retail stores. We expect the same type of response, perhaps even greater for our upcoming Covid-19 test kits. These Marketplaces are fast growing sister organizations to these retailers, and typically not a part of legacy manufacturers marketing plans. The company’s recent successes in the on-line Marketplaces has given the company a beachhead in this market as the uncertainty brought on by the J&J lawsuits has (finally) waned. In mid-March 2016 the largest US retailer agreed to raise the company’s standing to the highest retail “rung” by offering a new supplier contract and in mid-

March 2018 this retailer and its recently acquired wholesale products partner contacted the company and implemented a direct relationship. This decision led to inquiries by other big box sellers.

In March 2019 we entered into a long term relationship with PARAGON Sales and Marketing Inc. to support the national growth of both our branded and private label retail products sold under our "Gen" brand, and our private label brands of Alltara!, ConsumerValue!, Infatig!., and Medicius!. We have expanded this relationship to include our Covid-19 sales and distribution efforts.

Initial accounts were assigned to PARAGON for big box and private brand big box agreements include Walmart, CVS, Walgreens, Costco, Kroger and Cardinal Health. PARAGON will also work closely with us in evaluating other potential new retail product categories and products that we may launch in both branded and private label offerings in the future. Sadly, shareholders and non-shareholders have already attempted to contact PARAGON, one such incursion occurring during the writing of our 3Q 2019 Quarterly Report. The company has promised PARAGON that we will take legal action against these people should this activity continue. Instead we were notified that PARAGON contacted their own commerce lawyer and in addition verified the person (name, address, etc.) behind the incursion.



Alltara choice, and GenUltimate TBG is not yet available for sale or distribution in the United States or Puerto Rico.

Since March 2015 when we first we acquired special intellectual property and specialty manufacturing equipment which will shall serve our business interests now and into the future. We have increasingly turned to Alpha Capital Anstalt (“Alpha”), Navesink Device Initiatives, Sovereign Partners and Licgo Partners, whereby these organizations either purchased an 18-month 15% OID derivative instruments or Preferred C stock units, to facilitate the acquisition of intellectual property or manufacturing equipment, or to finance our growth. In 1Q, 2Q and 4Q 2016 and 2Q, 3Q and 4Q 2017, 2Q and 3Q 2018, and 1Q and 2Q 2019 we completed additional financing transactions with both Alpha and/or, Sovereign, and Licgo. Our most recent transactions with Alpha also financed an inventory credit line for the company so that we can meet many of the requirements of the largest retailers and maintain at least \$300,000 in stock on hand at any time. From time to time we drop below this \$300,000 threshold, primarily at the end of fiscal quarters. Alpha also financed our acquisition of new specialty manufacturing equipment to facilitate our contract manufacturer in Korea as they develop our new GenChoice! product.

In June 2018 the company came to terms with an international distributor who would sell the company’s products in Mexico, Puerto Rico and in select South American countries. Initially the sales by the distributor would have been our GenUltimate! test strips and meters, and our GenUltimate! Sure test strips and meters. Governmental approval was needed for these products. This distributor did not distinguish themselves and the association was ended.

However, in late July 2019 the company was contacted by a large Eastern European distributor of J&J/Lifescan, now (Platinum Equity) products. To begin, this distributor wishes to distribute the company’s GenUltimate! Precis product, a product that has no USA market, does not require FDA clearance to be sold overseas but appears to be a natural for Eastern European markets, particularly in CIS states and the Ukraine. The company must complete an “accuracy” test for the GenPrecis! product, complete the packaging in several Eastern European languages, and then schedule a manufacturing line.

## Additional Background and Foundation

In May 2010, we entered into agreement with Shasta Technologies, Inc. and Broadtree, Inc. This agreement granted our Pharma Tech Solutions, Inc. subsidiary the exclusive marketing rights to a new diagnostic product not yet on the market named Shasta Genstrip (“Genstrip”). The Genstrip product was developed to compete against the market leader in the then \$6.5 billion at home testing market. Shasta was in default of this 2010 Agreement within 90 days of its initiation. Penalties under that agreement and monies owed totaled in excess of \$2 million in “delay” penalties, which they were unable to pay. In April 2011, the company renegotiated its agreement changing its many roles and adding responsibility for regulatory approval, manufacturing and forecasting, international sales and additional sales markets in the U.S. Shasta defaulted under this agreement as well. On March 20, 2014 we acquired the GenStrip intellectual property, its marks and the cleared 510(k). Shasta defaulted on this agreement as well. In addition Shasta breached or defaulted on two insurance settlement agreements, owing to the aforementioned J&J litigation. Shasta also confessed to patent infringement of J&J’s three patents and for one reason or another thought it was in their best interest to sue their previous FDA lawyer, who supposedly did not stop Shasta from commercially damaging themselves.

On April 30, 2014 we first implemented our FDA mandated Quality Plan and are now operating as the manufacturer (operator) of the GenUltimate! test strip. We have implemented subsequent Quality Plans with our Korean contract manufacturer for our GenUltimate! product. Similar Quality Plans and FDA registrations will be in place for the company’s GenChoice! and GenUltimate! TBG products in the near term, and for our GenAccord and GenCambre products later in the coming months. Our overall Quality Plan, a living document, is in its fifth re-write.

The company brought suit against Shasta and the former contract manufacturer in Pennsylvania in November 2018. On December 31, 2018 the Pennsylvania court awarded the company with a \$3.6 million judgment against Shasta. We were pursuing collection of this judgment in Minnesota, California, Oregon and Pennsylvania. To that end we filed for a Writ of Attachment against Shasta for the \$3,600,000. This Writ will allow the company to bring an end to the litigation against Shasta in California and Minnesota (in an action stat that includes our FDA lawyer). On June 29, 2019 Settlement documents were executed by Shasta and the company to bring an end to the litigation in the four states. Shasta agreed to drop all claims against the company, and we agreed not to further pursue Shasta (but not Conductive Technologies, Inc. and not the former DECN shareholders). After five years, the company can now value its acquisition of the GenStrip technology and Marks, and any knowhow. We have done so as of the period ended September 30, 2019 (see financials) and have realized a gain in the period.

We continue to litigate in Pennsylvania against the former contract manufacturer and anticipate a handsome settlement in the coming months, who apparently while working for us, was also working against us and for Johnson & Johnson. The company is also pursuing those persons who owned stock in the company who may have traded stock in the market based on information and documents provided by Shasta, or who were given confidential documents by Shasta, gained through the litigation discovery and provided to these shareholders, who then posted the information on public message boards.

We currently employ nine professionals at or locally managed through our executive business office located at 2660 Townsgate Road, Suite 300, Westlake Village, California 91361. In addition, we maintain two full-time and seven part-time positions located throughout the United States. We also maintain a Quality Assurance office through our exclusive agent in Seoul, Korea as a means to fulfill our quality commitments to the FDA. Our telephone number is (805) 446-1973 and our website addresses are and [www.pharmatechsolutionsinc.com](http://www.pharmatechsolutionsinc.com) and [www.genultimate.com](http://www.genultimate.com). and [www.decisiondiagnostics.com](http://www.decisiondiagnostics.com). Additional web sites will be added for our GenChoice! product (site now in FDA 510K prosecution), our GenUltimate! TBG product and our GenViro! Covid-19 testing products.

As a part of the company’s strategic plans, we have applied (to register) for fourteen Trademarks with the USPTO. The company’s Genstrip product is a registered Trademark of Shasta Technologies LLC. Now that we own this Mark, we do not intend to renew it. Our applications were filed with the USPTO in 1Q and 2Q 2015 and throughout 2016, 2017, 2018 and 2019. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and the establishment of a family of Marks associated with our company and its place in our industry.

As of March 30, 2020, the company has received registration confirmation from the USPTO for the following Marks:

“Alltara!”  
“GenUltimate!”  
“GenSure!”  
“GenChoice!”  
“GenAccord!”

“GenCambre!”  
“GenUltimate! TBG”  
“Firefly!”  
“ConsumerValue!”  
“Infatig”  
“Medicius!”

Our marks for Alltara!, ConsumerValue!, Infatig!, and Medicius! will be used for product families as an integral part of our relationships with the “big-box” entities. We have several Marks that were filed to further enhance our GenUltimate! TBG product and technology. These Marks were first filed in 2Q 2019. Subsequently we have filed for trademarks for GenUltimate! TBG and Genviro!.

As a result of a product embargo by Shasta and Conductive Technologies, Inc. the company ran into an inventory shortage, and in fact ran out of product on several occasions. However, the inventory problem began to clear up in late May 2016, and with the advent of adding the GenUltimate! product from Korea, shortages were alleviated. The company’s capacity for GenUltimate! production is now 750,000 packages per month (50 count and 100 count packages), for the new GenSure! product 100,000 packages per month (25 count and 50 count packages) and the new GenChoice! product (initial) 150,000 packages per month (50 count and 100 count packages). A mega-retailer has requested minimum inventories of finished product of 150,000 units/boxes. We expect other retailers to make similar requests. The manufacture of GenUltimate! and GenSure! are very similar and this capacity can be viewed as interchangeable. Similarly the manufacture of GenChoice! and GenUltimate! TBG will be similar to the manufacture of GenAccord! and GenCambre! Manufacture of GenPrecis will require additional investment in plant and machinery. The company is also in discussions with Korean contract manufacturers to augment our GenViro! Products, a product line we expect to require capacity to manufacture millions of these kits.

The company is also in discussions with prospective partners for our GenUltimate! TBG and GenViro! Products. While we are much further along with our GenUltimate! TBG product, a competitive mainline, legacy products company. The interest expressed in our GenViro! product has been unprecedented, at least for us, both from large USA based manufacturers and distributors, as well as those overseas. We have thus far decided to take on our Russian Federation partner to distribute our GenViro! test kits in the Russian Federation and elsewhere in Eastern Europe.

The company’s stock currently trades on the OTCMarkets OTC Pink Current tier of the market. The company’s shares are DTC and DWAC eligible.

In mid-2018 the company chose to file a Regulation A offering in an effort to improve its disclosure to the SEC. The company had planned to use this filing, reviewed by the SEC without comment on August 23, 2018, to move toward uplist on the OTCMarkets exchange in 2019. In February 2019 the company, after completing all of the ancillary tasks required of a Reg. A filer, amended its registration with the SEC, a necessary requirement. Subsequently, the company’s stock price improved so that the registration offering price was much lower than the stock trading price. In early March, during the stock price rise, the company was informed that a certain party, who at that point claimed to own approximately 4% of the company’s outstanding shares, wished to buy the entire Reg. A offering on the date said offering became qualified. That would allow this certain party to gain control of the company for approximately \$5.3 million, a value much lower than the trading price of the company’s common stock. This was/is a common predatory M&A strategy often used by private equity funds. On March 18, 2019, acting on a resolution by the company’s Board of Directors, the Reg. A registration was withdrawn.

In February 2019 the company was approved for Deposit/Withdrawal at Custodian (DWAC) a method of electronically transferring new shares or paper [share certificates](#) to and from the [Depository Trust Company \(DTC\)](#) using a Fast Automated Securities Transfer (FAST) service transfer agent as the distribution point. DWAC transfer is a method employed by most funds and large investors.

#### Business activities throughout the next twelve months:

The company’s business on a day-to-day basis includes the distribution of our GenUltimate! products, (50 count and 100 count versions), International distribution of our GenUltimate! Sure and GenUltimate! Precis products (25 count and 50 count versions), and our PetSure! products (30 count and 60 count versions), and throughout 2020 our GenChoice! (25 count, 50 count and 100 count versions), at least in international markets, and the GenUltimate! TBG (25 count, 50 count, 100 count versions and a meter), also in 2020. The company’s GenUltimate! TBG product will be sold worldwide and will, require a strategic partner, unless a settlement of our litigation with Johnson & Johnson allows us to sell GenUltimate! TGB independently. The company has chosen one prospective partner looking to pay for the license rights to the GenUltimate! TBG product, a long term royalty for their continuing sales, and the

settlement of other matters. The company has just completed a redesign of its GenUltimate! TBG test strip, building a technology foundation around its GenUltimate! technology.

In 1Q and 2Q 2020 we began the development of our GenViro! test kits, two different proprietary and unique technologies. During the month of March 2020 virtually all available company resources have been directed to GenViro!.

In March 2019 the company announced the hiring of PARAGON Marketing and Sales, Inc., a nationwide retail accounts sales and management firm. The company has assigned several high worth “big box” retail accounts to PARAGON, including Walmart Stores, CVS Pharmacies, Walgreens Pharmacies, Cardinal Health (Wholesale), McKesson (private label brands), Kroger and others.

Companies in the manufacturing and marketing channels in the industry all employ packaging processes, including Korean, Chinese and Taiwanese manufacturers. In truth, the manufacturer operations collectively decided **not** to pay an extra \$10,000 for each of the packaging machines, or the \$0.10 for a slightly larger test strip vial (holder). The company believes this “me-tooism” to be a form of mental blinders. In implementing the company’s new private label strategy, Decision Diagnostics decided not to bow to the packaging machine or “me-too” limitations. Instead the new packaging to be employed by the company will take into account diabetic testing patterns and the average number of testing days in a month. Private label versions of the company’s products will be packaged in sizes of 30 count, 60 count and 120 count packages. This concept has been readily accepted by the company’s private label target list in a detailed survey, and it is believed that this new packaging concept will be a marketing coup. Diabetics test every day of the month, not just 1.67 times a day. So a vial of 30 of the company’s test strips (and 60 and 120) will accommodate the testing needs of the user, not the limitations of a particular type of packaging machine. Sales to the private label industry will be through private label product groups where every private label partner will own a private label group, each group containing all of the company’s products in selective private label packaging.

The company currently has three major private label targets, the largest drug store chain, another top-5 drug store chain, and the second largest grocery store chain. In addition, the private label packaging is being offered to the largest drug store chains in Mexico and Canada. The Mexican chain, who also has numerous stores in Chile and Argentina has moved quickly. However, in all cases the sales process is in the closing stages. Closes of this nature, do however, take time. The company has Trademarked four product label groups for exclusive sales of products to the private label concerns: Alltara!, Advant!, Infatig!, and Medicius!.

Our 12-month business objectives include:

4. The practice of specializing in the distribution of GenUltimate! and PetSure! and GenUltimate! 4Pets products, and the completion of the GenViro!, GenChoice!, and GenUltimate! TBG products. We also intend to add several brand-name medical diagnostic and medical disposable products, lancets through our Firefly! product, as well as several lines of insulin syringes and pen needles, all associated with the on-going care of diabetes-inflicted patients, and the world-wide distribution of our proprietary diagnostic products.
5. Combining our wholesale and retail diagnostics distribution with the major successes we have had in the on-line retail markets, and adding legacy retail organizations (already some legacy retailers of note). See discussion above concerning private label opportunities and our private label lines.
6. Continue to implement the plans provided by our agent MWK LLC, and PARAGON Sales and Marketing in efforts to secure big-box pharmacy chains, chain grocers and nationwide retailers in addition to the private label groups previously discussed.

Recent Business Milestones:

In 1Q 2019, 2Q 2019, 3Q and 4Q 2019 and 1Q 2020 the company has accomplished the following milestones.

7. In March 2020 we completed design of two Covid-19 test kits for commercial sale as soon as FDA Pre-EUA and EUA approval is gained (see Business Section Introduction).
8. We have prepared for introduction a premier version of our popular GenUltimate! test strip for launch on September 3, 2019. First deliveries for this test strip designed and provided for the benefit of big box stores will be in the 3<sup>rd</sup> week in September.

9. We completed the design and manufacture of PetSure! glucose test strips for the international markets, and completed development of our GenChoice!, GenUltimate! 4Pets and GenUltimate! TBG products.
10. We began FDA 510K prosecution, patient clinical, 3<sup>rd</sup> Party testing and/or clinical trials of two new test strip products, our GenChoice! and GenUltimate! TBG test strips and the GenUltimate! TBG Precise meter. Neither the PetSure! nor GenUltimate! 4Pets products required live patient (pet) clinical testing. We most recently added GenChoice! TBG to our Advanced Development schedule.
11. The company initiated a marketing program to the on-line Marketplaces sponsored by pharmacy chain, department store and grocery store retailers, as well as mass merchandisers, and including the largest retailers. This program has so far been the most successful endeavor since our inception.
12. The company has retained patent counsel to file three patents (in 3Q 2019) for our GenUltimate! TBG and GenPrecis meters and test strips, and for our newest adaptation, our teo GenViro! Covid-19 test kits.

## Financing Requirements

At December 31, 2019, we had cash of \$114,334 and negative working capital of \$3,644,036. We anticipate that we will require up to \$250 million in [trade debt financing](#) to finance our expected sales of our GenViro!, GenUltimate!, GenUltimate! Premier (for big box) GenUltimate! TBG, and GenChoice!. Trade debt financing is traditional debt where the borrower borrows cash, usually from a revolving line of credit used to finance pre-payment for inventory. Money for this type of debt is readily available from wealthy individuals, finance companies or a bank or other financial institution and at the term of the loan pays the lender back in cash. The company has noted substantial disinformation in public forums regarding trade debt financing. The above paragraph is the company's final position regarding its trade debt posture. We will borrow money, finance manufacturing of our product purchases, and then pay the money back to the lender. Fancy derivative and/or toxic equity financing will not be used. We will operate our business like a business. Most financing is hard to get for a small company, nonetheless we will aspire to endure. Without the financing our sales will be curtailed.

In July 2019 CEO Keith Berman approached the company Board of Directors with a plan and offer to, from time to time, lend the company up to \$450,000 through a combination of sources available to him. The Board accepted this offer, which came without pre-condition. Mr. Berman made it clear that he would rather lend the company money himself or through close friends and family, than instead to sell low priced equity to small institutions. Through this writing, the entirety of this \$450,000 has been rendered.

In March 2020 the company entered into four Notes (loans) with its main investor, Alpha Capital Anstalt for a total of \$1 million. As of this writing, Alpha has rendered \$700,000 in loans, based on Alpha's funding and fulfillment of three of these Notes. The remainder of the \$1 million in loans from Alpha is anticipated during the week beginning March 30, 2020.

In March 2012 we renewed our agreement with Alpha Credit Resources ("ACR") for a third time in order to obtain this debt financing. After the expiration of that agreement, in November 2013 we executed a new line of credit with Alpha Credit Resources, replacing our previous line. This credit line was for \$12.5 million, but with the velocity of our product sales, could yield over \$250 million in annually available credit. We never did draw down any credit financing from ACR, although we many times tried. On December 14, 2015 this credit line expired. Subsequently we learned that ACR and its parent, Platinum Credit became the subject of several Federal criminal investigations and trials. In September 2016, the major funds controlled by Platinum filed for liquidation. The company immediately froze all of its securities held by Platinum, securities paid from 2007 through 2014, but none subsequently. Platinum had not been granted any requests for any conversion or sale transactions since December 2014. As a part of this liquidation the company is now seeking return of most of the securities granted to the Platinum funds from 2007 through 2014.

We will from time to time continue to seek a combination of equity and long-term debt financing as well as other traditional cash flow and asset backed financing to meet our financing needs and to reduce our overall cost of capital. Additionally, in order to accelerate our growth rate and to finance general corporate activities, we may supplement our existing sources of funds with financing arrangements at the operating system level or through additional short-term borrowings. As a further capital resource, we may sell or



lease certain rights or assets from our portfolio as appropriate opportunities become available. However, there can be no assurance that we will be able to obtain any additional financing, on acceptable terms or at all.

### Results of Operations for the years ended December 31, 2019 and 2018, compared.

The following tables summarize selected items from the statement of operations for the years ended December 31, 2019 compared to 2018.

	Year Ended			
	December 31,			
	2019	2018	12 Months	%Δ
Revenue	\$ 2,379,234	\$ 2,235,989	143,245	6.41%
Cost of sales	1,528,882	1,454,819	74,063	5.09%
<b>Gross profit</b>	<b>850,352</b>	<b>781,169</b>	<b>69,183</b>	<b>8.86%</b>

Revenue and Cost of Sales remained relatively static for the year ended December 31, 2019 as compared to 2018.

### OPERATING EXPENSES:

	Year Ended			
	December 31,			
	2019	2018	12 Months	%Δ
<b>Expenses:</b>				
General & administrative expenses	952,123	541,950	410,173	75.68%
Consulting	200,269	130,658	69,611	53.28%
Compensation expense	416,527	473,973	(57,446)	-12.12%
Professional fees	575,815	1,487,750	(911,935)	-61.30%
Total expenses	2,144,735	2,634,331	(489,596)	-18.59%

### Year Ended December 31, 2019:

General and administration expenses include bad debt, office expenses (including rent, cleaning and maintenance, utilities, and telephone), insurance, and bank charges. During the year ended December 31, 2019, general and administrative expenses increased by \$410,173 to \$952,123 (2018 - \$541,950) due primarily to a standard increase general overhead and payroll related items, and a one-time bad debt write-off of \$175,000, which amounted to the remainder of the product sold prior to our settlement with Lifescan/J&J and increased marketing efforts in 2019 as compared to 2018.

Consulting expenses for the year ended December 31, 2019, increased \$69,611 to \$200,269 (2018 - \$130,658). The increase is due primarily to our “normalization” of outside marketing consultants as we continue to increase the visibility of our product lines.

Compensation expense for the year ended December 31, 2019 remained relatively static as compared to 2018.

Professional fees include accounting services, legal fees and regulatory reporting compliance. The decrease in professional fees of \$911,935 to \$575,815 (2018 - \$1,487,750) is due primarily to a decrease in legal fees incurred in connection with our product development costs wherein we engaged additional legal counsel in 2018 to assist in the review of potential new sales/distributing agreements and review general corporate matters. We anticipate our legal fees to continue into 2020.

## OTHER INCOME (EXPENSE):

	Year Ended			
	December 31,			
	2019	2018	12 Months	%Δ
<b>Other income (expense):</b>				
Financing costs	(348,655)	(195,877)	(152,778)	100.00%
Interest expense, net	(2,666,898)	(190,210)	(2,476,688)	-1302.08%
Loss on write-down of obsolete inventory	(162,359)	(902)	(161,457)	100.00%
Gain on intellectual property	1,340,000	-	1,340,000	100.00%
Total other income (expense)	(1,837,913)	(386,989)	(1,450,924)	-1002.08%

### Year Ended December 31, 2019:

Our other income and expense increased an overall \$1,450,924 from \$(386,989) for year ended December 31, 2018, to \$1,837,913 for the year ended December 31, 2019. Other expense includes costs related to our financing activities associated with our debt and equity offerings of \$348,655 (2018 - \$195,877) and interest expense of \$2,666,898 (2018 - \$190,210). Included in the 2019 interest expense is Original Issue Discounts of \$2,240,858 (2018 - \$0). We also incurred a gain on intellectual property in the year ended December 31, 2019 of \$1,340,000 (2018 - \$0) due to the out of court settlement with Shasta Technologies, LLC, whereby we were granted unobstructed rights to their patents.

We recorded a net loss for the year ended December 31, 2019 of \$3,132,295 compared to a net loss in 2018 of \$2,240,220. This change was due primarily to the recording of OID at year end totaling \$2,240,858 the recognition of a gain on intellectual property due to the out of court settlement with Shasta Technologies, LLC, whereby we were granted unobstructed rights to their patents in 2019 as compared to 2018.

### **Liquidity and Capital Resources**

A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate generating sufficient positive internal operating cash flow until later in 2019, as a result of several factors, including the change in our status from exclusive distributor of our GenStrip 50 (now GenUltimate!) our pet testing products and new products coming on-line, to the manufacturer of this product (now in process), complete additional financial service company acquisitions and generate substantial revenues, which may take the next few years to fully realize. We anticipate that in the next 12 months that we will be starved for cash from time to time as the need for cash to finance our FDA 510K prosecutions and product developments will outstrip our abilities to raise cash from traditional sources. The company's Board has established and reaffirmed that the company will **not** allow our need for cash to be exploited by toxic funding entities. We will, from time to time seek to raise capital from small funds. Our current cash position is critical.

As our GenUltimate! product grows along its product life cycle, and as we launch new products such as our GenChoice! and GenUltimate TBG products, we may not obtain the necessary capital to pursue our strategic plan. As of this writing we are in a short term "cash crunch." If this crunch continues it could materially impact our operations. However, the company is securing a revolving debt credit line and expects handsome settlement cash from two lawsuits.

As of December 31, 2019, we had cash and cash equivalents of \$114,334, inventory of \$166,635, and accounts receivable of \$1,045,166. Net cash used by operating activities for the year ended December 31, 2019 was approximately \$1,114,671. Current liabilities of \$4,972,419 consisted of: \$1,253,892 of accounts payable and accrued liabilities, accrued interest of \$348,549, contingent legal fees of \$240,000, and notes payable and OID of \$2,794,673. As of December 31, 2019, we have a negative working capital of \$3,644,036.

The accompanying financial statements have been prepared contemplating a continuation of the Company as a going concern. The Company has reported an accumulated deficit of \$49,729,923 and a net loss of \$3,132,295 for the year ended December 31, 2019. Additional investments are being sought, but we cannot guarantee that we will be able to obtain such investments. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, the trading price of our common stock and conditions in the U.S. stock and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Recently, we withdrew our registration statement filed under Reg. A with the U.S. Securities and Exchange Commission. We did so because we had been informed that a single entity, or related entities, was preparing to buy all of the underlying

securities registered in the Reg. A, and thereby take control of the company. Withdrawal of this registration created a “cash crunch” down line. Our current cash position is critical. Thus, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we may have to curtail our operations.

### **Cash to Operating Activities**

During the year ended December 31, 2019, operating activities used cash of \$1,114,671 compared to using cash of \$1,322,946 in 2018. Our net operating loss for 2019 was \$3,132,295 and included amortization of prepaid legal fees of \$101,239 (2018 - \$750,000), shares issued for financing fees of \$348,654 (2018 - \$195,876), shares and options issued for services of \$25,000 (2018 - \$0), bad debt write-off of \$175,000 (2018 - \$0), loss on write-down of obsolete inventory of \$162,359 (2018 - \$0), and gain on intellectual property of \$1,340,000 (2018 - \$0). Our change in accounts receivables increased \$241,523 to a use of \$270,370 (2018 - \$511,893 use). Our change in inventory increased \$144,225 to a use of \$78,282 (2018 - \$65,943 source). Accrued interest increased by \$2,476,688 to \$2,666,898 source (2018- \$190,210 source) due primarily to Original Issue Discounts totaling \$2,240,858 that were mutually identified by us and our noteholders during the course of a normal review of our debt with them. Our contingent liabilities remained constant in 2019 as compared to 2018 due to the recognition of liability due to our involvement in legal matters.

### **Cash from Investing Activities**

During the year ended December 31, 2019, investing activities used \$116,375 in cash (2018 - \$90,300 use) related wholly to our intellectual property.

### **Cash from Financing Activities**

During the year ended December 31, 2019, financing activities produced net cash of \$986,622 (2018 - \$683,242). This change is primarily a result of successful debt and equity offerings in 2019.

### *Internal and External Sources of Liquidity*

#### Alpha Credit Resources LLC (formerly Centurion Credit)

On November 17, 2007, we entered into an agreement with Alpha Credit Resources LLC to secure a \$1,000,000 revolving credit facility that is geared specifically to our business. As of October 2008, the company renewed its agreement with Alpha Credit Resources LLC until November 17, 2009 and as an inducement to renew the credit line was increased to \$2,000,000, with additional seasonal increases to \$2,500,000. In September 2010 we began discussions with Alpha Credit for an additional \$6.0 million credit facility to provide available credit to finance sales of our new at-home testing diagnostic product. The company last borrowed funds using the credit line in the Year ended December 31, 2011. The agreement matured on December 31, 2011 without renewal. In March of 2012, we executed a renewal agreement with Alpha Credit. The renewal Year matured on December 31, 2012. We borrowed no money under this renewal. In December 2013 we again renewed our credit line with Alpha Credit, expanding our credit line to \$12.5 million (Fourth Omnibus Renewal). As a part of the most recent renewal agreement all previous accrued debt and interest owed Alpha Credit was reduced to \$0.00. Alpha Credit Resources breached this renewal agreement. The agreement was allowed to come to term. In April 2016 the company brought its disputes with Alpha Credit to the attention of new management and while working on a resolution, the parent of Alpha Credit and its sister operations became embroiled in two Federal investigations. Subsequently the funds that capitalized Alpha went into liquidation. The company was standing still until these investigations are brought to a conclusion, but in 1Q 2018 we decided to cancel 1,000 Class B Preferred shares that Alpha did not earn, and over 300,000 shares of Preferred E stock that was not earned, and may have been a part of a scheme to defraud the company as principals of Alpha’s parent are now on trial, in sentencing proceedings, or both.

### *Cash Flow.*

Since inception, we have primarily financed our cash flow requirements through the issuance of common stock, the issuance of notes and sales generated income. With anticipated growth in 2020 we may, during our normal course of business, experience net negative cash flows from operations, pending receipt of revenue, which often are delayed because of the nature of the healthcare industry. Further, we may be required to obtain financing to fund operations through additional common stock offerings and bank or other debt borrowings, to the extent available, or to obtain additional financing to the extent necessary to augment our available working capital.

### *Satisfaction of our cash obligations for the next 12 months.*

As of December 31, 2019, our cash balance was \$114,334. Our plan for satisfying our cash requirements for the next twelve months is through additional equity, third party financing, and/or debt financing. We anticipate sales-generated income during that same year of time, but do not anticipate generating sufficient amounts of positive cash flow to meet our working capital requirements. Consequently, we intend to make appropriate plans to insure sources of additional capital in the future to fund growth and expansion through additional equity or debt financing or credit facilities. We are currently experiencing a substantial “cash crunch.” We are in the middle of three new product launches, two 510K applications (one in process and one almost complete) and their prosecution, an expansion to our manufacturing facilities, growth in a segment of overseas business, the funding of the commercialization of two products and the antecedent activities, and the prosecution and/or settlement of three legal actions. The company is in need of additional capital, estimated to be approximately \$1 million, to bridge to upcoming capital events, a settlement of a lawsuit with Johnson and Johnson, and the beginning of the partnership agreement discussed below.

As we expanded operational activities, we may continue, from time to time, to experience net negative cash flows from operations, pending receipt of sales or development fees, and will be required to obtain additional financing to fund operations through common stock offerings and debt borrowings to the extent necessary to provide working capital. It was not until the company entered into the agreement with Alpha Credit Resources, LLC that the company could fill orders for patients and customers on a continuous basis. Until the Alpha Credit line was put in place, we managed to keep a small portion of our distribution activities going when our limited resources allowed us which remains true as of this filing.

Predictions of future operating results are difficult to ascertain due to our historic operating activities. The recent addition of a credit line has helped but we have found it increasingly difficult to transact commerce in the very cash intensive prescription drug industry. Thus, our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in their early stages of commercial viability, particularly companies in new and rapidly evolving technology markets. Such risks include, but are not limited to, an evolving and unpredictable business model and the management of growth. To address these risks we must, among other things, implement and successfully execute our business and marketing strategy, continue to develop and upgrade technology and products, respond to competitive developments, and continue to attract, retain and motivate qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so can have a material adverse effect on our business prospects, financial condition and results of operations.

In March 2019 the company received its first communication from a 3<sup>rd</sup> party company about its new GenUltimate! TBG product and technology. Subsequently the company received additional communiques. Propositions covered much of what could be expected in a complicated M&A transaction.

The company’s Board entered a process of interview and elimination. This process concluded on June 30, 2019. The company asked this entity to clarify the earn-out.

#### *Expected purchase or sale of plant and significant equipment.*

We anticipate the purchase of significant equipment for our Covid-19 products to be placed and used by our Korean contract manufacturer. The cost of this equipment is anticipated to be \$1 million. We have previously disclosed other of these investments in previous reports.

#### *Going Concern*

The financial statements included in this report have been prepared in conformity with generally accepted accounting principles that contemplate the continuance of the Company as a going concern. The Company's cash position is currently inadequate to pay all of the costs associated with testing, production and marketing of products. Management intends to use borrowings and security sales to mitigate the effects of its cash position, however no assurance can be given that debt or equity financing, if and when required will be available. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and classification of liabilities that might be necessary should the Company be unable to continue existence.

#### Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our original Genstrip product required initial regulatory approval by the USFDA as well as on-going USFDA approvals during the product life cycle. Further, Genstrip required medical patient trials and competes directly with a major platform manufacturer.

We insure against any claims made against the company for our GenUltimate product. Our GenSure product is sold only in international markets. We are protected against claims of patent and/or trademark infringement by virtue of our 2016 settlement agreement with Johnson & Johnson and two J&J divisions.

Our GenChoice! and GenUltimate! TBG products will be sold worldwide. The company will have to protect against claims of infringement for both of these products. Patent and trademark infringement suits are often filed for strategic business reasons, having only a passing relationship to the patents or trademarks claimed to be at issue.

Healthcare, especially those segments where the company competes, is also very litigious. Competing companies often use litigation as a marketing tool, bringing litigation as a means to protect market share and limit market exposure. The medical industry is also intertwined. From time to time, we may become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, litigation that arises over payment disputes or claims of fair value. We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers. It is not uncommon in our industry to find that a litigant has filed claims in multiple jurisdictions involving the same transaction or a single transaction. The company maintains substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. The company has also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, the company accrues contingent legal fees and product liability fees. As of December 31, 2019, our accrual was \$485,069.

From time to time, the company may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management's judgment may be considered potentially material to us.

In December 2018 the company and Mr. Berman were sued by a former employee who made employment practices claims. This employee had been terminated some 16 months earlier, for insubordination. The company filed a counter-suit against the former employee for misappropriating and hiding company property, secrets, and for violating HIPAA statutes as a result of these actions. The company and Mr. Berman are both insured against these types of lawsuits. In 1Q 2020, with the assistance and resources of its insurer, this lawsuit was settled.

We were in litigation with Lifescan Inc. a subsidiary of Johnson & Johnson beginning in September 2011. Lifescan had maintained throughout that our Genstrip (now known as GenUltimate!) product infringed on three of their patents. One of these patents became the subject of peripheral litigation activities, and two Appeals (one for each side) to the U.S. Appeals Court for the Federal Circuit (the patents appeals court). In January 2016 the Court of Appeals for the Federal Circuit ruled in its Mandate that this one foundational patent and the claims made by the assignee Lifescan, Inc. was struck (killed) due to obviousness (a clever wording meant to obscure a connection between the Lifescan, Inc. invention and earlier generation technologies dating back to the late 1970s). Throughout this Appeal process, and a litigation process waged through the USPTO, the company prevailed. In addition, as a result of certain claims and allegations made by Lifescan after the close of the USPTO final determination (in favor of the company), the office of the Solicitor General intervened against Lifescan Inc. in the Federal Circuit court and was of great assistance in getting the Lifescan, Inc. patent revoked. Nonetheless the seeming baseless allegations and claims made by Lifescan against the company have taken their toll, limited our ability to sell our GenStrip (now known as GenUltimate) to large entities ("big box stores") and greatly extended the court processes.

In May 2016 the company became aware of a clause Lifescan had inserted in its Franchise agreements. This clause set a penalty structure whereby should any Franchisee who also bought non-Lifescan products (but more clearly our GenUltimate) they would lose their access to product rebates, and in certain instances their Franchise. Once aware of these illegal tie-ins the company complained to the Federal government, and in January 2017, for the first time since the onset of litigation with J&J, the tie-in clause was globally lifted by J&J. During the pendency of the 2011 and 2012 lawsuits, Lifescan was guilty of a number of unethical practices.

In March 2016 the company filed suit against Johnson & Johnson and two Lifescan divisions through our two IP subsidiaries. DECN filed the lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV, Case 2:16-cv-00564, titled Pharma Tech Solutions, Inc. et al v. Lifescan, Inc. et al naming Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. for alleged infringement in relation to U.S. Patent numbers 6,153,069, an apparatus patent, and 6,413,411, a method patent. The suit sought at least \$400 million in provable damages. The company lost this lawsuit on a contested technicality, and also lost its appeal.

In November 2018 the company filed a lawsuit in Pennsylvania court against Conductive Technologies, Inc. (CTI) and Shasta Technologies LLC, alleging, among other things, that these two former partners colluded along with Lifescan, Inc. to illegally embargo the company's GenUltimate! product and technology, and to attempt to seize this product and associated Intellectual Property. The suit

emerged as a result of a settlement the former partners entered into with Lifescan, Inc. and Johnson & Johnson to settle their issues (at our expense) in the above discussed patent infringement lawsuits of 2011 and 2012. On December 31, 2018 the Pennsylvania court granted the company a judgment in the amount of \$3,600,000 against Shasta Technologies LLC. The company had been in the process of enforcing the judgment in the states of Minnesota, Oregon (Shasta's domicile), and California. In late April 2019 the company filed and received a Writ of Attachment from the State of California Superior Court and proceeded to execute on this Writ.

Activities to enforce the judgment against Shasta in Minnesota and California ended the litigation and collection activities against Shasta as of the period ended June 30, 2019. The company, upon conclusion of the litigation then valued its acquisition of technology and Marks in the financials for the period ended June 30, 2019. The company shows a one-time gain in the 2Q 2019 period. Litigation against CTI continues. Recently the company was made aware of a conflict that involved a sister company of CTI, whereby this sister company had extensive undisclosed contract dealings with J&J. At the time of the Settlement by Shasta and CTI with J&J, CTI had recently appointed a new Chairman, the then CEO of the sister corporation. The company believes that this new Chairman, in an effort to preserve another agreement with J&J immediately ordered settlement with J&J and as a result of this settlement with J&J became the architect of the embargo against the company and its products, forcing the company to redevelop GenUltimate in Korea, at a cost of \$660,000. CTI also used the company's client list obtained as a part of the J&J litigation and hired a company distributor to distribute the company's products to other of the company's distributors. The company is seeking settlement with CTI but will be forced going forward to expand its suit against CTI to add the sister corporation and its Chairman to the expanded lawsuit.

### **Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

### **Error Repair**

The company will endeavor to repair any and all errors that new sets of eyes find in this document after posting, whether these errors are in spelling, grammatical, punctuation related or numeric. We are not perfect and we remind others that the people who point our errors out to us, along with their public comments, are not perfect either.